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ABSTRACT
The case for the involvement of lysosomal enzymes in the 
metastatic spread of cancer has been examined. A study of the 
effects of two potentially inhibitory compounds on a selection of 
these enzymes has been made both in vivo and in vitro. The two 
compounds, glucosaccharo-1,4-lactone (GSL) and the sodium salt of 
1-(3-benzamino-4-methylbenzamido)-naphthalene-4,6,8-trisulphonic 
acid (Suramin)» have been tested for their effects on hydrolytic 
lysosomal enzymes. GSL is a very powerful and specific inhibitor 
of 3-glucuronidase (BCD), (E,C.3.2,1.31): The of this inhibitor
was found to be in the order of 10  ^ to 10 depending on the 
enzyme source. Suramin, though a less powerful inhibitor, has been 
shown to inhibit BCD, acid phosphatase (APT) (E.G.3.1.3.2) and 
N-acetylneuraminidase (E.C.3.2.1.18), while showing a less marked 
effect on aryl sulphatase (E.C.3.1.6,1.).
In order to determine the effects of these compounds in vivo, 
experiments were made to observe the effect of GSL and Suramin on 
lysosomal enzyme activity and the composition of liver after 24-hour 
and 4-week administrations. Suramin, which appeared to have the more 
profound influences on the lysosomal enzymes and which, according to 
the literature, is metabolically inert, was also tested for its 
effects on the Ehrlich ascites tumour (EAT) and on involution of the 
rat uterus. The drug's effect on EAT was dramatic: tumour development
was markedly inhibited and levels of BGD, APT and N-acetyl-neuraminidase 
activity were reduced to those found in normal, healthy animals. The 
influence of these enzymes on EAT cell surfaces is discussed in relation
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to surface electrical charges and intercellular binding of malignant 
cells. The effect of Suramin on rat uterus involution was also
marked: the rate of involution was reduced, BGD and APT activities 
were lowered, and the rate of change found in tissue proteins was 
modified.
The significance of these findings is discussed and further 
relevant studies are suggested which might contribute to a clearer 
understanding of the process of metastasis and to a prediction of 
the usefulness of these compounds as antimetastatic agents.
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CFIAPTER I 
INTRODUCTION
1, The History and Definition of Cancer
The history of cancer has been traced back into antiquity and 
it has even been shown that malignant tumours occurred in dinosaurs 
(Lewison, 1955). Incidence of the disease today seems to be on 
the increasethough the situation is not readily defined. The 
problem is complicated by the ever-increasing life expectancy of 
Man, since this means that more people are surviving until cancer 
can strike and the proportion of fatalities due to the disease 
increases.
Cancer itself is not easily defined, and many workers hold 
that the problem is a variety of diseases all exhibiting largely 
similar symptoms. The early macroscopic identification of the 
disease is today considered inadequate, and one now relies for 
accurate definition on microscopic and biochemical observation, the 
aim of such study being to detect signs of malignancy - a state 
which itself is poorly defined. A benign tumour may be a large 
or small accretion of cells, which may cause no inconvenience to 
the host and consequently may be undetected throughout life. Many 
benign tumours are left untreated, because aggravation of such 
growths can promote malignant development - this propensity of 
tumours has long been known. HippçÇjfates wrote, referring to 
deep-seated tumours:
"It is better to omit treatment altogether, for, if 
treated (surgically) the patients soon die, whereas, 
if let alone, they might last a long time."
- 25 -
Currently, it is common practice not to disturb benign tumours such 
as cosmetically inconvenient nevi or other skin blemishes, removal of 
which frequently results in subsequent development of malignant 
tumours derived from the removed tissue.
On the other hand, a tumour may be malignant while still of 
microscopic size. One therefore relies on the histologist who, by 
inspection of a tissue sample, can determine the degree of 
differentiation, which gives a good indication of the nature of the 
sample. The less differentiated (or organised) the tissue, the more 
malignant it is considered to be. The rationale for this statement 
is that normal, healthy tissue has a well-regulated cell turnover with 
cells dividing and replicating in an orderly manner, whereas in a 
malignant tissue the cells proliferate at an abnormally high rate and 
in a random manner. This results in a chaotic, disordered tissue, 
containing an unusually high number of dividing cells. A further 
indication of malignancy is the occurrence of bizarre cells, with 
numerous, or single, giant nuclei, and even giant or multinucleate 
cells. The degree of malignancy has been related directly to the 
differentiation of the tissue by many workers - e.g. Pearse (1962) 
and Burstone (1962).
Such histological observations are frequently confirmed by 
biochemical or histochemical techniques, which may show abnormal levels 
of enzymes within the malignant cell (Majewski,1967; Stein et al., 
1967; Sherstén et al., 1972).
These methods also show that the malignant cell may lose some 
of its normal structures and functions (Weber and Lea, 1966).
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The histological appearance of tissue before it develops a 
completely malignant nature is used as an "early warning" sign 
(Oehlert, 1973), particularly in the case of such tissues as 
tracheobronchial, gastrointestinal and uterine cervical epithelia.
It forms the basis of the nationally-organised cervical smear test 
for uterine cancer.
2. The Development of Cancer Tumours
Current concepts of the way in which cancer develops must of 
necessity be based on observation of patients who have been exposed 
to some carcinogen. Such a study is not simple, because in many cases 
there is no possibility of identifying either the carcinogen or the 
point in the patient's history at which the exposure arose. These 
studies must extend over many years, as Goldblatt (1949) showed in his 
work on $-naphthylamine.
%
The hypothesis which is quite widely accepted today is basically 
that proposed by Berenblum (1954) and suggests a two-stage development:
(a) Initiation
The suggestion is that a single cell is modified in some 
way by its interaction with a carcinogen. What form this 
interaction takes is unknown: with more and more evidence
hinting at genetic control, it seems likely that the change 
may occur in some stage of the DNA-mediated functions of the cell 
(this could fit with the peculiar reproductive characteristics 
of the malignant cell). A cell which has reacted with a 
carcinogen must, for the "success" of the tumour, survive in 
the host in a viable and replicative state. This "initiated" 
condition is sometimes known as the "sub-threshold pre-neoplastic 
state" (Cunningham, 1958). Nothing is known about the initiated
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cell; not even whether after initiation the cell divides 
and replicates as do other, normal, cells around it, or 
whether the cell survives in its own right for an abnormally 
long time in some form of "suspended animation" until the 
second phase comes into operation.
(b) Promotion
To qualify for description as a cancerous growth the 
initiated cell must proliferate to form a colony which will 
become the primary tumour. The stimulus which causes the 
promotion is as much an enigma as that responsible for the 
initiation. A variety of evidence suggests that either 
physical and/or chemical irritation may be the answer.
Of the many experimental models used to study the process, 
perhaps the best known is that of Berenblum (1941). He found 
that while treatment of shaved mice with dimethylbenzanthracene 
(DMBA) painted onto the skin had no effect, subsequent 
applications of croton oil, even months later, would quickly 
result in the formation of tumours. Neither DMBA nor croton 
oil alone given at the same dose levels would cause the same 
response. Thus DMBA is described as the initiator and croton 
oil as the promotor. Such models have led to the idea of 
"co-carcinogens", weakly carcinogenic compounds which alone 
have little or no effect but which, with another compound of 
similar properties, can act synergistically.
Once the primary tumour is formed, it can spread either by 
invasion or metastasis. Both these mechanisms are clinically 
recognisable, but only invasion is really understood. Essentially,
the invasive tumour spreads by extending threads of cells along lines
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of low physical resistance, such as blood or lymph vessels, between 
muscle fibre bundles and into intercellular spaces, etc. These threads 
of cells may retain structural continuity with the primary tumour or 
may break off and form secondary foci. In either case, the result is 
a fairly discrete tumour mass which, with careful surgery, is curable, 
though it is obvious that the older and larger the growth, the more 
extensive the invasion may be and the poorer the patient's prognosis.
Metastasis is a much more dangerous and less well understood 
process. It appears to involve release from the primary tumour of 
single or small clumps of cells. The process has been extensively 
studied since it was first reported in 1869 by Ashworth. Association 
of circulating cancer cells with widespread dispersion of the primary 
tumour has since been well documented - e.g. Engell (1955), Fisher and 
Turnbull (1955) and Zeidman (1965).
The released cells seem to be peculiarly flexible, able to 
modify their shape in order to negotiate narrow spaces - e.g. capillary 
vessels or intercellular gaps in blood or lymph vessel walls. Once 
these cells have entered the blood o'Tf'lymph vessels, they are transported 
around the host's body and may settle to form secondary tumours. 
Metastasised tumours are thus found at sites remote from the primary 
site. The secondary target site for any particular primary tumour is 
not completely predictable, though some tumours seem to favour one 
tissue rather than another: for example, breast tumours commonly
metastasise to bone marrow. It is of note, too, that the lymph ducts, 
once thought to act as protection from tumour cells (Virchow, 1860), 
have no such function and once the metastatic cells have entered a 
lymph duct their dispersion is assured (Willis, 1958) Fisher and 
Fisher, 1968). Zeidman (1962) has shown that the large cells of the
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Brown-Pearce tumour are able to negotiate the capillary bed of the 
lung after injection intravenously into rabbits, leaving only some 
5% of their number trapped. However, treatment with cortisone, 
a well established enhancer of metastasis (Angosin et ai., 1952; Baserga 
and Shubik, 1954  ^ Wood et al., 1957), caused the proportion of cells 
trapped to rise from 5% to about 30%, and the number of resultant 
tumours increased from 137 per animal to 577 per animal.
It must be emphasised that simple entrapment of the cells in 
a suitable region does not guarantee that a secondary tumour will 
result. Firstly, the cells must not only be trapped in a small vessel 
but, as demonstrated by Kinsey (1960), the cells are tissue-specific. 
This was shown when he made free transplants of various tissues in sub­
cutaneous pouches in mice and inoculated the animals with the melanoma 
S91, The tumour, which metastasises to the lungs specifically, also 
formed secondary tumours in lung transplants within the skin pouches.
No other tissue transplant would accept this tumour, although the cells 
were trapped in all the tissues which were transplanted. Cells which 
settle elsewhere in the host's body may die, or may remain viable but 
non-proliferative.
Finally, the metastasising cells seem usually to have the ability 
to pass out of the blood or lymph vessels into the surrounding tissues, 
thus facilitating their establishment.
3. The Mechanism of Metastasis
Of the two modes in which a tumour may spread, invasion is the 
less dangerous, because direct observation of the tumour by the surgeon 
will enable him to see how far the growth has spread and to remove all 
the cancerous tissue. Also, the surgeon's normal approach to tumour
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surgery is "aimed at wide block resection into apparently healthy 
muscle, cellular tissue, lymph ducts, and lymph nodes within the widest 
limits compatible with the physiological needs of the body" (Petrow,
1962). In lay terms, the surgeon's tactic seems to be to remove as 
much of the host's body tissues as possible without causing death or 
complete incapacitation. However, even this drastic treatment is only 
effective in early stages of the disease. Numerous data have been 
published relating five-year survival times to the stage of development 
at which surgery was carried out. Raven (1958), for example, quotes 
figures of 65*5% at stage I , 52»5% at stage II, 35*2% at stage III 
and 7*1% at stage IV (these stages are the surgeon's assessment of a 
tumour's development and are largely subjective, depending on the 
individual's experience and observations). Kalmgren (1968) states that 
such data axe widely accepted and emphasises that the later the stage 
of the tumour's development, the poorer the patient's prognosis. Such 
a suggestion is implicit in the comments of Zeidman et al. (1950).
Roberts et al, (1962) related the development of the disease to the 
presence of metastatic cells in the bloodstream before, during and after 
surgery and also to the post-operative survival times. They showed 
that 38% of patients who had no malignant cells present in their blood 
survived, compared with only 20% of those in whom such cells were detected, 
The Gasics and their co-workers (1963, 1968, 1973) associated circulating 
metastatic cells with blood platelet efficiency and related this also 
to the process by which the metastatic cells penetrate into established 
tissues.
There is, therefore, considerable evidence suggesting that the 
mediator of metastasis is the circulating malignant cell. One could
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thus hope to curtail metastasis by preventing the release of these 
cells from the primary tumour. In order to achieve this object, one 
must determine what causes the release of these cells.
The simplest system for observation of cancer cells is an in vitro 
culture method which readily shows differences between normal and 
(potentially) metastasising cells. For example, both types of cell 
are able to move across the surface of a culture flask at speeds of 
4-6 microns per minute. However, when two normal cells come into
o
close proximity, they keep station at a distance of about 150 A 
(Abercrombie and Andrews, 1962). Over a period, normal cells will 
tend to form colonies of a single cell thickness on the wall of the 
culture vessel, which eventually combine to form a continuous cell- 
monolayer. This happens when the cells divide, an activity which only 
occurs at the periphery of such colonies, since the phenomenon of 
"contact inhibition" prevents both movement and division in normal cells 
when they are surrounded by other cells.
In the case of malignant cells, there is no contact inhibition, 
either between two malignant cells or between one normal and one malignant 
cell. The result is that a culture of malignant cells tends to form 
random clumps of cells in colonies several cells deep. In vivo, this 
trait is probably manifested as the malignant cell's ability to pass 
through confined spaces and to reproduce in the limited spaces between 
other tissues.
The adherence of different cell types has also been studied.
Berwick and Coman (1962) have defined cell-to-cell adherence as 
"adhesiveness" and cell-to-glass adherence (in vitro) as "stickiness".
They report that normal cells show high "adhesiveness" and low 
"stickiness", while malignant cells have the reverse properties, which
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they interpret as indicating that the malignant cells have weaker than 
normal intercellular bonds. This property has been studied ever since 
Beebe (1904) reported that cancer cell surfaces are deficient in 
calcium, a finding confirmed by others - e.g. Clowes and Frisbie (1905), 
de Long et al. (1950). The presence of calcium has been shown 
essential for normal cell-to-cell binding (hence the use of EDTA as an 
agent for dispersing cell monolayers). Some elegant work by Coman
(1944) first demonstrated the reduced adhesiveness of cancer cells.
He used flexible needles, calibrated in terms of force required to 
cause a given distortion of the needle, to tease apart cancer cells 
and ordinary cells. He found that less force was needed to separate 
cancer cells.
Another aspect of cell surface phenomena which may be relevant to 
metastasis is that the surface charge of cancer cells is more negative 
than that of normal cells (Ambrose, 1966a). This difference appears
to be due to the presence on the cell surface of more carboxylic acid
residues than normal. These residues can be removed by treatment with 
neuraminidase (Ambrose, 1966b).
Hence, modification of the cell surface may be involved in the 
display of malignancy. Such modifications must certainly involve 
enzymes in some way, conceivably extracellular enzymes which can act 
on established cell surfaces.
A large amount of work has been done on extracellular enzymes 
of the tumour and it is well known that malignant tumours are associated 
with abnormally high levels of acid hydrolases, as indicated by, for 
example, Shamberger (1969) and Majewski (1964). Among these enzymes 
are acid phosphatase (Kar et al., 1972), ^-glucuronidase (Boyland et al., 
1957, 1958} Neimi and Sylven, 1968), aryl sulphatase (Dzialozynski et al..
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1966} Campschmidt and Wells, 1968), cathepsins (Eolmberg, 1961;
Libenson and Jena, 1957; Schersten et al., 1972), aminopeptidase 
(Willighagen and Planteydt, 1959) and collagenase (Dresden et al.,
1972). All these enzymes are considered to be lysosomal in origin 
(Majewski, 1964} Dingle, 1972) and are primarily destructive in their 
functions. Moreover, Ghadially and Parry (1965) and Parry and 
Ghadially (1967), among other workers, have shovm by electron- 
microscopy that absolute numbers of lysosomes increase in tumour- 
bearing tissue.
Current concepts of the role of lysosomes have modified 
considerably since the early days of de Duve's "suicide bags" (1954) 
and currently they are thought to play a significant part in the economy 
of the cell by maintaining a balance between anabolic and catabolic 
processes. Also, many cells are capable of pinocytosis, a process 
which involves ingestion of foreign particles and their subsequent 
degradation by lysosomal enzymes, with the release of molecular 
components for the cell's own economy. ' In the same manner, cell 
turnover and replacement within a tissue can be mediated with reduced 
demands on nutritional components from outside the tissue. The process 
is well known in normal tissues and has been demonstrated also in 
spontaneous cancer tissue (Babai and Tremblay, 1972) as well as induced 
granulomas (Neimi and Sylven, 1968). Sylven (1962) considered that 
the high levels of lysosomal enzymes within and surrounding malignant 
tissue originate from the tumour and are secreted from it for the dual 
purposes of destroying the surrounding host tissue and aiding the 
release of tunjour cells (the latter by exposing their surfaces to 
enzymes which could disrupt the cell-to-cell bonds), thus providing
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both room and facility for metastasis to occur. Although there is 
opposition to this suggestion from several workers - e.g. Dao and Moore 
(1961) and Butterworth (1970), there is considerable evidence to support 
tlie idea. Histochemically, Burstone (1962) , and biochemically, Schersten 
Gtal, (1969 and 1972) and Nicholson et al. (1973), among others, 
have shown not only increased levels of APT, BCD, cathepsin and aryl 
sulphatase in metastatic tissue, but also a reduction of enzyme 
activities to normal levels in a clinically regressing tumour.
Fishman and Anlyan (1947) showed increased BCD levels both in 
malignant tumours and their métastasés: Piper et al. (1965) made
similar observations when comparing gastric tumours with normal fundic 
mucosa. Sylven (1968), with others, has been perhaps the main proponent 
of association between lysosomal enzymes and metastasis, extending the 
argument by suggesting that the enzymes may also be involved in
releasing tumour cells from the primary tumour mass. The evidence he
cites for this is that the enzyme levels seem to be highest in the 
oedema fluid at the periphery of the tumour mass. Simpson (1950) 
showed that there was hyaluronidase activity in carcinomas and suggested 
that this enzyme could be involved with metastasis. There is also some
supporting evidence from in vitro studies: Latner et al. (1973) showed
that invasion of mouse kidney cortex explants by polyoma-virus-transformed 
B.H.K. (^aby ^amster ^dney) cells could be inhibited by allowing the 
mouse kidney cells to take up Trasylol for 60 minutes before the explants 
were taken from the mouse (Trasylol, an effective inhibitor of collagenase, 
had previously been shown to be sequestered by the kidney). Troll et al. 
(1970) showed that DMBA-initiated tumour promoters could cause increased 
protease activity in the skin, and also that protease inhibitors could 
inhibit both the proteolytic activity and the tumour promotion. Similar
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observations have been made by Hozumi et ai. (1972), who used leupeptin 
(v/hich inhibits plasmin, trypsin, papain, thrombokinase and kallikrein) 
to influence DMBA-croton oil tumour induction in mice, and recorded 
a 75% reduction in tumour incidence.
Indirect evidence of lysosomal involvement may be inferred from 
the observations of the Fishers (1962), who reported a 240% increase in 
métastasés in animals after hepatectomy, a treatment which causes 
increased plasma levels of lysosomal enzymes (although there are other 
factors which are also likely to influence tissue growth patterns - e.g. 
humoral agents, which are necessary for intensive tissue growth). Other 
forms of trauma have also been shown to enhance metastasis; for example 
CCl^-induced liver cirrhosis or large doses of Indian ink (Fisher and 
Fisher, 1962). Vaitkevicius et al. traumatised the mouse gluteal muscle 
either by injection of 0*05 ml formalin or 0*1 ml boiling Hartmann's 
solution, or by physical crushing. The lysosomal enzyme activities 
associated with these traumata were elevated over a period of five to 
six days and returned to near normal by about eight days. The animals' 
response to tumour cell inocula followed this pattern closely, with 
greatest sensitivity to tumour cell injections occurring between 24 and 
96 hours after the trauma was administered.
Gullino (1966) has suggested that tumour cells may have a peculiar 
permeability characteristic which allows a leakage of proteins from the 
cell and a consequent build-up of enzymes of both lysosomal and other 
sources in the extracellular fluid. He suggests that in this way the 
tumour cells are able to compose a specialised extracellular medium 
which is specifically geared to the enzymic attack of diverse substrates 
in the form of host tissues. He also suggests that the products of
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such a broad-spectruin attack would provide a large proportion of the 
nutrients required by the growing tumour mass. Observations made 
on the extracellular enzymes of normal and tumour tissues would seem 
to support this idea (Sylven and Bois, 1960).
Holmberg (1961), using the Ehrlich-Landschultz ascitic cell 
line in mice, reported that these cells liberated into the incubation 
medium two to three times more cathepsin, glutathione reductase and 
lactate dehydrogenase than a similar cell concentration of strain L 
(clone 929) cells, a cell line of "dubious" malignancy. The enzyme 
release was independent of oxygen concentration and was shown not to 
be due to cell lysis or death.
The increased levels of enzyme activity are not exclusive to 
metastasis but have also been reported in tissue inflammation 
(Thomas, 1965; Mitrovic and De Seze, 1970), regeneration (Fisher 
and Fisher, 1962), degeneration (Kar and Pearson, 1972), trauma 
(Brandes et al., 1967) and rheumatoid conditions (Luscombe, 1963; 
Spitznagel, 1970). Proteases have also been shown to enhance cell 
growth and division in vitro (Goetz et al., 1972; Sefton and Rubin, 
1970).
Consequently, the large number of reports referring to lysosomal 
enzyme activities in relation to metastasis have been the basis for 
the current investigation, though it must be remembered that there is 
as yet no categorical evidence that these enzymes are responsible for 
metastatic spread: recent reports have suggested that these enzymes
may in fact originate either from the damaged host tissue itself or 
from the large numbers of phagocytes which are always present in areas 
of tissue inflammation rather than from the malignant tissue (Dao and 
Moore, 1961; Butterworth, 1970).
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CHAPTER II 
■- -\:THE 'PROJECT ■ \
1. Approach
The objective of this study was to find an antimetastatic drug. 
Since examination of the metastatic process seemed to emphasise the 
role of lysosomal enzymes, a search of the literature was made for 
compounds which were reported to influence lysysomal enzyme activity.
The first enzyme/inhibitor pair to be considered was ^-glucuroni- 
dase (BCD) and glucosaccharo-1,4-lactone (GSL). This was primarily 
because of the very specific nature and reported potency of this 
inhibitor, and because of the report of Boyland et al. (1958) that the 
very high urinary activity of BGD in patients suffering from cancer 
of bladder could be reduced to normal or sub-normal levels by daily 
oral administration of GSL. This treatment was proposed as anti- 
carcinogenic, on the basis that the reported carcinogens 3-hydroxy- 
kynurenine and 3-hydroxyanthranilic acid were "inactivated" largely 
by conversion to glucuronide derivatives. The argument was that high 
BGD levels would tend to swing the balance in favour of the free (and 
therefore carcinogenically active) forms of the compound and that GSL 
would reverse this swing.
More recently, it has been suggested (Williams, 1971) that as 
BGD is one of the lysosomal enzymes, specific inhibition of this enzyme 
would tend to reduce metastasis: as a result, BGD and its specific
inhibitor GSL were included as part of this study.
It was considered that, as such a large number of enzymes is 
encompassed by the terra "lysosomal enzymes", a broader based approach, 
aimed at a more widely spread and less specific inhibition of
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lysosomal enzymes, might offer more promise. With so many enzymes
present in the lysosome, even the complete inactivation of BGD might
well show only a small influence on tumour activity, particularly
since it is only one of two enzymes (the other being N-acetylneuramini-
dase) which together are probably mainly responsible for degradation
of mucopolysaccharide structures. Either of these two enzymes could
conceivably degrade such complexes to oligo- or disaccharide deriva-.
tives which are no longer of any structural significance.
Thus a search of the literature was made with the object of 
identifying other possible inhibitors of lysosomal enzymes. Hundreds 
of compounds have been mentioned as inhibitors of various enzymes, but 
it was noted that the action of Suramin in this respect was mentioned 
by several authors - e.g. Varner, 1960} Hawking, 1966} Allison, 1968. 
These workers suggested that Suramin inhibited a variety of enzymes 
including urease, B-glycerophosphatase, BGD, 0-galactosidase and 
cathepsin D. They also suggested that the drug would inhibit 
cytoplasmic division (though not nuclear division), that it might be 
sequestered in the lysosome and that it might modify the antigenic 
nature of the surface of trypanosomes. Also reported was an inhibitory 
effect by Suramin on the development of transplanted lymphosarcomas 
in mice. The decision was therefore taken to include Suramin as a 
less specific inhibitor of lysosomal activity, and hence a possibly 
more effective antimetastatic agent.
The project was hence designed as a study of two compounds, 
both of which could possibly be antimetastatic agents.
2. The Suramin Story
Late in the 19th Century, Ehrlich observed that methylene blue 
would stain tissues in a selective manner. He was particularly
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interested at the time in the microscopical study of the malaria 
parasite, Plasmodium, and his observations started a search for other 
dyes and related compounds which would react with microorganisms in a 
lethal manner and which might therefore be of therapeutic use to Man.
In 1904, Ehrlich and Shiga reported that Trypan Red, one of the 
Congo Red series of dyes, would cure experimental trypanosomiasis in 
mice, and attention was focussed on the so-called "cotton dyes". Tlie 
most effective of these was found to be Afridol Violet (Nicholle and 
Mesnil, 1906) , but the use of such a brightly-coloured compound in Man 
was obviously impracticable, even though the therapeutic results from 
animal and human experiments showed that it was effective. In 1920, 
after several years' study on substituted ureas of the amino-naphthalene- 
sulphonate type, two workers of the Bayer Company reported a colourless, 
anionic "dye" which had a very powerful effect on trypanosomiasis.
The compound had been synthesised by Dressel and Kothe in 1917 but Bayer, 
as sole producer of the drug and with a large market available for 
exploitation, would not publish details of either the structure or the 
preparation of the substance, which they marketed as Bayer 205.
It was not until 1924 that Fourneau et al, synthesised a compound 
having properties identical to those of Bayer 205. Once the compound 
had been identified, it was soon being synthesised by numerous pharma­
ceutical firms and marketed as a very effective trypanocide under a 
variety of trade names, including Antrypol, Bayer 205, Belganin,
Fourneau 309, Germanin, Naganol, Suramin, etc.
Chemically, evolution of the substance can be traced through a 
line of compounds from Trypan Blue, with increases in molecular weight 
and chemical complexity tending to parallel increasing trypanocidal 
activity (Fig. 1).
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The drug rapidly became very popular as a trypanocide and 
developed a dual role. Firstly, it was useful as a curative treatment
(though it was effective only in the case of early infections of
trypanosomes: once they penetrate the central nervous system the
organisms are impervious to Suramin and have to be treated with an 
arsenical compound such as Antricide, which will also penetrate cell 
membranes). Secondly, Suramin was a prophylactic with a remarkably 
long-term effect lasting from one to six months or more.
During the 1920s and 1930s, the treatment of trypanosomiasis
("sleeping sickness", carried by the Tse-tse fly in Africa) was 
carried out with great effect, due largely to Suramin and Antricide, 
and with the more recent advent of preventive measures the disease 
has now been almost eradicated in Africa (though these drugs are not 
so effective against the trypanosome T, cruzi which occurs in South 
America, where the disease still presents a problem). Consequently, 
interest in Suramin has waned over the last decade or more.
Fortunately, however, from the late 1930s until the mid-1950s, 
Wormall and his co-workers made extensive studies on the drug and its 
properties, including its effects on various enzymes. It was indeed 
largely owing to the reports of Wormall et ai. that the present study 
was made.
The longevity of the drug as an effective prophylactic was not 
explained until Dangerfield et al, (1938a) published a suitable assay 
method. The procedure which they outlined was both complex and tedious, 
involving a six-hour hydrolysis with 'V^5M-HC1 to break the -CO-NH- bonds 
(at X - X in the diagram), liberating from each molecule of the drug so 
treated two molecules each of 3-aminobenzoic acid, 3-amino-4-toluic acid 
and a-naphthylamine-4,6,8-trisulphonic acid. These three compounds
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were diazotised with nitrous acid and condensed with either a-naphthol 
or a-naphthylamine to give coloured products which were then assessed 
in a Lovibond Tintometer. The method was sensitive to Suramin levels 
down to 0*9 mg % on 3 ml samples of serum. Subsequent papers reported 
modifications to the assay procedure (Boursnellet al., 1939) Dewey 
and Wormall, 1948). The studies, sponsored by the Medical Research 
Council, were aimed at elucidating the course and duration of the 
trypanocidal action of the drug.
Dangerfield et al. (1938b) studied the drug in rabbits and dogs.
In rabbits given a single injection of Suramin (0*14 g/kg body weight 
in 0*9% NaCl) they found that the mean Suramin serum level was 98 mg % 
after 2h hours, 23*7 mg % after four days, 10*7 mg % after 14 days,
6*4 mg % after 21 days, 3*7 mg % after 39 days, 3*6 mg % after 53 days, 
and was still present at a level of ^1 mg % after 25 weeks (this latter 
figure is at the bottom of the sensitivity range of the assay method 
and is possibly not correct quantitatively, though the qualitative 
observation is still significant). A similar "duration curve" was 
obtained with two injections of 29 mg/kg in a dog, with a 32-day lag 
between the injections. They also reported from these studies that 
a large amount of the injected drug was eliminated in the urine. In a 
later publication, Dewey and Wormall (1948) reported the effects of 
Suramin injections more similar to those used in Man. The standard 
dose in Man varied from 1-2 g/50 kg body weight: some workers used
a constant dose independent of body weight, others made pro rata 
adjustments to the dose level. A typical therapeutic course would be 
a 500 mg test dose, to check the individual's tolerance, followed after 
24 hours by a 1 g/50 kg dose, then 4-5 weekly doses of a further 1 g/50 kg 
body weight. Children were frequently treated differently,receiving
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a 2 g oral dose, though later studies showed that intestinal absorption 
of the drug is very inefficient. There were still detectable serum
levels of Suramin, in the order of 1 mg %, 26 weeks after injection.
Boursnell and Wormall (1939) compared the retention of Suramin 
by different tissues after one, two and three injections of the drug. 
Some of their results have been averaged and are tabulated below:
TABLE SHOWING THE SURAMIN CONTENT OF VARIOUS
RABBIT TISSUES AFTER 1, 2 OR 3 INJECTIONS 
AT IITTERVALS OF 21 DAYS
Tissue
Kidney
Liver
Heart
1 Injection 2 Injections 3 Injections
0.163
0*058
0*061
Muscle (body wall) 0*042 
Lung 0*056
Brain 0*031
Adrenals 0*043
Spleen 0*108
Pancreas 0*037
Plasma 0*036
0*177
0*061
0*064
0*053
0*068
0.030
0*063
0*120
0*050
0*051
0.110
0*049
0*071
0*021
0*049
0*027
0*039
0*119
0*035
0*020
The above values all represent Suramin levels 
in the tissue as rag/g tissue, except for the 
plasma level, which is given as mg/ml.
Injection dose was 30 mg/kg. Animals killed 
21 days after 1 or 2 injections, but 3-injection 
group killed 70 days after third injection.
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Other data from the same paper showed that some 95% of the plasma 
Suramin was bound to plasma protein, most of it to the globulin fraction, 
and was alcohol-precipitable. This would account for a large part of 
the Suramin content of most tissues and, if the drug is generally protein- 
bound, this may also give an explanation of the low Suramin levels in 
the brain, since the brain has a comparatively low protein content. 
However, in the spleen, the Suramin level was too high to be due to 
the blood content, and no explanation for this was offered.
Accumulation of the drug in the kidney is probably due to the 
reabsorption of protein by this organ, following release of the Suramin- 
plasma protein complexes into the kidney tubules. If the carriers 
involved in reabsorption are blocked once they have taken up the 
Suramin-protein complex, they are then unable either to release the 
complex or to translocate it into the renal venules. This would result 
in both an increased retention of the drug in the kidney and the 
appearance of proteinuria, a condition frequently associated with 
Suramin therapy and so far unexplained.
Dewey and Wormall (1946) published a series of observations on 
the binding of Suramin to plasma and other proteins. It was shown 
that about 75% of Suramin added to plasma protein (up to 192 mg/20 ml 
plasma) became bound to the protein sufficiently firmly not to be 
removed either by ethanol precipitation or subsequent 6-hour extraction 
in a Soxhlet apparatus.
Similar studies on casein showed that the drug was bound to the 
protein almost instantly (no significant difference was observed between 
incubations of 0 , 60 and 120 minutes), and also suggested that a 
saturation point could be reached if a high enough Suramin concentration
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was attainedî below this saturation point, it seemed that 60-90% 
of the available Suramin would bind to casein. Very similar results 
were obtained using albumin.
A second report from Dewey and Wormall (1948) showed that red 
blood cells bound virtually no Suramin at all: the bound quantities
detected were 3-8% of that available, and this amount was probably 
due to traces of plasma protein present. This suggests that the 
presence of red blood cells in the spleen does not offer an explanation 
for the high Suramin content of this organ {vide supra).
Thus the available evidence indicates that the drug binds to the 
plasma proteins of the blood and is then circulated more or less 
uniformly throughout the body with only two sites of concentration, 
the spleen and the kidney.
Most of the enzyme studies on this drug have been carried out by 
Wormall's team. Few reports have come from elsewhere, although 
Beilinsohn (19 30) reported, for example, that 7 mM Suramin inhibits 
trypsin (although it seems likely from later studies, vide infra, that 
the trypsin preparation used here had a high content of foreign protein 
which protected the enzyme): Quastel (1931) reported that 175pM
Suramin inhibited fumarase, but had no effect on urease at pH 7*4.
Beiler eind Martin (1948) showed hyaluronidase to be very sensitive to 
the drug, losing 85% of its activity in the presence of 70 jiM Suramin 
and 15% of its activity in 0*7 pM (on a direct weight/volume calculation 
the therapeutic doses used give concentrations of 13*99 JiM and 27*99 jiM 
from 1 g/50 kg and 2 g/50 kg respectively) .
Town et al, (1949) reported that Suramin (330 jiM, pH 5*0) caused
I
90% inhibition of urease, while at a concentration of 70 jiM, the
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caused 25-60% inhibition, depending on the period of incubation of 
the inhibitor with the enzyme before addition of substrate. Neither 
pepsin at pH 2*0 nor invertase at pH 5*0 was Suramin-sensitive, though 
a trypsin preparation (presumably of higher specific activity than 
Beilinsohn's) showed a 30% inhibition in 1 mM Suramin and 20% inhibition 
in 500 JH4 Suramin, even at pH 8*9. Glucose fermentation by "yeast 
juice" (obtained by lysing yeast cells) was completely inhibited by 
Suramin levels above 20 |iM.
Wilson and Wormall (1949) reported that plasma protein mixed 
with Suramin at pH 7*5, and precipitated by bringing the pH down to 
4*0, could be dissolved and re-precipitated repeatedly by altering 
the pH in this manner, with no apparent loss of Suramin content, 
suggesting a very strong binding in the drug/protein complex. They 
showed a marked pH-dependence for the ffinding process, the amount of 
Suramin/g protein varying considerably from 228 mg Suramin/g serum 
protein at pH 1-3, to 111*2 mg/g at pH 5*0, 28 mg/g at pH 7*0 and 
7*2 mg/g at pH 9*0. A similar binding curve was obtained using egg 
albumin.
Studies in vitro and in vivo with whole and lysed red blood 
cells showed that Suramin would not penetrate the red cell membrane, 
but would combine with the haemoglobin from lysed red cells. There 
was no evidence for Suramin binding with the red cell membrane. Thus 
the impermeability of animal membranes proposed by Hawking (1940), 
who had detected little or no Suramin in the cerebrospinal fluid of 
patients with blood levels of the drug up to 17*2 mg %, was supported 
by some positive evidence.
The work of Spinks (1948) had been aimed at determining the 
"biological half-life" of various compounds related to Suramin.
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He found that the naphthalene sulphonic acid compounds showed the 
longest retention time, and his observations were supported by the 
work of Wilson and Wormall (1949), who concentrated on the retention 
time in vivo of more complex Suramin analogues,
Wilson and Wormall also showed that Suramin was not a sulphydryl- 
group inhibitor, as both urease and succinic dehydrogenase (both 
sulphydryl-dependent enzymes) were Suramin-sensitive in the presence 
of cysteine or glutathione.
Town et al. (1950) showed that, with urease, near-maximum 
inhibition was observed when the enzyme and drug were present in near 
mole-to-mole quantities, at pH 5*0. They also showed that few 
enzymes are strongly inhibited in the pH range 7*0 to 7*5, but that 
where enzymes were sensitive, sub-lethal drug concentrations would 
be high enough in vivo to cause marked «inhibition for several days 
after injection. In this paper. Town et al. also reported that the 
drug was not taken up by yeast cells, but that it would bind strongly 
to DNA preparations. Their observations on the yeast cells were 
rather different from those of Hawking (1939) , who showed that, in 
trypanosomes, virtually none of the drug was taken up by the living 
organism in vitro, but that dead preparations would take up considerable 
amounts of Suramin.
Wills and Wormall (1950) studied the effect of Suramin on a 
variety of enzymes and enzyme systems. These included soybean and 
jackbean urease, pig heart succinic oxidase, succinic dehydrogenase and 
cytochrome oxidase, yeast juice and yeast hexokinase, crude preparations 
from rat liver of choline dehydrogenase, arginase and D-amino acid 
oxidase, bovine blood and liver catalase, a- and 3-amylases from malt.
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milk xanthine oxidase, horseradish peroxidase, sheep and bovine 
carbonic anhydrase, cucumber and cabbage ascorbic acid oxidase, bovine 
glyoxalase, yeast carboxylase, invertase, almond meal 3-glycosidase, 
papain, rennin, pepsin and trypsin. Their results showed that both 
urease preparations were Suramin-sensitive: the inhibition was
pH-dependent to such an extent that it offered a method for determining 
the isoelectric point of both enzymes. (This observation, and the 
method used for such determinations, were reported in detail by Wills
(1952).) Anaerobic glucose fermentation by yeast was insensitive to 
the drug even at concentrations of 0*2m, but "yeast juice" was very 
sensitive at pH values of 6*0 and 7*0.
Other results obtained by Wills and Wormall showed that, at 
optimum pH levels for the enzymes concerned, 0*2M Suramin had no effect 
on D-amino acid oxidase, xanthine oxidase, peroxidase, tyrosinase or 
catalase. Succinic oxidase and dehydrogenase were 75% and 70% 
inhibited respectively by 250 pM Suramin, while 40% inhibition of ascorbic 
acid oxidase and choline dehydrogenase was obtained by 1 mM and 200 jiM 
Suramin respectively. A 25% inhibition of cytochrome oxidase was 
caused by 333 |iM Suramin. Papain and rennin both showed 'v»50% 
inhibition in the presence of 10 fiM Suramin, while the same degree of 
inhibition was caused in trypsin and papain preparations by 166 jiM 
Suramin.
A protective effect was observed when a protein was added to an 
enzyme under test: e.g. urease inhibition at pH 5*0 was greatly
reduced by the addition of egg albumin or serum protein. The protection 
seemed to be dependent to some extent on the isoelectric point of the 
added protein and the pH of the testj e.g. succinic dehydrogenase at
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pH 7*4 was not protected by albumin (isoelectric point 4*8) but was 
protected by serum protein (isoelectric point ^7*0 for serum y-globulin) 
Urease was also protected by "large excesses of urea" - an effect which' 
may have been due to the drug's affinity for urea.
Wills (1952) reported that, although the inhibition of tofoq was 
very pH-sensitive, the enzyme, once inhibited, appeared to be 
irreversibly modified, since increasing the pH of the solution did not 
alter the enzyme activity. He suggested that this was due to the 
vigorous binding of the drug to the enzyme, which caused sufficient 
distortion to the molecule to leave it permanently denatured. He also 
showed that similar compounds, e.g. Congo Red, "demethylated" Suramin 
and sodium dodecasulphate micelles, caused similar effects: the latter
showed reversible inhibition at 0*0005 M, but irreversible inhibition 
at 0*001 M. From these observations*it was concluded that the 
inhibition was due to the ability of the compound to bridge large areas 
of the enzyme surface, causing steric interference between enzyme and 
substrate (at 0*0005 M, the predominant conformation of the sodium
dodecyl sulphate will be as independent molecules, while at 0*001 M it
is strongly associated in micelle structures, which behave in effect 
as polyanions).
It is perhaps important to comment here that the biological 
activity of Suramin is greatly reduced if the methyl groups are removed 
from its structure (Williamson, 1962) , although déméthylation does 
not eliminate all the enzyme-inhibitory effects of the drug (Wills and 
Wormall, 1950).
More recently, there seems to have been very little work on 
the influence of Suramin on enzymes, other than the work of Davies et
al. (1971), who used a very elegant technique, injecting rats with
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Suramin 24 hours before an injection of formalin-denatured,
^^^I-labelled bovine serum albumin (2*5 mg/kg). Half-an-hour 
after this second injection the animals were killed, the livers 
homogenised and a lysosome-rich fraction prepared by taking the 
pellet formed by centrifuging the 1000 g, 10-minute supernatant at 
16,000 g for 20 minutes. Release of trichloracetic acid soluble 
**^I-iodotyrosine from this pellet was taken as a measure of proteolytic 
activity in the lysosomes. Suramin reduced the proportion of 
released from 17*2% in control animals to 15*5% (after 50 mg/kg Suramin), 
9*2% with 100 mg/kg and 3*1% with 250 mg/kg of Suramin.
Thus there is evidence for Suramin influencing the activity of 
at least one of the lysosomal enzymes in vivo.
These data, taken as a whole, suggest that Suramin might very 
well influence the activity of hydrolytic enzymes at the host-tumour 
interface and consequently reduce the degree or rate of metastasis of 
a tumour.
Only three reports have come to light connecting Suramin with 
cancer therapy: Peters et al. (1946) and williams (1945) both showed 
inhibition of solid transplanted lymphosarcomas in mice, which were 
simply growing and not metastasising. Similarly, Boyland and Sargent 
(1953) studied solid, spontaneous, mammary carcinoma transplants in 
mice, although they showed only 5% inhibition of the tumour growth 
over a 14-day period. No-one has apparently looked for anti­
metastatic effects of this drug.
3. Glucosaccharo-1,4-lactone and -Glucuronidase
B-glucuronidase (BGD) has been identified as a lysosomal enzyme 
(Walker, 1952) , sequestered almost exclusively in cell organelles: very 
little of the enzyme activity is found in the cytosol. The enzyme is 
apparently the product of a single gene (Paigen, 1961) and is therefore
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a useful model for genetic studies. The level of the enzyme varies 
greatly even between strains of a given species - e.g. the liver of 
CjH mice has only 5-10% of the activity found in DBA mice.
The enzyme appears to have at least two isoenzyme forms; the 
earliest suggestions of this come from Mills et al, (1953), who found 
three pH optima in preparations from ox spleen, while Smith and Mills
(1953) reported similar findings for ox liver BGD. The pH optima 
mentioned were at pH 3*4, 4*5 and 5-2 for ox spleen, and pH 4-3, 5*3 
and 6*5 for ox liver BGD. The activities were separable, at least 
in part, by ammonium sulphate precipitation. Recently, partial 
confirmation of these observations has come from this laboratory, where 
isoelectric focussing techniques have shown two BGD components, and 
possibly also from affinity-chromatographic separations of BGD from 
tissue extracts by the method of Harri» et al. (1973).
Preliminary results suggest that there may be one isoenzyme of 
BGD which has a lower substrate affinity than the other, since in 
the affinity column separation two enzyme peaks are apparently detectable 
using phenolphthalein 0-D-glucuronide substrate (the compound with the 
highest known affinity for BGD), while only one enzyme peak is detected 
if p-nitrophenyl &-D-glucuronide is used as a substrate. The iso­
electric points of these two components are found at pH 5*3 and pH 6»1 
(Harris, unpublished).
The role of BGD is not easy to define, because of its high level 
of activity and its ubiquity. The enzyme has been identified in all 
mammalian tissues and body fluids (Lewy and Marsh, 1960) , with the 
highest levels appearing in liver, spleen, kidney and cancer tissue.
Total body levels vary widely from one species to another: in the rat.
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for example, BGD activity is very high, with a total liver content of 
t20,000 units (Conchie et al., 1959), The ubiquity of the enzyme led 
Fishman (1967) to suggest that the BGD is primarily a structural protein 
of the lysosome, while its enzymic activity is of secondary importance.
There would seem to be only two biologically relevant substrates 
for the enzyme, and one of these is an unlikely target. The most 
likely targets are probably components of the connective tissues of 
the body, which themselves are almost as ubiquitous as BGD. There are 
two major components of the ground substance in connective tissue, 
hyaluronic acid and chondroitin sulphate, of which three types. A, B 
and C, have been identified (West et al., 1966).
Hyaluronic acid is found as a gel-like substance forming an 
interstitial filling material: it also serves as a shock-absorbing
and lubricating medium in skeletal joints, as well as an intercellular 
cementing agent, contributing to the tissue barriers of selective 
permeability that offer resistance to bacterial invasion but not to 
metabolites.
Chemically, hyaluronic acid is a polymer of a disaccharide, 
N-acetylhyalobiuronic acid. The disaccharide itself is glucuronyl- 
3“1»3-N-acetylglucosamine, which polymerises via 3-1,4-glucosaminidic 
bonds to form the polysaccharide with a molecular weight of up to 
3-8 X 10®. Its structure is depicted in Fig. 2 (overleaf).
The three forms of chondroitin sulphate which are known are also 
glucuronide derivatives, as can be seen from the diagram. Chondroitin A 
is found in cartilage, adult bone and cornea. It is a 3-1,4-polymer of 
chondrosin, which in turn is a disaccharide of glucuronyl 3-1,1-N- 
acetylglucosamine-4-sulphate. Chondroitin B, also known as dermatin 
sulphate because of its high concentration in skin, is also found in
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FIG. 2 : CONNECTIVE TISSUE POLYSACCHARIDES
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heart valves and in tendons. It, too, is a p-l,3-hexosaminidic 
polymer of a disaccharide, this time of iduronyl $-l,4-N-acetyl- 
glucosamine-4-sulphate, while chondroitin C, found in cartilage and 
tendons, is also a &-l,3-hexosaminidic polymer of a disaccharide, 
differing from chondroitin A only in that the N-acetylglucosamine is 
sulphated at the position.
All these polysaccharides are reported to cause partial 
competitive inhibition of EGD but also, after pre-treatment with 
hyaluronidase, they are all degraded in a stepwise manner by BGD 
and N-acetylneuraminidase, which act alternatively from the non­
reducing end of the oligosaccharide (Meyer, 1958).
Thus it seems likely that these mucopolysaccharides are the 
prime targets of EGD, a view supported by the well-known fact that 
their biological half lives, as shown fcy and ^^C-glucose
incorporation, are quite short, even in normal tissues. An interesting 
observation here is that, in rheumatic joints, the mucopolysaccharide 
turnover is much higher than normal, and the degree of polymerisation 
is abnormally low. In conjunction with this, acid phosphatase and 
catheptic activities are much higher than normal (Luscombe, 1963); one 
might also predict that BGD levels would be elevated in these 
circumstances.
The less likely group of substrates for BGD is made up of the 
variety of compounds which the body routinely detoxicates or inactivates, 
before excretion, by conjugation with glucuronic acid via a transferase 
(see Chapter III - 1.).
The reasons for this group of compounds being unlikely candidates 
for the role of substrate are twofold. Firstly, conjugation is an 
energy-demanding process, involving the synthesis of glucuronyl
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uridine diphosphate (UDP-glucuronide) and the body is unlikely to 
synthesize a compound in this way only for it to be degraded to its 
component parts almost instantly. Secondly, the whole purpose of 
glucuronidation is to inactivate, or make more readily excretable, 
compounds for which the body has no further use. BGD activity 
could render this process almost completely inoperable. It has been 
observed by Miettinen and Leskinen (1963) that, in the case of 
starvation in rats, which caused the UDP-glucuronyl transferase enzyme 
to be induced and therefore increased in activity, the activity of 
the hydrolytic enzyme was reduced. These authors suggested that this 
was in order to preserve the glucuronides formed.
According to Basu (1973), this suggestion may also apply to 
situations other than starvation. There are as yet no reports which 
correlate the increase of BGD activity in cancerous conditions with 
any change in the glucuronide-synthesizing enzyme activity.
Early studies on BGD were aimed at demonstrating that the 
enzyme was both synthetic (therefore involved in detoxication processes) 
and degradative. Fishman and Green (1957) succeeded in obtaining a 
small degree of transferase activity in vitro from BGD, but this 
involved concentrations of receptor molecules of between 2M and 3M,
Also, the transferase reaction would occur only between aryl and 
alicyclic glucuronides as donor molecules and aliphatic alcohols and 
glycols as acceptor molecules. This reaction is therefore too 
stringent in its conditions and too selective in its substrates to be 
acceptable as the main physiological process.
Confirmation of the presence of a second enz^nne, specifically 
responsible for the synthetic reactions, comes from a variety of
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workers (e.g. Lathe and Walker, 1958; Karimairatnam and Lewy, 1949; 
Teague, 1954). These workers have all shown that enzymic synthesis 
of glucuronides will occur in the presence of a specific inhibitor 
of BGD.
The presence of high levels of BGD activity has been shown in 
many different forms of cancer (see Chapter I, sections 1 and 3), and 
has resulted in considerable speculation about the significance of 
the enzyme, but the general consensus seems to be that it is involved 
in degradation of host connective tissues in order to facilitate growth 
and spread of the tumour.
However, this powerful invasive weapon in the tumour's armoury can 
also be turned against the tumour itself very successfully. Recently, 
Bukhari et al. (1972) have reported some very elegant work in which 
they showed that, by treating mice bearing a well-established plasma 
cell tumour weighing 30% of the mouse's weight with a single injection 
of aniline-mustard-0-D-glucuronide, a complete cure was possible.
The results of these studies showed that the glucuronide and the 
methyl ester of the glucuronide both had much higher antineoplastic 
activity than had the parent aniline mustard. The glucuronyl 
derivative had a chemotherapeutic index (Cl)* nearly twice that of 
the parent mustard, while the methyl derivative showed almost five 
times the activity of the parent compound. The explanation for this 
is suggested as being that the high BGD activity of the plasma cell 
tumour hydrolyses the drug, releasing the aniline mustard selectively 
at the site of the tumour. The aniline mustard, which has already
L D 5  Q
* Cl =   where LDjq = dose causing 50% mortality, and CDgg is dose
C D 9 0
giving cure in 90% of the cases. Therefore, the higher the Cl, the 
better the compound.
- 5 7  -
been established as a potent alkylating agent, is thus "activated" 
and reacts with surrounding cells (predominantly malignant in the 
area of high BGD activity), resulting in selective destruction of 
the tumour cells. Indications that this explanation is valid come 
from Connors et al. (1973), who have identified several metabolites 
which fit with the explanation offered.
GSL inhibits BGD with a high degree of specificity. The activity 
of this compound was discovered by L e w y  and his co-workers, who made 
a series of detailed studies in the late 1940s and early 1950s.
In 1949, Karunairatnam and L e w y  reported studies on fifty or 
more compounds as inhibitors of BGD. Of those tested they found by 
far the most effective compound to be glucosaccharic acid. More 
careful examination showed that the active agent was in fact not the 
saccharic acid but the 1,4-lactone, which forms spontaneously in 
acidic solution. Two lactones are found - the 3,6- and 1,4-lactones - 
but of these only the 1,4-lactone shows significant inhibitory activity. 
The of the "saccharic acid" was reported at 6 x 10 ^M, but when a 
clearer picture of the situation was available (Lewy, 1952) , a
of 2*5 X 10 for GSL was reported. This inhibitor was found to 
have an affinity for the enzyme 240 times greater than that of the 
substrate of highest known affinity, phenolphthalein-^-D-glucuronide.
The way in which the inhibition occurs has not yet been 
satisfactorily explained. L e w y  (1952) attempted to identify the 
side groups of the molecule required for binding. He found that 
alteration of configuration of H-C^-OH reduced inhibition, as did 
méthylation of C-3. He also suggested that the -COOH group was 
essential. However, recent evidence from our own research using the
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technique of affinity chromatography suggested that the carboxyl group 
was not essential (Harris et al., 1973). This technique involved 
the binding of GSL to a solid polysaccharide matrix by coupling a 
6-carbon diaminoalkane first to the matrix and secondly to the lactone, 
via the free -COOH group of the lactone at C-6 (according to the 
chemistry of the reaction as expounded by Cuatrecasas, 1970).
The 3,6-lactone was found to have no inhibitory effect on the 
enzyme, suggesting that reversal of the conformation of the OH-groups 
at C-2 and C-3 prevents binding of the inhibitor. Using the lactone 
of galactaric acid (reversing the -H and -OH positions at C^) also 
reduced inhibition.
Both Becker and Friedenwald (1949) and Mills, Paul and Smith 
(1953) , reported that ascorbic acid inhibited BGD. Walker and L e w y  
(1953), as well as Becker and Friedenwald, reported inhibition of the 
enzyme by heparin. The observation regarding heparin is easily 
explained, since this compound is a polysaccharide made up of the 
disaccharide glucuronic acid 2-sulphate a-1,4- linked to glucosamine: 
this disaccharide is polymerised into long chains connected by 
a-1,4-glucosaminic bonds, and one could assume that the BGD binds to 
this complex glucuronyl structure, which is a potential substrate.
Also, as the enzyme assay was carried out using phenolphthalein-#-D- 
glucuronide as a substrate, the assay measured only phenolphthalein 
production and would not have detected any enzyme activity resulting 
in cleavage of glucuronyl bonds in the heparin, which may have been 
occurring simultaneously.
The effect of ascorbic acid was, according to Becker and 
Friedenwald, to cause an 83% reduction in activity when present at 
a concentration of 20 mg % (equivalent to ^1'3mM). Thus, the inhibition
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is much less than that caused by GSL, although the structure is very
similar (Fig. 3). Levvy (1952) refutes this observation, but admits
that ascorbate did inhibit mouse liver BGD in earlier studies made in
his department (Karunairatnam, 1950, quoted by Levvy, 1952). It seems
possible that the reason for these variable results may be due to the
redox state of the compound, which, in solution, is quite readily oxidised
or reduced. Thus, in liver homogenates, which were used by both groups
of workers, it is conceivable that the ascorbate could have been either
+++oxidised by, for example, cytochrome b-Fe , fumaric acid, oxaloacetate,
or one of many other likely candidates present in such a complex mixture:
alternatively it could have been maintained in the reduced form by the
++
presence of an electron donor, such as cytochrome c-Fe
This may be why different results were obtained from different 
experiments, but it certainly seems reasonable that ascorbate should have 
some effect on BGD, since its profile is very similar to that of GSL, 
particularly when it is in the reduced form (Fig. 3).
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FIG. 3 ! SIMILARITIES BETWEEN GLUCOSACCHARO-1,4-LACTONE (GSL) Aim 
THE OXIDISED AND REDUCED FORES OF ASCORBIC ACID
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No final explanation is yet available to account for either the 
peculiarly high affinity for BGD shown by GSL or for the biosynthetic 
substrate phenolphthalein-3-D-glucuronide having so much higher an 
affinity for the enzyme than a more biologically probable substrate.
The effect of GSL in vivo has been demonstrated by Boyland,
Wallace and Williams (1958), who treated bladder cancer patients with 
4 X ig doses/day. The treatment reduced urinary BGD from four times 
the normal level to less than normal levels. Unfortunately, they made 
no studies on other biological fluids, e.g. blood or lymph, nor did 
they look for changes in tissue levels of BGD activity. Also, there 
were no reports of studies undertaken to observe the effects of GSL 
on the development of the tumour.
However, for the purpose of this study there was conclusive 
evidence that BGD is very strongly inhibited in a very specific manner 
by GSL, and it was on this evidence that this particular enzyme-inhibitor 
pair was examined.
4, Experimental Models
Since this project was concerned with enzymes of lysosomal origin, 
it seemed advantageous to use a tissue for which a large amount of data 
regarding these enzymes was available for reference.
Following the now classic reports of de Duve et al. concerning 
tissue fractionation (e.g. de Duve et al,, 1954, 1955, 1963), liver 
seemed to be a promising tissue. There were several practical 
advantages to be gained by using this material: it is a soft, non-
fibrous tissue, easily homogenised using a mild and readily-standardised 
technique, there is a widely-accepted routine procedure for fractionation 
of the tissue to yield "standard" fractions and also there is a 
considerable amount of data available relating to the constituent
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enzymes, proteins, lipids, carbohydrates, etc., which could provide 
convenient background information.
Another consideration was that, if one was working with lysosomal 
enzymes, then a tissue which had an above-average content of these 
enzymes would be an advantage. Also, the liver is involved with so 
many different metabolic processes that, if a compound under test was 
having any metabolic side-effects, there was a good chance that one 
or more of them would be detectable as a change in some aspect of the 
liver's composition.
On a more practical note, it is economically good sense to use 
a tissue which can be obtained from single animals in large enough 
quantities for the relevant observations to be made on samples from 
individuals. Here again, the liver is an ideal tissue, since it 
forms some 4-5% of the animal's body weight (if one were to work on, 
say, lymph nodes, or even spleen, several animals would be required 
in order to give enough tissue for an accurate fractionation to be 
carried out).
Finally, the liver is in many cases a prime target for a 
metastasising tumour. Thus, if the tissue surrounding a tumour site 
is (as some workers suggest) the source of the lysosomal enzymes, and 
if lysosomal enzyme activity can be modified in the normal liver, it 
may well also be modified in the tumour-bearing liver in such a way 
as to reduce or inhibit tumour growth and/or metastasis. Hence the 
selection of the rat liver as the basic model for experimentation.
Tlie problem of a metastatic model was more difficult. Among 
commonly used cancer models are solid tumours (implanted either by 
surgery or by inoculation of a tissue mash) and ascitic tumours.
- 6 2  -
Of these three alternatives, the first has .serious disadvantages 
insofar as surgical implantation involves traumatising the animal and 
running the risk of major internal infection, resulting in loss of 
animals or failure of the tumour implants to "take", thus ruining the 
experiment. The process also requires a degree of surgical ability 
in order to obtain a high rate of transplant "takes". A further 
disadvantage to sewing a piece of tumour tissue against an internal 
organ is that this is a very unphysiological process and, while it 
may produce a thriving tumour, it may not allow the resultant tumour 
to metastasise.
The second method is perhaps more acceptable, but again has 
disadvantages. Here, one must guard against bacterial infection of 
the tumour tissue during several rather complex preparative 
procedures, and the addition of protective antibiotics to the 
suspending medium may itself be deleterious to the resultant cell 
suspension. Also, such a crude preparation must of necessity contain 
a significant proportion of cell debris, subcellular organelles and, 
of course, a supernatant fluid which can contain a high level of 
enzyme activity resulting from degradation of mitochondria, lysosomes, 
etc., which may directly influence the nature of the surface of the 
whole cells about to be used for inoculation. There are some 
advantages to this method over the solid transplant system: host
trauma is minimised and also it is possible to make a rough estimate 
of the number of cells inoculated by using a cell counting method.
The biggest advantage of the system is probably that the 
"single-cell" preparation makes it possible to reproduce in some 
degree the metastatic proliferation of the normal tumour. Thus, by
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intravenous injection, one can simulate the release of cells from 
a metastasising tumour - although, needless to say, such inocula are 
unlikely to be in an actively metastatic condition simply because 
they have been prepared in this way.
The third alternative is probably the most convenient for small 
scale experiments. From a single animal, simple withdrawal of 
ascitic fluid from the abdominal cavity by means of an hypodermic 
syringe will yield sufficient cells to inoculate large numbers of 
animals with enough of the malignant cells to ensure 100% "takes".
In this way, inoculum preparation is reduced to withdrawal of 
the cells from a host animal, dilution with readily available sterile 
medium (e.g. saline, phosphate buffered saline, etc.) and subsequent 
injection of appropriate volumes of the cell suspension. The host 
trauma is also minimised to a single injection, made with a fairly 
fine needle (though the needle must not be too fine, or cell destruction 
results from the shear forces exerted during the injection process), 
and awareness by the host of the procedure is almost eliminated.
Ascitic cells are freely suspended in the ascitic fluid and require 
no preliminary mashing, sieving or other disruptive handling: 
additionally, it is not difficult to wash such cell suspensions under 
sterile conditions in order to eliminate any extracellular protein 
which may otherwise modify the cells' surfaces.
The use of an ascitic cell line seemed, therefore, to be very 
close to a "natural" metastatic process, and had the added advantage 
that one could make an accurate estimate of the number of cells in 
a given volume by means of a particle counting device such as the 
Coulter Counter. This is not really useful in the case of cell
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suspensions prepared from a tissue mash, because it counts virtually 
all the particles which pass through the counting orifice. With the 
ascitic tumour, only whole cells are involved, so that there is 
little or no cell debris to give spurious counts.
A final argument in favour of the ascitic tumour was the fact 
that the Ehrlich ascites tumour was already being maintained in the 
animal house. This procedure was decided upon as being the most 
useful compromise for a metastatic model.
It would have been possible to obtain from external sources a 
tumour line which would be transplanted in the solid form and which 
would subsequently form métastasés (e.g. the Lewis Lung sarcoma), 
but this would have involved the problems already outlined above 
as well as those of making available facilities for a new strain of 
mouse in an already overcrowded animal house.
A second tumour, the L.1210 leukaemia, was used for a single 
experiment. This is one of the most widely used and well-documented 
mouse tumours currently in use (D.C. Roberts, 1964-1973) , although it 
has two major disadvantages. Firstly, it is transplanted by homogenisa­
tion of the spleen in a Potter-Elvehjem type homogeniser and subsequent 
injection of the resultant suspension. One cannot readily count the 
leukaemic cells present and the preparation is also vulnerable to 
bacterial infection. Secondly, the tumour is maintained in C.57/DBA^ 
Fj hybrid mice - a cross which is extremely difficult to produce in 
usable numbers, as the DBA^ seems to introduce a marked weakness in 
the offspring (even pure-bred DBA^ animals have a very low rate of 
survival). Consequently, with the limited animal house facilities 
available, it would not be possible to rear animals in numbers large
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enough to provide a regular supply of statistically reliable groups 
of animals, and this particular Fj strain is not available commercially.
Another possible source of tumour cells considered was an in 
vitro culture of a standard cell line, which would enable one to harvest 
cells as and when required for inoculation into animals. The major 
disadvantages here were that such tissue culture requires specialised 
apparatus and techniques, as well as frequent maintenance operations: 
also, a large quantity of culture flasks and medium would be required 
to produce sufficient cells for an in vivo experiment.
Once the decision to concentrate on the study of lysosomal 
enzymes had been made, it seemed advisable to find a source of 
unusually high, but physiologically "normal", lysosomal enzyme activity. 
This would enable one to correlate drug effects in different tissues 
and perhaps to draw conclusions about the effects of a drug at other 
sites within the body. What was hoped for was a model which would 
display normal characteristics to the extent that it required no 
external irritation or excitation in order to exhibit high levels of 
lysosomal enzyme activity, so that one could consider the tissue to 
have at least some of the characteristics of a tumour, with no 
preliminary unphysiological trauma.
The obvious choice of tissue is one used by many workers, which 
is therefore well documented - the regenerating rat liver. The liver 
can be reduced surgically to some 25% of its normal size and will recover 
its natural weight over a period of four to five days. However, the 
partial hepatectomy requires some surgical skill and must involve 
considerable trauma for the animal: this possibility was therefore
rejected.
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It was eventually concluded that the involuting rat uterus 
might be an alternative. A comparison of newly post-partum and 
15-day post-partum rat uteri showed that the tissue lost about 3*8g 
in weight over this period, which on a linear basis suggested an 
average weight loss in the order of 10 mg/hr. Wet weight/dry weight 
comparisons and assays for protein, BGD, aryl sulphatase and APT 
all indicated that the weight change was due to tissue degradation 
and not water loss. This implied that the lysosomal enzymes might 
be concerned in tlie involution process and it was therefore decided 
to use the involuting rat uterus as a model. Very near the end of 
this project the work of Woessner came to light, offering confirmatory 
support for the approach outlined here and giving useful reference 
data for some of the enzymes studied (see Chapter III, 4.).
Thus, three experimental models were selected: the normal
rat liver for basic studies regarding the effects of a drug on the 
lysosomal enzymes, the involuting rat uterus as a tumour mimic and 
the Ehrlich ascites tumour as a model of a truly metastatic state of 
affairs, (An attempt was made to convert the L.1210 leukaemia to 
a C 57 B1-borne line, by injecting cell suspensions into these animals 
at very high dose levels in the order of 10^-10 ®^ cells per animal. 
Limited success was achieved in that the tumour "took" occasionally, 
causing the animals' death after 7-8 days, but it was never possible 
to prolong the tumour in this form beyond two passages in the new 
host animals. Success was so limited that the project was abandoned 
in favour of tlie already established EAT line available.)
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CHAPTER III 
BACKGROUND II'JFORMATION
1. Drug Detoxication
The liver is well known as the major site in the mammalian 
body for drug detoxication, the enzymes involved in the various 
processes being located in the microsomal fraction of liver 
homogenates (Brodie et al,, 1958).
It is worth remembering here that the term "microsome" does not 
identify a particular structure, or collection of structures, within 
a cell. It is applied to the complex mixture of membranes and sub- 
cellular particles which comprise a pellet obtained by a more or less 
standardised centrifugation procedure. Normally, the pellet is the 
result of centrifuging at 100 - 110,000 g for 50 -90 minutes the super­
natant from a cell or tissue homogenate previously spun for 5- 20 minutes 
at 8,000 - 10,500 g (times and g-values vary from one worker to another, 
but most fall within these ranges). The resultant "microsomal" 
pellet will contain Golgi apparatus, lysosomes, rough and smooth 
endoplasmic reticulum and ribosomes. Nuclei and the bulk of the 
mitochondria, cell debris, etc., are all eliminated by the low-speed 
centrifugation. Thus the term "microsomes" has an operational 
significance only.
The two membrane components prepared in this way are involved 
in different processes. The rough endoplasmic reticulum is well known 
to be associated with protein synthesis, while the smooth membranes 
seem to be involved in compartmentalisation of cellular constituents: 
this latter suggestion was supported by Pouts (1961) who proposed 
that drug-metabolising enzymes were located in the smooth endoplasmic
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reticulum. Remmer and Merker (1965) confirmed this suggestion by 
using sodium phénobarbital, which had previously been shown to induce 
abnormal synthesis of drug-metabolising enzymes (Kato et al., 1962) 
Remmer and Merker, 1963). Orrenius and Ernster (1964) showed that 
this enzyme induction is rapid though not instantaneous and that the 
enzymes involved included the "CO-binding pigment", now generally known 
as cytochrome
A large number of foreign compounds are metabolised in the body 
by a two-stage process (Williams, 1967). In the first phase, the 
compounds are "activated", and rendered vulnerable to the second phase - 
usually one in which the compound is so modified as to make it 
sufficiently polar to be transported across membranes and eventually 
excreted.
The "activation" stage may be one or more of oxidation, reduction 
and hydrolysis which, singly or in combination, result in the unmasking 
of functional groups, rendering an erstwhile non-reactive (and usually 
non-polar) molecule susceptible to the second phase. The product of the 
first phase is usually a more polar compound, which in the second stage 
is conjugated with a biologically available radical. The resultant 
compound is usually a water-soluble conjugate which is readily excreted. 
Some compounds which require detoxication before they are excretable 
may already possess one or more functional groups: such substances
will therefore undergo only a conjugation reaction - e.g. benzoic acid 
is conjugated primarily with glycine to form hippuric acid, or 
alternatively with glucuronic acid to form benzoyl glucuronide.
It has long been known that the reactions involved in detoxication 
are NADPH- and O -dependent (Brodie et al,, 1958). It seems that, in
— 69 —
liver microsomes, NADPH reduces a component which then reacts with 
atmospheric oxygen to form an "active oxygen" radical. This in 
turn is subsequently involved in the oxidation of a variety of substrates 
by a collection of non-specific microsomal enzymes. Gillette (1962) 
formulated the following coupled reactions for microsomal oxidation 
of drugs:
1. NADPH + H + A  h NADP + AH^
2 . AHj + Oj — — "active oxygen"
3. "active oxygen" + drug — — A + Hj 0 - oxidised drug 
Total : NADPH + H^ + 0% + d r u g  *■ NADP + H%0 + oxidised drug,
where A represents a microsomal flavoprotein, NADPH-cytochrome c reductase, 
Omura and Sato (1964) have shown that a haemoprotein, the reduced 
form of which binds CO, is present in microsomes and gives a Soret peak 
at 450nm when in the CO-complex form. They termed the protein 
"cytochrome P^gg" and suggested its importance in drug metabolism.
Remmer and Merker (1965), Kato and Gillette (1964) and Orrenius and Ernster 
(1964) have all reported that administration of phénobarbital caused a 
large increase in levels of cytochrome P^gg and NADPH-cytochrome c 
reductase, as well as drug-metabolising enzyme activities. The latter 
authors also showed that CO inhibited méthylation of N-methylaminopyrene, 
suggesting a role for P^gg in the oxidation of such drugs.
A second cytochrome, bg, has also been implicated in drug 
detoxication processes by Sato et al, (1969). Their scheme proposes 
a paired system of oxidative chains:
N A D H  k fpj ? --- ^ cyt b g  ^ CN-sensitive factor
NADPH ——— fP2 ? ——— )^ P^gg —— >• drug hydroxylation
where fpj = NADH/cytochrome bg reductase 
and fp, = NADPH/cytochrome c reductase.
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From their observations it seems that NADPH is the main source 
of electrons for Pi»50 reduction, whilst NADH reduces bg. It is known 
that P|»5o acts not only as the oxygen-activating enzyme (Omura et al.,
1965), but also as the site of substrate interaction (Remmer et al,,
1966).
Also, increase in the microsomal content of cytochrome P^gg
results in accelerated metabolism of barbiturates. This is frequently
demonstrated by the dramatic reduction in sleeping time observed on
administration of hexobarbital to phenobarbital-pretreated rats.
Thus the microsomal content of cytochromes involved in drug
metabolism, in particular P^gg, can be used as a convenient indicator
of the effects of the drugs on the liver because (a) their measurement
is quite rapid and uncomplicated and (b) they are the final link in
the enzyme system oxidising drugs in the liver.
As P^gg is inducible, increase of its concentration by a drug
could indicate that the latter is detoxicated via P . Furtliermore,
4 50
if P^gg is induced by treatment with phénobarbital, then administration 
of a second drug may affect the rate of this very rapid protein synthesis. 
(In the present investigation it was hoped to discover whether the 
lysosomal enzyme inhibitors studied also inhibited protein synthesis.)
Finally, there is a wide variety of drugs that induce cytochrome 
P^gg and it was of additional interest to determine whether the inhibitors 
under scrutiny here could be included in this category.
The second stage of detoxication was of less interest in this 
project. T"ne main point of note was that some of the early work on 
BGD was aimed at showing this enzyme to have both synthetic and 
degradative roles in vivo. The present studies could have been
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widened to include observation of the drug-glucuronide-conjugating 
enzyme, UDP-glucuronyl transferase. However, all the current 
evidence suggests that GSL has no effect on the glucuronyl transferase 
enzyme. It was felt that, if Suramin (the second inhibitor studied) 
was detoxicated by the microsomes, then preliminary activation of 
one or more of the non-polar centres of the drug would be necessary, 
and changes would probably be seen in the levels of cytochrome P^gg.
In the light of previous comments from the work of Wormall et ai., 
metabolism of Suramin was not expected, since these workers had already 
shown the drug to be excreted unchanged in the urine. No experiments, 
therefore, were carried out on the conjugating system.
2. Cell Electrophoresis
Cell electrophoresis is a technique which is claimed by some 
workers to be one of the most sensitive methods currently available 
for studying the surface of living cells. Certainly, it is a non-lethal 
method, which allows one to observe individual cells without destroying 
their integrity and to use the same cells subsequently for other 
studies - e.g. culture in vivo or in vitro.
Not only does the method permit direct measurement of cell 
surface charge, which can be calculated from the cell's electrophoretic 
mobility (Bangham et al,, 1962) but, when complemented by the use of 
enzyme probes and changes in the pH and/or ionic composition of the 
suspending medium, makes it possible to identify individual groups 
contributing to the overall cell surface charge (Forrester, Ambrose and 
McPherson, 1962; Bangham, 1961).
A comprehensive discussion of the topic has been written by 
Ambrose (1966b), who not only describes the general principles of the
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technique, but also indicates its significance in relation to cell 
malignancy.
One of the points frequently apparent in such work is that 
malignant cells seem to be more negatively charged than their normal 
counterparts. For example, Ambrose, James and Lowick (1956) showed 
that cells from hepatoma and kidney tumours have almost twice the 
mobility observed in the normal liver parenchymatous cell or kidney 
cortex cells from which these two tumours had been derived. Ben-Or 
et al. (1960) found a similar increase in cell mobility occurred when 
a liver regenerated after partial hepatectomy. In this case, the 
change occurred very rapidly, being detectable within six hours of 
surgery. Observations by Ruhenstroth-Bauer et al. (1961) suggested 
that the phenomenon was due to mitotic activity, an argument which may 
well account, at least in part, for the change in mobility of malignant 
cells, since these tend to divide more rapidly than non-malignant cells.
Abercrombie and Ambrose (1962) correlate the high negative charge 
concentration of malignant cells with their reduced "adhesiveness"
(see Chapter I. 3, also Berwick and Coman, 1968), and Ambrose (1966b) 
suggests that the increase in negativity is due largely to the presence 
of extra sialic acid residues on the cell surface. In an attempt to 
neutralise these charges, Yarnell and Ambrose (1969a) treated polyoma- 
transformed BHK cells with polylysine and toluidine blue. They showed 
that the presence of these cations was not sufficient to alter the 
cells' malignancy. However, after treatment with neuraminidase or 
trypsin (the latter had been shown by Cook, Heard and Seaman (1960) to 
release sialomucoprotein from the cells), a reduced electrophoretic 
mobility was detected. Moreover, after neuraminidase treatment, cells
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required a four-day recovery period before they showed the same degree
of malignancy as untreated cells (Yarnell and Ambrose, 1969b).
A more impressive demonstration of the sensitivity of cell
electrophoresis as an indication of malignancy is perhaps that of
Purdom et al, (1958), who used four different subcultures of the MCjM
sarcoma. The four sublines were:
M__ - a solid tumour;
bo
Mt l f ” cin ascitic form converted to a solid
subcutaneous form;
^AS ascitic derivative of
_ - a derivative of M,„ with much more rapid
AA AS
growth and metastasis patterns than the 
original
The malignancy of these four lines was in the order
"ss < "TLP < »AS < "AA •
Electrophoretic evidence gave a striking parallel, with mobilities 
in the order
"ss < "tlf < "as < "aa % 2"ss •
Discussion of the way in which malignant cells could thus 
apparently be to some extent "calibrated" in their degree of malignancy, 
and the early results obtained with Suramin in EAT development, led 
Dr. A.D. Bangham to offer the use of his apparatus (Bangham et al,,
1958) for studying the effect of Suramin on the EAT cell surface.
3. The Ehrlich Ascites Tumour
The Ehrlich Ascites Tumour (EAT) used for these studies had been
maintained in our animal house since 1963. No information from the
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animal house records gave any indication of the origin or nature 
of the tumour, or of its growth characteristics. Because of this 
dearth of information, it was decided to work from the detailed and 
comprehensive reports of Klein and his co-workers, hoping that 
information derived from one EAT strain would approximate to that 
relevant to another.
Our own experiments were hence based largely upon the data 
provided by Klein and Revesz (1953). Such an approach was necessary 
because other workers in our laboratories had found that, while the 
development of the L.1210 leukaemia tumour could be measured quite 
accurately by recording survival times, this criterion was not 
applicable to the EAT, which would kill the host animal in anything 
from 14-20 days (VJtiur et al., 1971).
In 1951, Klein had reported that*there was a "minimum effective 
dose" for ascitic cell lines. Below this dose two phenomena occurred: 
firstly the number of "takes" decreased; secondly, the further below 
this dose one went the higher was the incidence of solid tumours among 
the "takes". Above the minimum effective dose level, a guaranteed 
100% "take" rate could be obtained.
Klein and Revesz reported in 1953 several useful pieces of 
information. Firstly, they determined the intraperitoneal fluid 
level for a 20 gm mouse to be 0 » 12 ml. In this volume of fluid they 
found an average of 4*8 x lO® cells per mouse. Subsequently, they 
found that, by using an inoculum of 10® tumour cells or more, they 
were able to obtain a quantitative recovery of cells from the peritoneum. 
Secondly, the tumour cells were shown to multiply rapidly with a mean 
generation time which increased as the cell population increased. The
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shortest time was found with the lowest inoculum that they used and 
was found to be in the order of 5 hours, while the highest inoculum, 
at the later stages of the tumour's growth, had a generation time of 
80 hours. The increase in cell numbers was more or less continuous, 
providing that a minimum dose level of about 10® cells was used.
Below this does, a lag phase of 1-2 days was observed, after which 
the normal continuous increase was recorded. Klein and Revesz,were 
unable to fit their cell counts after different periods of time with 
the widely-accepted "logarithmic" plot commonly associated with 
microbiological culture systems.
They referred to the work of Mayneord (1932), who studied the 
solid Jensen sarcoma, and to that of Schrek (1935 and 1936), who 
studied the solid Walker and Flexner-Jobling tumours (1935) as well 
as the R.39 and Brown-Pearce tumours (1936). Both these workers 
showed that the development of the tumours could be followed by 
measuring their diameters and that the diameters increased in a 
linear manner with time. As the profile of the solid tumour 
approximates to a sphere, a linear increase in diameter must result 
from an increase in cell numbers following a cube function.
Following this reasoning, Klein and Revesz (1953) plotted the 
cube roots of the cell counts against time and found a good fit with 
their predictions, closer than with the logarithmic plot.
The numbers of ascitic tumour cells in an EAT-bearing mouse 
rose from the inoculum level to a maximum of 1-2 x 10® cells per 
animal, at which level the numbers no longer increased but tended to 
remain constantJ soon after this plateau had been reached, the 
animal died.
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Lettre (1951), quoted by Klein and Revesz and others, claimed 
that there was a direct relationship between the weight increase of 
the animals and the number of tumour cells present in the peritoneum. 
Klein and Revesz confirmed this observation and produced mathematical 
support for their observed data. They derived an equation which not 
only fitted their results and enabled them to calculate the proportion 
of non-tumour cells in the ascitic fluid, but also allowed them to 
plot the volume of ascitic fluid formed against time. From their 
graph, it was possible to derive peritoneal fluid volumes which could 
be compared with observations made in our own experiments.
Finally, they compared their tumour-growth data with that of 
other workers and showed that the EAT, although among the fastest- 
growing tumours known, does not develop as rapidly as embryonic tissue.
The tumour line which they used was tetrapoid and would grow 
progressively in C^H, DBA, Cg^BL, Cg^L, hybrid albino, and in Fj crosses 
of any of these strains.
The inoculation technique which they used was to suspend tumour 
cells (they used four standard dose levels for these experiments - 
0*7 X 10®, 1*8 X 10®, 17-5 X 10® and 40 x 10®) in 0*1 - 0-2 ml saline, 
which was then injected intraperitoneally (i.p.) into the animals.
Using this method, they had a 100% "take" rate and, with the Ehrlich 
ascites tumour, no spontaneous regressions in over 2,000 transplantations
4. Uterine Involution
Involution of the uterus involves an extremely rapid breakdown 
of tissue in the organ. The speed at which the degradation occurs is 
quite remarkable: Harkness and Moralee (1956) reported that the half
life of collagen (normally a very stable structure of connective tissue)
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could be as short as 24 hours in the uterus during involution.
Maibenco (1960) showed that uterine involution did not involve 
either necrosis or degeneration, but a controlled intracellular 
resorption process which would reduce the levels of materials such 
as muscle protein. He showed that uterine smooth muscle undergoes 
hypertrophy during pregnancy and, during involution, loses cytoplasm 
but does not experience cell death.
Woessner's early studies (1962) indicated that, in the case of 
collagen, the degradative process was enzymically mediated. He 
deduced a mathematical model from which he showed that the degradation 
which he observed was occurring from the outer surfaces of the collagen 
fibres. Such a demonstration supports the idea of enzymic degradation 
because the collagen fibres, while composed of tropocollagen sub-units, 
are effectively solid threads exposing only their outer surfaces to 
degradative enzymes.
In a subsequent paper, Moessner and Brewer (1963) studied the 
involution of human uteri and observed changes in both collagen and 
elastin. An example of their observations, illustrating the rate at 
which the tissue is resorbed, is given in the table below:
Collagen and Elastin Content of the Human Uterus at
Different Staaes
Non-gravid Term
Nine Days 
Post-partum
Wet Weight (g) 77*0 878 314
Collagen 4.g 33.4 11.3
(g/uterus)
Elastin 0-97 5-39 1-58
(g/uterus)
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Thus it can be seen that, in the human female, pregnancy 
results in an 11-fold increase in uterine weight,a 6 *8-fold increase 
in collagen and a 5»6-fold increase in elastin. It appears, therefore, 
that in the human some 70% of the involution has occurred in nine days 
(the 9-day figures were obtained from only four women - one at 8 days, 
two at 9 days and one at 11 days post partum, all grouped together), 
with about 77% of the collagen and 86% of the elastin having been 
resorbed.
In the same paper, Woessner and Brewer also showed that, in 
the gravid uterus, the catheptic activity (which shows two pH optima, 
one at pH 3*5 and a very minor one at pH 8*5) was reduced by about 
50% when calculated in terms of activity units per g tissue. This 
seems to be a "tissue dilution" effect, caused by a more rapid 
increase in uterine tissue than in totSl catheptic activity.
During the involution stage the catheptic activity per g tissue 
rises to about 50% above the non-gravid level, but this too seems to 
be due to a greater change in tissue than in enzyme. The total 
enzyme activity per uterus rises from the non-gravid level to about 
six times this amount during pregnancy, in which period the uterine 
weight has increased by a factor of 11.
Probably owing to a shortage of material, a comprehensive 
study on human uterine involution does not seem to have been made. 
However, Montford and Perez-Tomayo (1961) reported that the 22-day 
post partum human uterine weight is greater than that of the non-gravid 
uterus, while Morrione and Seifter (1962) observed that the uterus was 
hyperinvoluted by 28 days post partum.
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Lobel and Deane (1962) , by staining histochemically for acid 
phosphatase, showed that in the gravid uterus the number of lysosomes 
is greatly increased over that in the non-gravid organ. The likelihood 
of extracellular lysosomal enzyme activity has been made more acceptable, 
according to Woessner and Brewer, by the findings of Weiss (1962), which 
are not quoted in detail but which indicate that the generally 
accepted "physiological" pH of 7*4 may not be that which is found
at the cell surface: Weiss suggests that the value here may be as low
as 5*0, a pH which would make lysosomal enzyme activities much higher.
In a later paper on uterine involution Woessner (1965) examined 
other enzymes. He compared the levels of cytochrome c oxidase and 
aspartate aminotransferase with those found in normal liver. He found 
that the uterine enzyme activities were much lower, being at only 
2*7% and 6% of the levels found in the liver. Similar comparisons 
of acid DNAse, cathepsin, BCD, B-galactosidase and APT activities 
showed that the non-gravid uterus had 170%, 77%, 17%, 95% and 30% 
respectively of the liver activity per gram of tissue, while the 
uterine protein content was only 34% that of the liver.
From these data, Woessner concludes that the uterus is more 
oriented towards a catabolic metabolism than the liver. He pursued 
his previous studies on collagen and elastin and also looked for 
changes in the five lysosomal enzymes during and after pregnancy.
He found that DNAse does not seem to show any pattern in its change,
though the other enzymes do show recognisable patterns. BCD and
cathepsin increase throughout pregnancy to about 8 times the non-gravid 
level (as total activity per uterus). From parturition the total 
activity then falls slowly, though the activity per unit weight of
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tissue rises during the first four days post partum from about 60% 
of the non-gravid level to a maximum which is about 400% of that level. 
Thereafter, these enzyme activities decrease to the normal non-gravid 
level over a period which extends beyond the 12-day post-partum stage, 
the point at which Woessner ended his study. APT and B-galactosi- 
dase showed a slightly different pattern. They too rose to a maximum 
at about four days post partum, but returned towards normality at a 
rather slower rate: at about 12 days post partum their concentration
was still in the order of 150-200% more than the non-gravid, while 
BCD and cathepsin activity levels were a little lower, at about 
120-150% of the non-gravid levels.
These studies strongly suggest that uterine involution is a 
process mediated by degradative enzymes, most probably of lysosomal 
origin. Woessner (1965) postulates a mechanism by which their 
activity could ben encouraged. He suggests that at parturition, when 
the uterus collapses, the blood flow is constricted and the oxygen 
tension in the tissue will fall. One of the well-known ways of 
reducing the stability of lysosomes is to reduce the oxygen tension: 
this may therefore be one of the activating factors which will promote 
involution. Also, as a result of reduced circulation, the pH within 
the tissue will fall as lactic acid builds up. This will result in 
an approach to near-optimal conditions in which the lysosomal enzymes 
can act.
Further stimulation of the involution process will presumably 
come from the mother's suckling of her offspring: stimulation of the
mammary glands causes a secretion of oxytocin, a hormone which causes 
the contraction of smooth (involuntary) muscle. Such muscular
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contraction will further decrease the blood supply to the uterus 
and encourage lysosomal activity.
Thus, the original considerations which resulted in the use 
of the involuting rat uterus as a model lysosomal enzyme system 
were vindicated largely by Woessner's work, and all the evidence 
available suggested that this particular process could be a very 
useful tool for studying the effects of agents inhibiting lysosomal 
enzymes.
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CHAPTER IV 
EXPERIMENTS
1. Studies with Enzymes in vitro
In the first instance, commercially available enzyme preparations 
were studied. Samples of bovine BCD and aryl sulphatase and wheat 
germ APT were obtained from Sigma Chemicals. Substrates, phenolphthalein 
B-D-glucuronide, phenolphthalein sulphate and phenolphthalein diphosphate 
were also obtained from Sigma.
Using these materials, solutions of enzyme (10 pg/ml) and 
substrate (3 xlO M^) were made up in water and the pH optima of the 
enzymes were determined. Fresh solutions of enzyme and substrate 
were then made up in buffer of the optimum pH, and values were
measured. The method used was to start with a 10 solution of the
appropriate substrate and then to add constant volumes of doubling 
dilutions of the substrate to constant enzyme/buffer mixtures. Assays 
were carried out in duplicate and the whole procedure was repeated 
to ensure that the results were reliable.
Subsequently, rat liver enzymes were studied after extraction 
in the following way: rat livers were homogenised in saline
(25%(w/v) in 0'9% NaCl). To the homogenate was added 1% of a l%(w/v) 
solution of Arquad detergent, which was found to solubilise the 
lysosomal enzymes. The homogenate was centrifuged at 10,000g for 
20 minutes and the supernatant was aspirated, leaving the lipid and 
cell debris to be discarded. The extract was then washed free of 
detergent by repeated flushing in an Amicon ultrafilter assembly under 
a nitrogen atmosphere of 5-10 Ib/sq. in.
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The resultant enzyme solution was used for the assays after 
diluting to a suitable protein concentration (determined by carrying 
out a protein estimation before dilution).
Kjq values for the three enzyme preparations were determined 
in the same way as for the commercially available enzymes.
An identical extraction procedure was applied to a solid breast 
tumour of rats, the Huggins E tumour, which was routinely maintained 
in Sprague-Dawley rats (the tumour was transplanted by sewing small 
pieces of tissue, 3 x 3 x 10 mm, onto the left ventral lobe of the 
liver of rats under ether anaesthesia). Enzyme extracts of the tumour 
tissue were also used for determination of values.
'the effect of Suramin on enzymes from both the rat tissue and 
commercial preparations was observed by incubating enzyme and substrate 
in the presence of 70 fiM Suramin. As ^ this level of the drug was 
found to be inhibitory to the enzymes, doubling dilutions of the 
substrate were made, and the enzymes incubated in the presence of 
substrate plus drug in order to determine the concentration which 
showed a 50% inhibition of the enzyme (the K^).
A preliminary incubation of these three enzymes with glucosaccharo- 
1,4-lactone (GSL) showed that this compound gave inhibition of BGD 
specifically. determinations for GSL and BGD were made on bovine
and rat liver, as well as Huggins tumour enzymes.
2. Animal Experiments
(a) Ehrlich ascites tumour (EAT) studies
These experiments were set up using male, 25g, outbred 
Swiss albino T.O. mice, supplied by A. Tuck & Sons, Rayleigh,
Essex. The procedure was to inoculate 10® cells per animal on
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day 0, and to inject Suramin (500 pg/animal - approximately 
20 mg/kg) on day 1, after the tumour had had 24 hours in which 
to become established. Groups of animals were then killed 
after 1, 2, 3, 4, 5, 7, 10, 12 and 14 days. Experimental 
groups were usually of 20 animals, though on occasion numbers 
were reduced to 16-17/group, depending on availability.
Animals were sacrificed by cervical fracture, and 5ml 
of saline containing 100 I.U. of heparin was immediately 
injected intraperitoneally. The animals' carcasses were 
palpated for half a minute or so to circulate the saline and 
then 0*1 ml peritoneal fluid was withdrawn for cell counting.
The heparin was essential, because it was found that, in the 
older EAT tumour (10 days +),there was an increasing probability 
of the extracted fluid clotting rapidly.
For other purposes, e.g. enzyme assays on the ascitic 
fluid, as much as possible of the injected 5 ml of saline was 
withdrawn (in the case of older tumours of 10 or more days, 
the volume of liquid withdrawn frequently exceeded 10-12 ml).
In order to characterise the particular strain of EAT used 
for these studies, and to correlate with the work of Klein and 
Revesz (1953), two steps were taken. Firstly, several series 
of paired weight records were made. This involved taking equal 
numbers of untreated and tumour-bearing mice in two groups.
They were kept in as near as possible identical conditions: 
their cages were placed side by side on the rack, and particular 
attention was paid to food and water to ensure that there were 
no restrictions. The cages were cleaned at the same times and
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bedding (sawdust) always came from the same bag, in order to 
minimise differences between the two groups. Daily, from 
Monday to Friday, the animals were weighed individually at the 
same period of the day (between 9.00 a.m. and 10.15 a.m.) in 
order to minimise diurnal variations. Over several weeks it 
was possible to run some 17 series of weight comparisons in this 
way, with numbers of mice in any one group ranging from five to 
twenty, and with tumours of between 0 and 17 days old.
Eventually, all the data were pooled and a graph was 
drawn to show the difference in the rates at which normal and 
tumour-bearing mice increased in weight. The difference in weight 
was assumed to be due entirely to the presence of the tumour
(cf. Lettré, 1951 and Klein and Revesz, 1953).
Secondly, with the results «of cell-count experiments, it 
was possible to obtain a rough indication of the total number of 
ascitic cells rather than just the concentration of cells in an 
unkno\<m volum:e of peritoneal fluid. The tumour used by Klein 
and Revesz was a tetraploid line, and it was thought that the 
ploidy of our "anonymous" EAT line should be determined. In 
order to do this, a series of chromosome spreads was made and 
photographed to ascertain the chromosome number.
An experiment was made to determine the effect of 
different patterns of Suramin dosage.
Four groups of animals were inoculated with EAT on day 0.
One group was treated with Suramin on day 1, a second group on
day 5, and a third group was treated on both days 1 and 5. The 
fourth group was given no Suramin treatment. This gave four 
groups as follows:
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A - Suramin on day 1 only
B - Suramin on day 5 only
C - Suramin on days 1 and 5 
D - No Suramin
The ascitic cells were harvested, photographed and counted on 
day 8.
Another experiment was made to compare the effects of a 
10-fold increase in Suramin administered: in this case, three
groups of animals were set up and inoculated with EAT. The first 
group was untreated, the second given 0*5ml Suramin at 20 mg/kg, 
and the third given 0*5ml Suramin at 200 mg/kg. Five animals from
each group were killed on days 2, 4, 7, 11 and 14. Cells were
counted and the size frequency distribution measured. The BGD
activity was also measured for both the intracellular enz^nne and 
ascitic fluid. Electrophoretic experiments were made with 
Dr. A.D. Banghara's electrophoretic apparatus (Bangham et al.,
1958). Cells were removed and their mobilities were determined 
as described in Chapter V, 2{n).
An immunological experiment was set up as a result of the 
electrophoretic studies, because it seemed that one interpretation 
of the results was that the tumour cell surface was modified by the 
presence of Suramin. Thus it seemed worthwhile to raise antiserum 
to the normal EAT and to Suramin-treated EAT cells and to see if 
any difference between the two could be detected. Antisera were 
raised by inoculating rabbits intravenously with 1*7 % 10® tumour 
cells every 10-12 days for four weeks or so, then bleeding the 
animals after a further 10 days. The blood collected was allowed 
to clot and was then centrifuged. The sera produced were stored 
at -20°C until required for reaction with cells.
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(b) Rat liver studies ,
From the Merck Index (1968) it was found that the LD^q 
of Suramin in mice was 40 mg/kg and it seemed reasonable to 
use a dose of half the for our studies (enquiries of
Bayer Pharmaceuticals about the toxicity of the drug in animals 
produced no information: all that was offered was data relating
to dose levels in humans). The dosage of 20 rag/kg was used 
for all animal experiments (except one using EAT) and injections 
of the drug were invariably made by the intraperitoneal route.
The first experiment was to determine the effect of 
Suramin and/or PBT on normal weanling Sprague-Dawley rats after 
24 hours. Four groups of animals (mean weight 60 g) were used, 
one group injected with Suramin at 20 mg/kg, one with PBT at 
100 mg/kg, one with both Surami» and PBT, and the fourth (control) 
group with 0*5 ml of isotonic saline. After 24 hours, the 
animals were killed and their livers were removed and fractionated. 
Assays were made on the various fractions to determine protein, 
total hexose, lipid, lipid-phosphorus, BGD and APT levels. The 
treatment was repeated on a further four groups of animals 
which, after 24 hours, were injected with 100 mg/kg hexobarbitone, 
to determine their sleeping times. The whole procedure was 
repeated using Wistar rats to compare their responses with those 
of the Sprague-Dawley animals used originally.
Subsequently, a more complex four-week study was made to 
compare the effects and interactions of Suramin, GSL and PBT 
in Sprague-Dawley rats only. Eight groups of six animals were 
used, caged 12 rats to a cage, and treated as follows:
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Cage 1 Group A Controls: 0*5 ml saline, i.p.
" B Suramin (20 mg/kg, i.p.)
Cage 2 Group C PBT (100 mg/kg, i.p.)
" D PBT + Suramin
Cage 3 Group E GSL (1 mg/ml in drinking water,
ad lib.)
" F Suramin + GSL (1 mg/ml in drinking
water, ad lib.)
Cage 4 Group G PBT + GSL (1 mg/ml in drinking water,
ad lib.)
" H Suramin + PBT + GSL (1 mg/ml in
drinking water, ad lib.)
A record was made of the daily water consumption and,
from this, an estimate of GSL dosage was possible, as GSL was
\
administered in the drinking water. This was done by dissolving 
two tablets, containing 250 mg GSL, per 500 ml of drinking water. 
Previous comparison of the BGD-inhibitory activity of such 
solutions with standard GSL solutions showed that these two- 
year old tablets still contained 95-105% of the stated quantity 
of GSL. The resultant GSL solutions were rather turbid, as the 
tablets were composed largely of bran and chalk, but were 
acceptable to the animals.
To give some data on the intermediate time scale (1-28 
days), three groups of 42 animals were treated with Suramin or 
PBT or GSL only, and six animals from each group were killed 
on days 1, 3, 5, 7, 14, 21 and 28. Those surviving more than
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seven days were given further Suramin (or PBT) on every 7th 
day, up to 21 days, while those on GSL were given a constant 
Img/ml in their drinking water. Livers from these animals
were removed and fractionated as soon as the animals were 
killed. Whole liver homogenate and microsomal fractions 
only were analysed in this experiment, and these two fractions 
were treated as detailed above, except that the estimation 
of N-ethylmorphine demethylase activity was not made.
Cytochrome assays were made on the day of sacrifice, as 
previous experiments showed that these activities were lost 
rapidly on storage, even at -20°C.
I mention with gratitude the invaluable discussions 
with Dr. Basu which led to the use of PBT in this project, 
and also his kindness in demonstrating the techniques used 
for cytochrome and demethylase measurements.
(c) Rat uterus experiments
The rat uterus experiment was designed for two purposes: 
firstly, to show any change occurring in the rate of uterine 
involution due to the presence of Suramin (this would be 
apparent from a weight record) and, secondly, to indicate 
whether any effect of Suramin was exerted by way of lysosomal 
enzymes.
Virgin rats of the Sprague-Dawley strain, weighing 
180 - 230 g, were mated with males of the same strain. When 
pregnant animals neared term, they were isolated in the 
normal individual breeding cages and maintained on the standard 
stock feed (Diet 41B). Once isolated, animals were observed
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at least twice daily - before 10,15 a.m. and between 4.30 and 
5.00 p.m. - in order to record as accurately as possible the 
time of parturition. As litters arrived, the mothers were 
numbered consecutively, the odd-numbered animals being kept 
as controls. Even-numbered animals were designated "test" 
and were weighed and injected intraperitoneally with 20 mg/kg 
Suramin as soon after parturition as possible. When animals 
produced their litters overnight, they were used for later 
stages of the involution study - e.g. 8 , 12 or 15 days post 
partum - because it quickly became apparent that the rate of 
change in the uterus v;as very fast indeed during the first 
two to three days.
The intention was to build up, over a period, test and 
control groups of uterine tissue taken from at least six 
animals in each group, at 1, 2, 3, 5, 8 , 12 and 15 days post 
partum, as well as another group of six animals killed within 
the first five hours post partum (and classified as time 0).
For comparison, the uteri of six similarly-sized virgin 
females were removed and treated in the same way.
Uteri from animals which aborted, produced stillborn 
young, failed to suckle their young, or lost their litters 
before they were due to be sacrificed, were not included in 
the experiment.
Once the uteri had been removed, the two horns were weighed 
individually and the lighter of the two was then dehydrated 
to obtain a wet weight : dry weight ratio. The larger section 
of the uterus was stored at -20°C until required, at which time
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it was homogenised. Aliquots of the whole homogenate were 
then used for BGD, APT and protein determinations. Also, an 
aliquot was deproteinised and hydrolysed with HCl for 3 hours 
before measuring the "peptide" hydroxyproline. The protein . 
pellet was extracted with water in an autoclave at 15 Ib/sq.in. 
for three hours. The extract and resultant residue were each 
subsequently hydrolysed in HCl and assayed for hydroxyproline. 
These three hydroxyproline assays thus furnished data on the 
peptide-bound, collagen-bound and elastin-bound levels of the 
amino acid, and could be interpreted as indications (a) of the 
rate of collagen and elastin degradation and (b) of the amount 
of catheptic and collagenolytic activities in the tissue 
(cf. Woessner, 1955).
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CHAPTER V
METHODS
1. Preparation of Samples
(a) Liver fractions
Five liver fractions were prepared from each animal as 
follows:
The rats were killed by cervical fracture, weighed and 
dissected as rapidly as possible to remove the liver, which 
was rinsed in ice-cold 0*95% NaCl (slightly hypertonic saline 
was used to discourage cell lysis), blotted dry on filter paper 
and weighed, before being transferred to a teflon-in-glass 
Potter-Elvehjem homogeniser (0*003" - 0*005" all-round clearance). 
The tissue was homogenised with three times its weight of 
0*9% (w/v) NaCl to give a 25% homogenate (w/vj.
An aliquot (10 ml from horaogenates of less than 20 ml 
volume, 16 ml from larger volumes) was centrifuged at 10,000 g 
for 10 minutes in an MSE 40 centrifuge, using the 8 % 25 ml 
angle head, at 12,500 rev/min.
The pellet from this centrifugation was resuspended and 
made up to the original volume of the aliquot taken (either 10 or 
16 ml) and termed the "particulate fraction".
6 ml of the 10,000 g supernatant was taken and centrifuged 
at 100,000 g (37,500 rev/min.) for 1 hour, using either the 
MSE 40 with an 8 X 10 ml angle head, or the MSE 65 with a 10 x 10 ml 
angle head. The resultant pellet was resuspended and made up 
to the original volume (6 ml) in 0*9% NaCl, and termed the
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"microsomal fraction", while the 100,000g supernatant was 
termed the "cytosol".
This procedure yielded the following five fractions:
(i) Whole homogenate.
(ii) Particulate fraction - 10,000g pellet 
resuspended.
(iii) 10,000 g supernatant.
(iv) Microsomal fraction - 100,000 g pellet
resuspended.
(v) Cytosol - 100,000 g supernatant.
For all subsequent assay procedures these fractions 
were taken to be equivalent to a 25% liver suspension, i.e. 
results obtained were calculated on the basis that 1 ml of 
the fraction was equivalent to 250 mg liver.
Cytochrome P^g^ and b^ assays were carried out on 
samples immediately, since these substances deteriorate. 
Thereafter, all samples were stored at -20°C until required.
(b) Uterine samples
Pregnant rats were observed at least twice daily and were 
killed at predetermined times after parturition (see experimental 
data). Killing was done by stunning and cervical fracture, 
after which the uterus was removed rapidly. Removal of the 
uterus was a two-stage procedure to the extent that one Fallopian 
tube was removed at a time, each in turn being transferred to 
a pre-weighed vial which was then re-weighed to determine the 
weight of tissue removed. Care was taken to ensure that a 
minimum of fatty or connective tissue remained attached to the 
uterine samples.
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The lighter of the two pieces of tissue from the uterus 
was dried under two changes of acetone, and finally in an oven 
at 50°C overnight to determine the water content.
The heavier piece of tissue was stored at -20°C until 
required. For enzyme assays, etc., these frozen tissues were 
homogenised in 0*9% NaCl to give a final homogenate volume of 
25 ml, using cm Ultra Turrax homogeniser. The whole homogenate 
was then used for assays.
(c) Ehrlich ascites cells
When cell counts were to be made on the Ehrlich ascites 
tumour cells (EAT cells), the procedure was as follows;
The mice were killed by cervical fracture and 5 ml of 
0*9% NaCl containing 100 units/ml of heparin was injected i/p.
The animal's belly was then palpated for a few seconds to 
ensure that the saline was flushing throughout the body cavity; 
as much fluid as possible was then withdrawn. Cell counts were 
made on 0*1 ml aliquots of these washings, after dilution to 
20 ml with Isoton (supplied by Coulter Electronics Limited).
The resulting dilute suspension was counted on the Coulter 
Counter Model F^, using an orifice of 100 ji diameter, an attenuator 
setting of 2 and an aperture setting of 128. The threshold 
voltage was raised by increments of 13 units (it was found by 
calibration that such an increment corresponded to an increase 
of 500 p.® in the mean volume of the particles counted) .
Enzyme assays were made on the supernatant from the 
washings after centrifuging at 10,000 g for 10 minutes in an 
MSE 40 centrifuge. The cells and supernatants were stored at
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4®C until required for use. For assays on the EAT cells, the 
pellets were re-suspended in their original volume of distilled 
water and aliquots of this suspension were used.
Transplantation of the EAT was made by diluting the 
ascitic fluid obtained to give a concentration of 5 x 10® cells/ml 
and injecting 0*2 ml into male T.O. mice weighing 25 - 30 g. Such 
transplantation was made routinely once a week, and cells from 
7-1 0  day transplants were used for most experimental work.
(d) Blood samples from L.1210 leukaemia-bearing mice
For red and white blood cell counts, blood was taken from 
the tail vein by the following technique:
A short cardboard tube, about 2*5 cm diameter and 8 cm long, 
was fitted with a rubber bung at each end. The bungs were each 
drilled with a cork-borer to give holes of 4-5 mm diameter.
The mouse was then persuaded to enter the open tube, which 
was too narrow for the animal to turn around in once it had 
entered. Its egress was prevented at the opposite end by a 
perforated bung and at the point of entry by a forefinger over 
the end of the tube. This gave time to fit the mouse's tail 
through the hole in the second perforated bung, which could then 
be slipped up the animal's tail and into the cardboard tube 
(Fig. 4).
Air
Vent
FIG. 4 : TECHNIQUE FOR TAKING SAMPLES OF MOUSE BLOOD
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In this way the mouse was completely immobilised, and 
bleeding was carried out by carefully cutting off the skin 
at the tip of the tail and collecting drops of blood in 
heparinised vials. Bleeding could be encouraged by massaging 
the tail gently to squeeze out the blood or by warming the 
animal for 10 minutes beforehand in a box heated to 30*C.
Eight to ten drops were sufficient for cell counts to be made.
2. Assay Methods
(a) Sleeping times
Male weanling rats were used, of similar age and weight to 
those used for biochemical experiments. They were divided into 
groups of six animals and treated just as in the biochemical 
studies. After 24 hours the animals were injected i/p with 
hexobarbitone (10 mg/ml) in 0*9% (w/vj saline at the rate of 
100 mg/kg, and were observed as they lost consciousness. The 
time at which each individual animal lost and regained the 
righting-reflex was recorded. The duration of the period in 
which this reflex was missing was defined as the "sleeping time" 
and was recorded to the nearest minute,
(b) Protein
Protein assays were carried out by the reactions described 
by Lowry et al. (1951). Modifications were made to allow for 
the very high protein content of some of the samples (particularly 
the whole homogenate, particulate fraction and 10,000 g supernatant) 
The method used was as follows;
To a sample of 50-200 p.1 (depending on protein content) was 
added 1*95 -1*80 ml alkaline reagent (see below). The tube was
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mixed and left to stand for a minimum period of 20 minutes 
at room temperature,
200 jj.1 Folin-Ciocalteu reagent, previously diluted for 
use (see below) was added to the tube, the contents of which 
were mixed and left in a dark cupboard at room temperature for 
the colour to develop. The optical density was measured at X  
between 500 nm and 700 nm on an SP 600 spectrophotometer.
Results were calculated by reference to dilutions of a 1 mg/ml 
bovine serum albumin standard solution treated in the same 
manner.
The reason for using different wavelengths was that, while 
the colour response was linear with respect to concentrations, 
very low colour intensities could be read at 700 nm to give 
accurate assays in the 5-25 pg protein range, while at lower 
wavelengths - e.g. 500 nm - the response would extend the assay 
range up to ^480/ig protein. It must be emphasised that standard 
curves were constructed at the same wavelengths as those used 
for the protein assay, so that altogether four standard curves 
were made, at 500 nm, 550 nm, 600 nm and 700 nm, as required 
for the samples being assayed.
A further modification, which was found convenient for the 
high-protein samples, was to take a larger aliquot of perhaps 
100 ^1 and to dilute this 1 ; 10 with the alkaline reagent.
A 100 [Xl aliquot of this was used for the assay.
Reagents \
1. Alkaline reagent:
(i) 2% CuSO^ (w/v)
(ii) 2% sodium potassium tartrate (w/v)
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(iii) 2% Na^COg (anhydrous) in O'IN NaOH 
For use, 1ml (i) plus 1 ml (ii) was diluted to 
100 ml with (iii) .
2, Folin-Ciocalteu Reagent:
Supplied ready-made by B.D.H. and kept at 4®C 
until required. 2 vol. reagent was diluted 
with 3 vol. HjO for use.
(c) Lipid and Lipid-Phosphorus
The lipid assay used was a simple gravimetric method 
based on the extraction procedure of Folch et al, (1957).
To an aliquot of sample (usually 500 p.1, but for 
low-lipid samples - e.g. cytosol and microsomal samples - 
750 pi or I'Oml would be used) was added 5 vol. chloroform/ 
methanol (v/v) containing 0»1% 5N HCl.
The mixture was agitated thoroughly to form a single 
phase and left to stand for 10 minutes, whereafter 1 vol. 
water was added and mixed thoroughly. The resultant emulsion 
was centrifuged for 2 - 3  minutes at 400 g to break the 
emulsion. The lower, chloroform-rich phase was carefully 
removed and transferred to a pre-weighed screw-top test tube.
The aqueous phase was re-extracted with more acid 
chloroform/methanol (about 3 vol. was required to re-establish 
a single phase). Another 1 vol. water was added and mixed. 
The tube was centrifuged as before and the chloroform layer 
removed and pooled with the first extract.
The chloroform was subsequently evaporated over a water 
bath at 40°C (the screw top of the tube being removed for this
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purpose). Any water present was removed by leaving the 
uncapped tube overnight, under reduced pressure, in a 
desiccator containing concentrated HgSO^.
The difference in weight recorded after this procedure 
was taken as being due to the lipid of the sample.
Lipid phosphorus was measured by adding to the weighed 
lipid sample already obtained 1 ml 50% HCl, screwing on the 
tube cap firmly and autoclaving the contents for 1 hour at 
15 Ib/sq.in. After cooling to room temperature, the 
hydrolysate was used for inorganic phosphate determinations, 
according to the method of Lowry and Lopez (1946) , with some 
modification. It was found necessary to modify the method 
in order to maintain the pH close to 4*0, because if it fell 
below this value colour development was impaired. By using 
a 2M acetate buffer, the problem was eliminated. The following 
procedure was hence employed:
250 pi sample was diluted with 2 ml 2M acetate buffer.
0*2 ml ascorbic acid was added and mixed, followed by 0*2 ml 
molybdate reagent, which was also mixed. The reaction mixture 
was left in the dark for 5 minutes for the colour to develop. 
Optical densities were measured at 700 nm on the SP 600 
spectrophotometer and compared with standard curves made with 
dilutions of a standard KH^PO^ solution (136*1 mg % = 10 mM Pi)
Reagents
1. 2 M sodium acetate buffer, pH 4*0
2 . 1% ascorbic acid in water (freshly made)
3. 1% ammonium molybdate in water
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(d) Total hexoses
The anthrone reaction of Dreywood (1946) , as modified by 
Seifter et al. (1950) and Fong et al. (1953), was used, since 
glycogen and other hexose sugars could all be measured directly 
as total hexose sugars with no previous treatment. The method 
did not, of course, distinguish between free hexose sugars 
and glycogen.
The method was as follows:
To a sample of homogenate (size varied between 10 p.1 
and 250 pi, depending on hexose content) was added water to 
bring the volume up to 250 pi. 3 ml anthrone reagent was added 
and thoroughly mixed.
The reaction mixture was then heated for 15 minutes in 
a boiling waterbath and cooled in Iced water to approximately 
room temperature. The optical density was measured at 650 nm.
Standard curves were constructed using aliquots of a 
1 mg/ml glucose solution.
(e) 0-glucuronidase (BCD), acid phosphatase (APT) and aryl
sulphatase
The method used was basically that which Fishman (1947) used 
for BGD and the procedure was as follows:
To a 0*2 ml aliquot was added l«2ml acetate buffer and 
O' 1 ml substrate solution. The tube was shaken to mix and 
incubated in a waterbath at 37*C for a suitable time (the 
reaction was found to follow a linear course, so that lov; 
activities could be measured by longer incubations while high 
activities were measurable after 15 - 30 minutes).
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The reaction was stopped by addition of 0*5 ml glycine 
buffer, pH 10*4, and the optical density due to liberated 
phenolphthalein was read at 540 nm.
7i standard curve was made by diluting aliquots of a 
standard phenolphthalein solution. Enzyme activity was 
calculated as m-mol phenolphthalein liberated/hour.
With all three enzymes measured in this manner - BGD,
APT and aryl sulphatase - it was found that, at pH 5*0, a 
flocculent white precipitate could form which did not always 
redissolve in the glycine buffer. The precipitate was eliminated 
by centrifuging the sample in an MSB 4L centrifuge at 2,500 
rev/min. in the 6 X 8 head for 10 minutes. The supernatant could 
then be decanted into cuvettes for measurement.
Both aryl sulphatase and A8T could be assayed using the 
method outlined above, changing only the substrate as required.
Reagents:
(1) Acetate buffer: 0*2 M acetate, pH 5*0, containing
50 mM NaCl
. (2) Substrate solution; 3 x 10  ^M substrate (either
glucuronide, diphosphate or sulphate of phenol­
phthalein) dissolved in the acetate buffer
(3) Glycine buffer: 2M glycine, brought to pH 10*4
with NaOH.
(f) N-acetylneuraminidase
This assay, used to determine neuraminidase activity of 
ascitic fluid, was carried out by the method of Warren (1959) 
and was as follows:
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To 0*5 ml substrate solution was added 0*5 ml ascitic 
fluid. The mixture was incubated for 18 hrs. rather than for 
the shorter period - 1 hr.) suggested by Warren, because 
the enzyme activity levels in ascitid fluid were found to be 
rather low.
After incubation, the reaction was stopped by the 
addition of 0*5 ml phosphotungstic acid and centrifuged to 
precipitate the protein component.
To a 0*5 ml aliquot of the clear supernatant was added 
O' 1 ml sodium metaperiodate solution. The mixture was left 
at room temperature for 20 minutes before the addition of 1 ml 
sodium arsenite solution and 3 ml thiobarbituric acid. The 
reaction mixture was mixed well, heated at 100*C for 15 minutes 
and then cooled in ice.
4*6 ml cyclohexanone was used to extract the pink colour 
by thorough mixing and gentle centrifugation.
The coloured cyclohexanone was then carefully removed 
and read against a blank at 549 nm.
Reagents:
(1) Substrate: Mucin 2 mg/ml in 0*2 M acetate buffer,
pH 5*0
(2) Phosphotungstic acid: 5% (w/v) in water
(3) Sodium metaperiodate: 0*2 M in 9 M-H^PO^ (freshly
made)
(4) Sodium arsenite: 10% (w/v) in 0*5 M-Na^SO^, 0*05M-H^SO^
(5) Thiobarbituric acid: 0*6% (w/v) in water
(6) Cyclohexanone: AR grade
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(g) Hexosainines
These were assayed by the method of Elson and Morgan 
(1933) as modified by Rimington (1940).
The sample to be assayed was hydrolysed in 20% (v/v) ECl 
(approximately 2*5 N) in an autoclave at 15 Ib/sq.in. for one 
hour.
After cooling to room temperature, the hydrolysate was 
neutralised by adding 0*4 ml 28% (w/v) NaOH. The neutralisation 
was not exact, because the subsequent addition to an aliquot of 
the hydrolysate of 1 ml acetylacetone reagent dissolved in 
sodium carbonate completed the process.
V?hen the effervescence had subsided, the reaction mixture 
was heated at 100°C for 15 minutes, cooled to room temperature, 
and mixed with 1 ml 95% ethanol éhid 1 ml PDA reagent.
After waiting for 15 minutes for the colour to develop, 
the samples were compared with standards ranging from 0-50 pg 
galactosamine, by recording the optical density at 530 nm.
Reagents ;
(1) Cone. HCl
(2) 95% (v/v) ethyl alcohol
(3) 28% (w/v) sodium hydroxide
(4) 0*5 M - KagCOg containing 2% acetylacetone
(5) PDA reagent: 0*8 g p-dimethylaminobenzaldehyde (AR)
dissolved in 60ml ethanol/conc. HCl (v/v)
(h) Hydroxyproline
The method used for hydroxyproline assay was the Woessner 
(1961) modification of tlie original Stegemann (1958) method.
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The sample was hydrolysed in 20% (v/v) conc. HCl for 1 hour 
at 15 Ib/sq.in, 0*25 ml aliquots of the hydrolysate were mixed 
with 1*75 ml citrate buffer before 1 ml of Chloramine T reagent 
was added and mixed. The mixture was left at room temperature 
for 20 minutes for the pyrrole structure to be disrupted.
The reaction was stopped by the addition of 1 ml perchloric 
acid solution and left for a further 5 minutes, after which 1 ml 
PDA reagent was mixed in and heated at 60*C for 20 minutes.
The pink colour which developed was measured at 557 nm and 
calibrated by reference to a series of standards from 0 to 10 pg 
hydroxyproline.
Reagents;
(1) Standard hydroxyproline 100 pg/ml in 0*001 N-HCl
(2) Citrate buffer; citric acid monohydrate 50 g
glacial acetic acid 12 ml 
sodium acetate (3 H^O) 120 g 
sodium hydroxide 34 g 
The compounds were dissolved in water (about 900 ml 
total vol.), the pH was adjusted to 6-0 and the 
voluir.e made to 1 litre. The buffer was kept at 4*C 
under toluene.
(3) Chloramine T - made fresh daily; 1*41 g Chloramine T
was dissolved in 20 ml water, to which was then added 
30 ml methyl cellosolve and 50 ml citrate buffer.
(4) Perchloric acid: 3*15 N HCIO^ (27 ml of 70% HCIO^
was made to 100 ml with distilled water).
(5) PDA: 20% solution p-dimethylaminobenzaldehyde (AR grade
from Merck) in methyl cellosolve (AR grade).
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This method could be used to determine "free" hydroxy­
proline by deproteinising the test solution with equal volumes 
of 7% (v/V) Ba (OH)2 and 14% (w/v) ZnSO^. The resultant 
precipitate was centrifuged and aliquots of the supernatant could 
be assayed as above.
Collagen was assayed by adding to an aliquot of the sample 
an equal volume of distilled water and autoclaving for 3 hours 
at 15 lb/sq. in. sealed tubes. As soon as the autoclave could 
be opened safely (i.e. while it was still hot), the hot, aqueous 
extract was decanted and the residue washed twice with boiling 
distilled water (with tissue homogenates, centrifugation was 
frequently necessary during this washing procedure). The washings 
were pooled with the extract and to the combined extract was added 
0*25 vol. (approximately) conc. HCl, to produce a roughly 2*5 N-ECl 
solution. This was autoclaved at 15 Ib/sq.in. for 3 hours and 
assayed for hydroxyproline.
To calculate the amount of collagen present from the hydrox^?- 
proline value, the conversion factor of 7*46 determined by Neumann 
and Logan (1950) was applied.
Elastin was determined in the insoluble residues left after 
collagen extraction. To the residue was added 2 ml 20% (v/v) HCl 
and the resultant mixture was autoclaved at 15 Ib/sq.in. for 3 hours 
in a sealed tube. Aliquots were taken for hydroxyproline assays 
and the value obtained was converted to weight of elastin by 
applying the factor of 62*5, determined by Partridge and Davis 
(1955).
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(i) Cytochrome Pi* 50
The cytochromes were assayed only in the microsomal 
fractions. Whenever possible, these assays were carried out 
on the freshly prepared microsomal sample. Alternatively, the 
microsomal pellet was stored overnight in the freezer at -20*C , 
and resuspended immediately before making the assay. It was 
found that cytochrome content fell very rapidly in the resuspended 
preparation and was short-lived even in the solid pellet.
P%50 was measured by the method of Sladek and Mannering 
(1966) , with slight operational modifications for economy. However, 
these did not alter the basic method, which was as follows:
A 2-3 ml aliquot of resuspended microsomal pellet was 
diluted with 2 vol. 0*2 M phosphate buffer, pH 7*4, and a micro- 
spatula-tipful of sodium dithionite crystals added to reduce the 
haemoprotein present. After mixing thoroughly by inversion, 
about half the suspension was poured into a cuvette (1 cm light 
path) for use as reference. The remainder was reacted with CO by 
bubbling coal gas (containing approximately 14% CO) through it 
fairly briskly for a minimum period of 30 sec. before transferring 
it to a second cuvette.
TTie difference spectrum between the two was then drawn on 
a double-beam recording spectrophotometer, between 550 nm and 
400 nm. concentration was calculated from the difference
in extinction values at 490 nm and 450 nm using the molar 
extinction coefficient of 91/cm/mH determined by Omura and Sato 
(1964).
It was found that the calculation would simplify to a single
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factor: the actual calculation carried out on individual
samples was - E%go)132 = nM P^gg/g liver.
For operational modifications, see method following 
cytochrome bg assay.
(j) Cytochrome bg
Determinations of cytochrome bg were made essentially by 
the method of Schenkman et al, (1967). The process was as 
follows:
To a 2-3 ml aliquot of resuspended microsomal pellet was 
added 2 vol. 0'2M phosphate buffer, pH 7*4, and mixed. About 
half the suspension was then poured into each of two 1 cm cuvettes:
to one was added 10 ill of 2% NADH in 0*2M phosphate buffer pH 7*4,
which was mixed by inversion. The two cuvettes were then scanned 
in double-beam recording spectrophotometer from 480 nm to 400 nm, 
using the NADH-containing cuvette as the test sample.
The concentration of cytochrome bg was calculated from the 
molar extinction coefficient of 185/cm/mM, based on the difference 
in extinction between 424 nm and 410 nm.
As in the P\gQ assay, the calculation simplified to a single 
factor and became
(2^24 - E^iq)92 = nM bg/g liver 
In practice, it was found much more economical of sample 
to combine the two assays as follows:
A 2*5-3 ml aliquot of microsomal suspension was diluted 
with 2 vol. phosphate buffer. About 2*2 -2*5 ml was poured into 
each of two 1 cm cuvettes (the volume was not critical, providing 
the meniscus was above the light path inside the spectrophotometer)
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One cuvette was used as the reference, while to the other
was added 10 p.1 NADH solution. The contents of each cuvette
were mixed by inversion to minimise differences due to settling 
out of particles, and the difference spectrum between 480 nm 
and 400 nm was recorded. The reference sample was then
returned to the rest of the microsomal dilution and the NADH-
containing portion was discarded.
To the remainder'of the dilution was added a micro- 
spatula-tipful of sodium dithionite crystals, which were 
dissolved by inversion. About 2*2 -2*5 ml of the reduced 
suspension was poured into a cuvette, and coal gas was bubbled 
through the remainder for 30 seconds. A second cuvette was 
then filled with the CO-treated suspension (the "test" sample) 
and the contents of each cuvette mixed by inversion, before 
recording the difference spectrum between 500 nm and 440 nm.
was then calculated as already described.
This procedure reduced from 6*5 ml to 2*5 ml the volume 
of microsomal suspension necessary for separate assays.
Reagents ;
(1) 0*2 M phosphate buffer, pH 7*4
(2) 2% (w/v) NADH in phosphate buffer, pH 7*4
(3) Sodium dithionite crystals
(4) A CO gas source, conveniently coal gas
(k) Enzyrie assays by diffusion
An attempt was made to design a technique for carrying out 
a large number of enzyme assays in a rapid, trouble-free manner 
to screen large numbers of samples. The technique decided upon 
was a gel diffusion method, as follows:
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In order to assay for BGD, APT or aryl sulphatase, the 
relevant substrate was dissolved at a concentration of 
3 X 10  ^ M in 1 ml buffer, pH 5*0, IM with respect to acetate 
cUid 250 nM with respect to NaCl, The substrate solution was 
then mixed with 9 ml 2% molten agar and poured into 90 mm 
petri dishes. The agar was allowed to cool and wells about 
4 - 5  mm in diameter were cut in the gel using a cork borer. 
Subsequently, 20 p.1 aliquots of the samples to be assayed 
were placed in the wells and the dishes were incubated overnight 
at 37*C. On the following morning, the agar plates were washed 
for 2 - 3  minutes in 2 M glycine buffer, pH 10*4 (about 10 ml/plate), 
to stop the reaction and convert the liberated phenolphthalein 
to the basic form so that it was rendered visible. The plates 
were then scanned using a Joyce-Loebl Scanning Microdensitometer 
fitted with an integrating attachment and a green filter 
(approximately 560 nm maximum transmission), along two diameters 
roughly perpendicular to each other over each pink zone on the 
plate.
The principle of this technique was that the enzyme would 
diffuse away from its site of inoculation and would hydrolyse any 
substrate with which it came in contact. The level of enzyme 
activity would thus be proportional to the size of the area 
containing liberated phenolphthalein.
The same method was also applied to non-specific protease, 
using a 0*5% suspension of either casein or dehydrated, heat- 
denatured egg albumin buffered to pH 5*0. In these cases, the 
enzymic hydrolysis of substrate resulted in a clear region of 
agar developing radially from the inoculation well. No alteration
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in pH was required in order to measure the cleared area: the
scanning microdensitometer was used simply to monitor the light 
transmission through the agar plate.
(1) Cell electrophoresis
Animals were killed by cervical fracture and the peritoneal 
cells washed out in 145 mM saline containing 20 I.U./ral heparin. 
After washing in 145 mM saline without heparin, the cells were 
resuspended in 1 - 2 ml of the same solution. 1 - 5  drops of this 
suspension were added to a further 7 - 8  ml of saline to produce 
a faintly turbid solution which was used for electrophoresis.
The electrophoretic apparatus was set up and used as 
described by Bangham et al, (1958), and mobilities were measured 
as the cells traversed a grid marked on the eye-piece graticule 
of the viewing microscope.
In order to minimise the likelihood of polarisation in the 
cells, each cell was timed as it traversed sections of the grid 
in two opposing directions. This was done by reversing the 
direction of the current flowing through the electrophoretic 
chamber and only those cells which could be so timed were used 
for the experiment. Because of the discrepancy in density between 
the cells and the saline, the cells tended to sediment out. They 
would thus frequently disappear from view before the timing was 
completed, or alternatively would drift out of the plane of focus 
of the instrument. As the microscope was carefully adjusted to 
observe only cells in the stationary phase of the electrophoretic 
chamber, those drifting out of focus were considered to be entering 
a zone of fluid mobility, and their rate of migration would thus
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be affected by the motion of the suspending medium. Times 
recorded for such cells were discarded as being suspect.
Because of the unknown nature of the cell population in 
the peritoneal cavity of a mouse bearing EAT, at least 50 cells 
per animal were timed. This meant that the process was rather 
slow and extended over two days. Animals were therefore killed 
singly and cells from one animal were timed before the next was 
sacrificed. This, it was hoped, would minimise cell mortality 
in vitro and, by taking one animal from each of the four 
experimental groups in turn, any progressive changes occurring 
between days 8 and 9 of the experiment would have been apparent 
to the same extent in each experimental group.
I should like to record my thanks both to Dr. Bangham for 
offering me the use of his apparq,tus and to Mr. N.G.A. Miller 
for his patience in teaching me how to set up and calibrate the 
equipment.
(m) Chromosome counts
The cells to be spread were washed in 0*9% (w/v) NaCl 
(sterile) and incubated at 37°C for 2 - 3  days in a mixture of 
0*5 ml calf serum + 4 ml Eagle's culture medium containing anti­
biotics + 0*05 ml phytohaemagglutinin solution. For the last 
3 hours of the incubation, 0*5 ml of a 0*02% (w/v) solution of 
colchicine was added. The cells were then spun to a pellet in 
a bench centrifuge (using a low g-value to preserve cellular 
integrity) and resuspended in 75 mM KCl. After standing for 
^5 minutes in KCl, the cells were gently spun doim and the 
washings discarded. The cells were resuspended in fixative 
solution (methanol : glacial acetic acid 3:1) which was changed
three times.
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To make a chromosome spread, the cells were resuspended 
in a fresh aliquot of fixative. A drop of the suspension was 
immediately put on a clean, degreased slide and left to dry.
To ensure a good spread, it was found best to make several 
smears and to treat some of them by warming over a flame: the
more heat that was applied, the more the cells would spread 
and break.
Microscopic examination was made under oil immersion 
(lOOOx magnification) and photographs were taken of suitable 
chromosome spreads on a 35 mm Zeiss photomicrographic microscope.
The pictures were printed on 10 x 8 paper and the chromosomes 
were counted on some 30 or so prints. The mean chromosome count 
was taken as the chromosome nuiriber for the tumour cells.
Reagents :
(1) Foetal calf serum (Burroughs Wellcome)
(2) Phytohaemagglutinin (Burroughs Wellcome)
(3) Eagle's tissue culture medium (Burroughs Wellcome) 
to which was added 10 ml 10% NaHCOj, 10,000 I.U. 
penicillin and 100,000 I.U. streptomycin per 100 ml.
(4) Colchicine (Colcemid - pure, Ciba Laboratories Ltd.)
(5) Orcein lactate acetic stain: a mixture of 50 ml
70% w/v lactic acid in water and 50 ml glacial 
acetic acid was wanned and 1 g orcein dissolved in 
it. The stain was filtered before use.
(n) Cell counting for L.1210 experiment
Blood samples, taken from mice as already described, were . 
diluted 1 : 20,000 and counted in an Improved Neuberger Haemocytometer
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under a Beck microscope, using a magnification of 250x. Red 
cells were counted in this way, while a separate aliquot of 
the remaining sample was lysed by adding one drop of "Zaponin" 
(supplied by Coulter Electronics, Ltd.) before counting the 
white cell population in the same way, after diluting 1 ; 500. 
Counts were made on a minimum of ten squares of the haemocytometer 
per sample.
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CHAPTER VI
RESULTS
1. Studies on Enzymes in Vitro
The first experiments attempted were to determine the 
characteristics in vitro of the lysosomal enzymes under investiga­
tion. With this object, commercially available bovine BGD was 
checked for its pH optimum. A comparison was made of the enzyme 
alone and in the presence of 235 jiM Suramin (Fig. 5). The assay 
did not involve any pre-incubation of enzyme with inhibitor other 
than the time lag involved in pipetting operations (to minimise 
this, the enzyme was the last component added to the reaction 
mixture before transfer to the incubating waterbath).
Subsequently, the time course of the enzymic activity was 
followed and found to be linear, providing that excess substrate 
was present (Fig. 6). This observation was invaluable in later 
work when, particularly in the case of EAT experiments, very low 
enzyme activities could be measured by overnight incubations.
A linear reaction rate was also observed when similar 
experiments were made on crude rat liver APT in order to optimise 
the assay conditions.
The first problem was to obtain enzymes from the various 
tissues with reasonably high specific activities. Extraction 
procedures were kept fairly simple and, of those tried, the most 
effective was found to be the following:
Samples of tissue were roughly chopped with scissors and 
suspended in 9 vol. distilled water containing 2% Arquad cooled in
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ice. The suspension was kept cold and was homogenised by 
3 X 30 sec. bursts on the Ultra Turrax homogeniser. The homogenate 
was then centrifuged at 20,000 g for 20 minutes and the supernatant 
liquid aspirated, leaving the disc of lipid material and the 
compacted pellet to be discarded. The supernatant was taken to 
20% w/v with ammonium sulphate and the flocculant precipitate which 
formed on standing in ice for 30 -60 minutes was centrifuged down.
The Arquad and (NH^j^SO^ were then removed by one of two methods, 
which were equally effective; either the solution was dialysed 
against running tap water for 48 hours and centrifuged clear to 
give a very active extract containing approximately 9 mg protein/ml, 
or alternatively the extract was filtered in an Amicon pressure- 
operated molecular filter under an atmosphere of at 5-10 Ib/sq.in. 
and washed exhaustively with distilled water. This latter method 
had two advantages: firstly, the extract could be cleared of both
detergent and salt in 2 - 3 hours and secondly, the resultant enzyme 
preparation could be concentrated very rapidly to a few ml from an 
original volume of perhaps 200 ml or more. The filtration method 
was frequently used as it was much more convenient for other workers 
in the laboratory who required the same enzyme preparations for 
electrophoretic studies.
Using such extracts of liver, lactating breast and Huggins 
breast tumour tissue, all from Sprague-Dawley rats, the pH dependence 
and Suramin sensitivity over a pH range were determined for BGD 
(Figs, 7, 8 and 9 respectively), and for APT (Figs. 10, 11 and 12 
respectively), while aryl sulphatase activity was checked in liver 
and Huggins tissue (Figs. 13 and 14 respectively). No sulphatase
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FIG. 13
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activity at all was detectable in the rat breast preparations 
studied. Because of this and the unpromising response of aryl 
sulphatase to the presence of Suramin, this enzyme was not studied 
further.
Kjjj values were determined for both BGD and APT: the results
are listed in Table I.
To discover whether either of the compounds selected for 
this project was suited to the purpose, values were determined 
for Suramin with both APT and BGD from all three sources. Both 
Kjjj and values were obtained by calculation of regression lines 
based on Lineweaver-Burk double reciprocal plots. values are
listed in Table II.
These kinetic observations were invariably made on duplicate 
aliquots of enzyme and repeated at least twice on different batches 
of the enzyme preparation. Determinations of values for APT 
showed such peculiar results that they were repeated up to five times 
on preparations from any given source. All the results obtained 
were comparable and two typical graphs are shown in Fig. 15 (liver APT) 
and Fig. 16 (Huggins tumour APT).
The inhibition data show that the compounds selected for 
investigation were indeed worth studying in vivo, on the grounds 
that the enzymes observed showed marked sensitivity to the presence 
of the inhibitors in vitro,
2. Ehrlich Ascites Tumour Studies
The tumour which was found to be easily maintained and propagated 
in a commercially available strain of mice was the Ehrlich Ascites 
Tumour (EAT) and this was used for a variety of experiments.
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TABLE I
VALUES OBTAINED FOR g-GLUCURONIDASE AND ACID PHOSPHATASE 
FROM VARIOUS PAT TISSUES
(a) BGD
pH Liver Breast Huggins Tumour
4-5 4*25 X 10“*'m 2-19 X 10"**M 2*22 X 10”**M
5-0 1-46 X lo“‘*M 3*09 X 10”'*M 1*88 X 10"‘*M
(b) APT
pH Liver Breast Huggins Tumour
4-5 (i) 204 X 10"‘*M 
(ii) 0-106 X 10”“m
(i) 35-6 X 10"‘*M 
(ii) 0-459 X lO'^M
(i) 53-2 X 
(ii) 0-676 X lo'^N
5-0 (i) 74*1 X lo'^M 
(ii) 0-268 X 10'"‘m
(i) 10-3 X 10“‘*M 
(ii) 0-229 X 10"“m
(i) 13-7 X 10“V  
(ii) 0-206 X 10"‘*M
These results were obtained bu pooling all the 
data for any given enzyme preparation (up to 
7 Kjjj determinations were made in duplicate for 
the phosphatase preparations) and calculating 
a regression line from the combined data plotted 
as Lineweaver-Burk graphs.
Results (i) and (ii) refer to the two apparent 
values which could be detected: typical
Michaelis-Menten plots showing the two regions 
of maximal activity can be seen in Fig, 15 and 
Fig, 16,
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TABLE II
Kj^  VALUES OBTAINED FOR SURA.MIN AND CLUC0SACCHAR0-1,4-LACT0NE 
WITH B-GLUCURONIDASE a n d a c i d PHOSPHATASE FROM VARIOUS RAT TISSUES
3~Glucuronidase
pH Liver Breast Huggins Tumour
With Suramin
4*5 2" 34 X 10“‘*M 22 X 10“®M 1-94 X 10“‘*M
5-0 1-09 X 10"‘*M 21 X 10“®M 18 X 10"^M
With GSL
4-5 1-5 X 10”’m 5-1 X 10"®M 1-0 X 10"?M
5*0 2-6 X 10"?M 1-1 X 10"®M 4-1 X lO'^M
Acid Phosphatase
pH Liver Breast Huggins Tumour
With Suramin
4*5 86 X 10”®M 3*0 X lo"®M 25 X io"*M
5-0 72 X 10”‘*M 2-83 X 10"'*M 1-4 X 10”®M
Kj^  values were obtained from pooled results of 
at least two determinations, each made in 
duplicate,
The protein content of all three enzyme preparations 
was very similar■ approximately 9mg/ml, The 
"protective" effect of the protein on inhibition 
by Suramin is therefore assumed to be constant for 
these cnzyir^s.
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The Coulter Counter used for the cell counting was 
calibrated to yield both optimum counting accuracy for tumour cells 
and an indication of cell size. This was done by using a series 
of styrene-divinylbenzene polymer latex beads of known dimensions.
It was found that a linear relationship existed between the threshold 
settings of the counter and the mean volume of the particles being 
counted. Thus, by increasing the theshold setting, counts of 
smaller particles could be eliminated. In this way, by subtraction 
of counts made at any two threshold settings, the number of cells 
falling in that threshold bracket could be considered to correspond 
to the number of cells of a specific volume range.
The first aspect of the EAT study which had to be clarified 
before results could be interpreted in a significant manner was the 
problem of measuring the size of an ascitic tumour. This was done by 
weighing large numbers of mice and comparing the rate of weight 
increase between untreated control and tumour-bearing mice. The mean 
daily increase in weight of the control animals was subtracted from 
the mean daily increase in weight of the tumour-bearing animals: the 
difference was considered to be due entirely to the fluid associated 
with the tumour. The weight of the ascitic fluid was considered to 
be equivalent to the size of the tumour for any given day. Cell 
counts/ml of EAT fluid were multiplied by the estimated tumour volume 
to obtain a somewhat arbitrary value for the total number of cells 
present. No allowance was made for the possibility of animals 
"wasting" in the later stages of the tumour development (Fig. 17).
No coincidence correction was made because observation of EAT 
cells under the microscope showed some evidence of "clumping"
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or aggregation and it was felt that,as counts were bound to be 
inaccurate as a result, the simplest approach would suffice. 
Furthermore, if significant reductions in counts were to be 
achieved in the experiments made in vivo, they would have to be 
much greater than any coincidence correction factor.
The first experiment made on EAT with Suramin was to inject 
the EAT cells on day 0, and the Suramin 24 hours later. The 
animals were killed six days after the tumour had been inoculated 
and cell counts made (Table III). The cell size and frequency 
distribution was also plotted as an histogram (Fig. 18).
Further work on the development of EAT and the effect of 
Suramin was undertaken using groups of 20 animals and making cell 
counts at 2, 3, 4 and 5 days after inoculation of EAT - i.e.
1, 2, 3 and 4 days after the injection of Suramin. The results 
of these studies are tabulated in Table IV.
In conjunction with these experiments, a group of animals 
was injected with 0*5 ml Saline on day 0 and Suramin on day 1. 
They were killed in fours at daily intervals over a 14-day period, 
The peritoneal cells removed from these animals were counted as 
in the above experiments: the results over a 14-day period
showed no great variation (Table V).
Considerations of space made it impossible to organise 
experiments in which large groups of animals were killed at more 
than four time intervals. In order to follow the development of 
EAT over a longer period, the above EAT experiment was repeated 
with incubation times of 6, B, 12 and 14 days after tumour 
inoculation. The results are given in Table VI.
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TABLE III
THE EFFECT OF SURAMIN ON PERITONEAL CELL SIZE AND FREQUENCY 
DISTRIBUTION IN NORMAL AITD 6-DAY EAT-BEARING MICE'
Particle Size x 10  ^
(P*)
Cell Counts x 10
Control Suramin EAT EAT-Suramin
3 - 5 355 270 1003 444
5 r 10 110 150 1709 359
10 - 15 15 24 521 96
15 - 20 4 4 110 21
20 - 25 3 0 33 4
25 - 30 1 1 17 1
30 - 35 0 0 3 0
TOTAL 488 459 3396 925
Figures quoted are means for 20 animals.
Cells were counted in suspensions removed from 
aninals and diluted 1 : 200 in. Isoton, Cell size 
distribution was calculated by reference to 
standard diameter latex bead suspensions. This 
technique was the standard procedure used for 
all EAT counts.
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FIG. 18
EFFECT OF SURAMIN ON E.A.T CELL SIZE AND FREQUENCY DISTRIBUTION
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TABLE IV
THE EFFECT OF SURAMIN ON EAT CELL POPULATION OVER 
5 DAYS AFTER INOCULATION INTO N0RÎ>ÎAL MICE
Cell Counts x 10
-k
Cell Size x lo”^ Control Test
(p:) (Untreated EAT) (Suramin-treated EAT)
Day 2
3 - 5 247 166
5 - 1 0 290 135
10 - 15 131 15
15 - 20 1 7
Total Number Cells 669 X 10** 323 X lo“
Day 3
3 - 5 558 215
5 - 1 0 1663 192
10 - 15 445 118
15 - 20 76 52
20 - 25 25 26
25 - 30 13 11
30 - 35 10 6
Total Number Cells 2790 X 10*^ 620 X 10**
Day 4
3 - 5 1618 922
5 - 1 0 3178 1926
10 - 15 543 365
15 - 20 32 57
2 0 - 2 5 17 26
25 - 30 6 13
30 - 35 6 7
Over 35 0 0
Total Number Cells 5400 X 10** 3316 X 10**
Day 5
3 - 5 2692 1510
5 - 1 0 4228 3744
10 - 15 576 350
15 - 20 87 56
20 - 25 16 9
25 - 30 10 6
3 0 - 3 5 5 3
Over 35 4 7
Total Number Cells 7618 X lO" 5685 X 10**
Figures quoted are means derived from 18-20 mice per group
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TABLE V
THE EFFECT OF SURAI4IN ON THE PERITONEAL CELL POPULATION 
OF NORMAL MICE OVER 14 DAYS AFTER INOCULATION
Cell Counts x 10“**
Cell Size x IcT* 
(p3) Control
6 Days 8 Days 12 Days 14 Days
3 - 5 355-0 270-0 390-0 372-0 210-5
5 - 1 0 110-0 150-0 125-0 180-0 109-3
10 - 15 15-0 24-5 24-0 25-0 16-0
15 - 20 4-0 4*0 5-0 1-4 0
20 - 25 2-7 1-0 1-3 0 0
25 - 30 1-0 1-0 0-5 0 0
Total 487-7 450-5 545-8 578-4 335-8
Number Cells
Cell counts made as described under Table III,
Results given are means from groups of four 
animals.
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TABLE VI
COMPARISON OF SIZE AND FREQUENCY DISTRIBUTION OF N0Rt4AL 
AND SURAMIN-TREATED EAT CELLS OVER 14 DAYS
Cell Counts x 10 ^
Cell Size — 2
X 10 
(P*)
Day 6 Day 8 Day 12 Day 14
Un­
treated
Suramin
treated
Un­
treated
Suramin
treated
Un­
treated
Suramin
treated
Un­
treated
Suramin
treated
3 - 5 2006 888 4200 1591 8174 1218 16300 1950
5 - 1 0 3418 718 4503 2474 26774 25722 43000 38856
10 - 15 1042 183 999 483 11324 8504 13904 9808
15 - 20 220 42 1580 110 3748 2674 3828 3080
20 - 25 65 7 42 40 1152 782 1108 804
25 - 30 33 2 15 12 358 238 352 268
30 - 35 6 . 1 5 3 61 37 120 56
Over 35 3 0 2 1 - - - -
Total
Number
Cells
6793 1841 9924 4714 51591 39175 78612 54822
SUMMARY - TOTAL NUMBERS OF CELLS PER MOUSE - COMPARISON OF UNTREATED
AND SURAMIN-TREATED EAT
Day Untreated Suramin--Treated
Treated ^ 
Untreated
6 6793 X 10** 1841 X 10** 27%
8 9924 X 10** 4714 X 10** 47.5%
12 51591 X 10** 39175 X 10** 75-9%
14 78612 X 10** 54822 X 10** 69*7%
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It must be emphasised that, probably because of the variability 
of batches of mice in age and size, the response to a standard 
inoculum of EAT cells was not uniform and cell counts of one 
experiment cannot easily be matched with those of another. While 
qualitative agreement between duplicate experiments was always found, 
results varied quantitatively with respect to cell counts. Therefore, 
tables of cell counts reported here refer to one experiment only. 
Duplicate results are not recorded.
In view of the effect of Suramin on the lysosomal enzymes 
(already shown in vitro), assays were carried out on both the ascitic 
cells and on the suspending medium to determine the levels of BCD 
and APT present in the system at various stages of the tumour 
development. The results of these assays (shovm in Tables VII 
and VIII) were accumulated from several different experiments: they
can with some justification be directly compared, because results 
are expressed as activity per 10® cells. This reduces the problem 
of variation in tumour size between groups of animals.
A third enzyme, N-acetylneuraminidase, was measured on days 4,
8, 12 and 14. The activity detected was rather lower than expected, 
but was measurable after an 18-hour incubation. Results are shovm 
in Table IX and refer to the ascitic fluid only.
Non-specific proteinase activity was measured by gel diffusion, 
using casein as substrate. (See Chapter V, Section 2k). The results 
of these assays, which were carried out on the ascitic fluid and 
not on the cells,are tabulated in Table X.
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TABLE VII
LEVELS OF B-GLUCURONIDASE IN EAT CELLS AND ASCITIC FLUID 
AT DIFFERENT STAGES OF EAT DE\T:LOPbT:NT (CONTROL) AND 
THE EFFECT OF SURAMIN TREATMENT (TEST)
Enzyme activity as mmol substrate hydrolysed/hr/10 Cells 
(values in parentheses represent mmol substrate hydrolysed/hr/tumour)
Day Intracellular Extracellular
Total Activity 
(Per Tumour)
2
f Test 
[ Control
0-185
0-155
(1-66)
(1-35)
0-703
0-649
(4-63)
(5-65)
6-29
7-00
4
r Test 
Control
0*044
0*050
(1-45)
(2-70)
0-475
0-093
(1*65)
(5-02)
3-10
7-72
8
r Test 
^ Control
0*220
0-350
(3-50)
(6-51)
0-051
0-065
(8-93)
(12-09)
12-43
18-60
12
r Test 
\ Control
0-047
0*059
(8-48)
(13-27)
p-097
b-090
(18-33)
(22-94)
26-81
36-21
14
f Test 
\ Control
0-021
0-024
(11-25)
(27-53)
0-008
0-042
(4-28)
(48-17)
15-53
75-70
Results listed are means of 16-20 de terminations/group
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TABLE VIII
LEVELS OF ACID PHOSPHATASE IN EAT CELLS AND ASCITIC FLUID 
AT VARIOUS STAGES OF EAT DEVELOPMENT (CONTROL) AND 
THE EFFECT OF SURAMIN TREATMENT (TEST)
Enzyme activity as mmol substrate hydrolysed/hr/10 cells 
(values in parentheses represent mmol substrate hydrolysed/hr/tumour)
Day Intracellular Extracellular
Total Activity 
(Per Tumour)
f Test 
^ Control
1-370 (12-29) 
0-710 (6-18)
0-025 (0-16) 
0-042 (0-37)
12-45
6-55
r Test 
^ Control
2-410 (19-42) 
2-890 (156-00)
0-056 (0-18) 
0-291 (15-70)
19-60
171-70
8 i
[ Control
2-080 (47-20) 
2-770 (515-20)
0-356 (6-23) 
0-354 (65-80)
53-43
581-00
12 jTost.
^  Control
0-330 (59-50)
1-200 (269.90)
0-181 (34-20) 
0-089 (22-70)
93-70
292-60
14 1 Test
^  Control
0-450 (241-00) 
0-520 (596-50)
0-226 (120-90) 
0-083 (94-40)
261-90
680-90
Results listed are means of 16-20 determinations/group
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TABLE IX
THE EFFECT OF SURAMIN ON NEURAMINIDASE ACTIVITY IN THE 
PERITONEAL FLUID OF NORMAL AND EAT-BEARING MICE OVER 14 DAYS
mp mois N-acetylneuraminic.-acid released •
Day Control Suramin EAT EAT + Suramin
4 7-6 6*0 8-8 5-2
8 7-2 189-7 45-0
12 5-4 486*0 172-8
14 6-1 559-6 286*2
Figures are means of 10 determinations 
for all but the control group, which 
was made up of 14 animals.
TABLE X
COMPARISON OF PERITONEAL FLUID PROTEINASE ACTIVITY 
IN THE PRESENCE AND ABSENCE OF BOTH SURAMIN AND EAT IN MICE
Enzyme Activity
Untreated
Control
Suramin-
Day treated
Control
EAT EAT + Suramin
6 0-725% 0-875 1-975 0-725
8 0*325 1-350 0-350
12 0-280 1-650 0-975
14 0-250 1-750 1-075
Results expressed as % concentration of 
1 : 200 trypsin giving equivalent activity 
in control assay (see standard curve. Fig,19)
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A further study made with the Ehrlich ascites tumour was 
related to the effect of Suramin given at different stages in the 
tumour's development. A total of 80 mice was given 10® EAT cells 
per mouse on day 0; the mice were divided into four groups of 20 
animals and treated as shown on page 86, All four groups were 
killed on the eighth day after EAT inoculation and the ascites 
cells from each animal were counted (Table XI),
TABLE XI
EFFECTS OF TIMING ON SURAMIN TREATMENT OF EAT
Cell Counts x 10  ^ Made on Day 8
Cell Size Untreated Suramin on Suramin on Suramin on
X 10-2 EAT Day 1 Days 1 & 5 Day 5
2 - 5 2951 2070 2550 3511
5 - 10 4743 2019 3271 4759
10 - 15 2434 659 1366 2300
15 - 20 490 92 235 549
20 - 25 178 38 110 195
25 - 30 42 8 26 41
Over 30 12 2 7 19
TOTALS 10850x10** 4888X10**
,
7565X10** 11374X10**
Results are means of counts on 20 animals.
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Microphotographs were taken of mounted, Geimsa-stained smears 
of these cells (Figs. 20 and 21). From the photographs taken, it 
seemed that there was little morphological difference between cells 
from animals in groups 1 and 4 (i.e. untreated EAT and EAT-treated 
after five days), while groups 2 and 3 differed from groups 1 and 4 
but were very similar to each other. Photomicrographs of typical 
untreated EAT cells and Suramin-treated cells are shown (Figs.20 and 
21).
Comparison was also made of the effects of a 10-fold increase 
in Suramin dosage, applied at day 1, Animals inoculated with EAT 
cells on day 0 were given either 20 mg/kg or 200 mg/kg Suramin on 
day 1, and then killed in groups on days 2, 4, 7, 11 and 14. Total 
cell counts were recorded (Table XII) and the distribution of BCD 
between cells and ascitic fluid was measured (Table XIII).
TABLE XII
COMPARISON OF TBE EFFECT OF SURAMIN AT 20ir.g/kg AND 
200 mg/kg ON TOTAL EAT CELL COUNTS AFTER 8 DAYS
Cell Counts x 10 ^
Day 20 mg/kg 200 mg/kg
% of 20 mg/kg 
count
2 8'97 6 * 64 74*0%
4 18-55 13*37 72*0%
7 186*00 175*00 94*0%
11 255*00 189*30 70*3%
14 1147*80 536*60 46*7%
Results are means of 10 animals/group
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TABLE XIII
COMPARISON OF THE EFFECTS OF SURA.MIN AT 20 mg/kg 
AND 200 mg/kg ON THE ACTIVITY OF p-GLUCURONIDASE IN EAT
Enzyme activity at mmol substrate hydrolysed/hr/10® cells 
(values in parentheses represent mmol substrate hydrolysed/hr/tumour)
Day
Suramin
Dosage
Intracellular
Activity
Extracellular
Activity
Total Activity 
Per Tumour
20mg 0-910 (8-16) 0-150 (1*37) 9-53
2
200mg 1-12 (7-43) 0-180 (1*23) 8 - 66
20mg 0-630 (11-77) 0-200 (3*75) 15-52
4
200mg 0-570 (7-85) 0-120 (1*66) 9-51
20mg 0-069 (12-88) 0-035 (6-60) 19-48
7
200rag 0-062 (10-89) 0-022 (3-79) 14-68
20mg 0-068 (17-62) 0-059 (14*97) 32-59
11
200mg 0-070 (13-29) 0-047 (8*80) 22-09
20mg 0-016 (18-83) 0-024 (27-17) 46-00
14
200mg 0*028 (14*89) 0-021 (11*44) 26-33
Results are means of 10 determinations/group
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The electrophoretic mobility of the EAT cells was compared 
with that of normal mouse peritoneal cells. Suramin-treated normal 
mouse and Suramin-treated EAT peritoneal cells. This experiment was 
not repeated, as the apparatus used for these measurements was not 
readily available, the work reported here having been done in the 
laboratory of Dr. A.D. Bangham at the A.R.C. Institute of Animal 
Physiology, Babraham, Cambridge.
The results are shown on the graph (Fig. 22) and are expressed 
as electrophoretic mobilities in p/second/volt/cm. The more mobile 
the cells, the stronger is the charge on their surfaces.
From this experiment, it seemed that Suramin must be having a 
profound effect on the surface of the tumour cell type: an attempt
was made to test this observation immunologically. Two rabbits were 
injected subcutaneously with 5 x lo^ EAT cells, together with 1 ml 
Freund's incomplete adjuvant at 10 - 12 day intervals for six weeks 
(four injections) . The animals were tiien bled, and the serum was 
removed. Smears of untreated and Suramin-treated EAT cells were 
exposed to the rabbit antiserum and subsequently were treated with a 
fluorescent anti-rabbit serum to detect any rabbit antibodies bound 
on tlie EAT cell surfaces. The technique, which is reportedly very 
sensitive, was not as straightforward to use as had been suggested 
in the literature and results were found to be unrepeatable from day 
to day. On separate occasions both types of cell, or neitlier, 
would react. The untreated cells may have reacted with the anti­
serum a little more frequently than the Suramin-treated cells, but 
the result was not clear-cut, since both types could be shovm to 
fluoresce.
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riQ. 22
ELECTROPHORETIC MOBILITY OF NORMAL MOUSE PERITONEAL CELLS
AND E.A.T. CELLS AND THE EFFECTS OF SURAMIN
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Finally, In order to try to establish whether there was 
any similarity between the EAT line used for these studies with 
that used in the classical work of Klein and Revesz (1953), a 
chromosome count was made on some 30 or so smears of cells taken 
from five untreated EAT-bearing animals. The number of 
chromosomes found in any one cell varied quite widely, from 
38 to 48. The mean, taken as the chromosome number, was found 
to be 44*5, which suggested that this tumour cell line was 
hyperdiploid, as the normal mouse cell has a chromosome number 
of 40.
3. Studies on Rat Livers
A study was made of the effects of Suramin in vivo in 
normal, healthy rats. Careful observation of a variety of liver 
properties was made, in the first instance, 24 hours after the 
administration of a single dose of Suramin. Rat livers treated 
in this way were compared with those from animals treated with 
either PBT or Suramin and PET together. All three liver types 
were compared with normal, untreated rat livers. As an
extension of the study, the experiment was carried out on both 
Sprague“Dawley and Wistar strains of rat, to see whether there 
was any significant strain difference. Results are tabulated in 
Tables XIV to XXIII.
The above experiment was extended to a four-week study on 
Sprague-Dawley rats, with animals being treated once a week and 
groups of animals being killed on days 1, 3, 5, 7, 14, 21 and 28. 
Also the treatments were modified slightly: four groups of
animals were used, one being given saline injections, the second
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Suramin, the third PBT and the fourth GSL at 1 mg/ml in their 
drinking water ad lib, A daily record of the water consumption 
of the GSL-treated rats was kept (Fig. 23) and from this the mean 
GSL dose/rat/day was calculated.
30-
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FIG. 23 WATER CONSUMPTION OF PATS IN PJELATION TO BODY V7EIGKT
On sacrifice, the animals' livers were removed, weighed and 
homogenised in the usual manner. Aliquots of the whole homogenate 
and the microsomal pellets were assayed and the results are given 
in Tables XXVIII to XXXIX.
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TABLE XIV
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AND WISTAR 
STRAINS OF RAT TO A 24-HOUR TREATMENT WITH EITHER 
SURAMIN AND/OR PHENOBARBITONE - BODYWEIGHT INCREASE 
FROM DAY 0 TO DAY 1
(Means for 6 animals ± s.e.m.)
Sprague-Dawley Wistar
Control 3*8 ± 0-2 5«9 ± 0.2
Suramin 4*4 ± 0*3 5*7 ± 0-2
PBT 4*6 ± 0*3 6*5 ± 0*3
Suramin + PBT 5-2 ± 0-2 5-1 ± 0*2
TABLE XV
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AND WISTAR 
STRAINS OF RAT TO A 24-HOUR TREATMENT WITH EITHER 
SURAMIN AND/OR PHENOBARBITONE - LIVER WEIGHT AS A 
PERCENTAGE OF BODYWEIGHT
(Means for 6 animals ± s.e.m.)
Sprague-Dawley Wistar
Control 4.56 ± 0.34 4.68 ± 0.21
Suramin 4-83 ± 0.07 4.93 ± 0.15
PBT 5'79 ± 0-20 5-70 ± 0.20
Suramin + PBT 5'34 ± 0.14 5*78 ± 0*18
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TABLE XVI
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AND WISTAR 
STRAINS OF RAT TO A 24-HOUR TREATMENT WITH EITHER 
SURAMIN AND/OR PHENOBARBITONE - SLEEPING TIMES (IN MINUTES)
INDUCED BY HEXOBARBITAL
(Results as means ± s.e.m. for 6 animals/group)
Sprague-Dawley Wistar
Control 69-0 ± 6*5 102-2 ± 12-1
Suramin 71*0 ± 10-9 89-7 ± 11-4
PBT 16-7 ± 4*6 18-3 ± 2-7
Suramin + PBT 23*8 ± 4-7 16*0 ± 0*9
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TABLE XVII
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AND WISTAR 
STRAINS OF RAT TO A 24-HOUR TREATMENT WITH EITHER 
SURAMIN AND/OR PHENOBARBITONE - SUBCELLULAR DISTRIBUTION 
OF LIVER PROTEIN AS mg/g TISSUE
(Means of duplicate determinations on 6 animals ± s.e.m.)
Sprague-Dawley Wistar
Particulate Fraction
Control
Suramin
PBT
Suramin + PBT
47*1 ± 2-5 
49*5 ± 3-2 
47*5 ± 4*9 
48-9 ± 3-6
47-5 ± 5*5 
44'3 ± 5*2 
44*8 ± 5-2 
54-4 ± 4*7
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
31*4 ± 1-7
27-8 ± 1-7 
29-4 ± 1-6
28-9 ± 1«1
28-5 ± 0*9 
30*0 ± 1*3 
28-3 ± 1*7 
26-8 ± 1*1
Microsomes
Control
Suramin
PBT
Suramin + PBT
15*7 ± 1-4 
16*4 ± 1-5 
21-6 ± 1-6 
26*9 ± 1*5
13*1 ± 0*7 
12-4 ± 1*5 
14*1 ± 1-0 
13*2 ± 1*1
Cytosol
Control
Suramin
PBT
Suramin + PBT
9*2 ± 0-7 
9*0 ± 0*6 
11*5 ± 1*2 
11*5 ± 0*9
19*0 ± 0*9 
19*3 ± 0*5 
18*5 ± 0*9 
18*7 ± 0*6
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TABLE XVIII
COMPARISON OF RESPONSES OF SPRAGUE-PAWLEY AND WISTAR STRAINS 
OF RAT TO A 24-HOUR TREATMENT WITH EITHER SURAMIN AND/OR 
PHENOBARBITONE - SUBCELLULAR DISTRIBUTION OF LIVER TOTAL HEXOSES
AS mg GLUCOSE/g TISSUE
(Results as means of duplicate determinations ± s.e.m. on 6 animals)
Sprague-Dawley Wistar
Particulate Fraction
Control
Suramin
PET
Suramin + PBT
8-19 ± 0*45 
9*61 ± 0-30 
21*90 ± 1-70 
9*37 ± 1*12
8*72 ± 0*50 
9*00 ± 0*90 
15*10 ± 1*70 
13*70 ± 1*40
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
36*80 ± 1*70 
26*90 ± 0*40 
28*30 ± 1*00 
15*10 ± 0*50
27*00 ± 1*50 
19*50 ± 1*70 
44*70 ± 6*30 
28*40 ± 2*70
Microsomes
Control
Suramin
PBT
Suramin + PBT
11*90 ± 2*30 
12*30 ± 1*10 
21*20 ± 0*70 
15*10 ± 0*30
6*21 ± 0*41 
6*09 ± 0*43 
7*24 ± 0*41 
7*69 ± 0*44
Cytosol
Control
Suramin
PBT
Suramin + PBT
1*97 ± 0*46 
1*81 ± 0*44 
2*30 ± 0*38 
2*82 ± 0*34
1*91 ± 0*13 
1*80 ± 0*19 
2*14 ± 0*11 
1*62 ± 0*11
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TABLE XIX
COMPARISON OF RESPONSES OF SPR?iGUE-DA?7LEY AND WISTAR STRAINS 
OF RAT TO A 24-HOUR TREATMENT WITH EITHER SURAMIN AND/OR 
PHENOBARBITONE - SUBCELLULAR DISTRIBUTION OF LIVER LIPIDS
AS mg/g TISSUE
(Results as means of duplicate determinations ± s.e.m. on 6 animals)
Sprague-Dawley Wistar
Particulate Fraction
Control
Suramin
PBT
Suramin + PBT
48*5 ± 2.2 
41-3 ± 2-5 
47*4 ± 1*9 
48*1 ± 2*6
44*6 ± 2-6 
40-9 ± 3-1 
47*3 ± 1*7 
48*4 ± 2*1
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
44-2 ± 1-3 
37-3 ± 1*9 
47-4 ± 2-8 
49*3 ± 1-9
39-0 ± 2-9 
28-0 ± 3*0 
35*3 ± 4-4 
55-4 ± 8*3
Microsomes
Control
Suramin
PBT
Suramin + PBT
17*2 ± 2*4 
21-3 ± 1*4 
30-7 ± 2*1 
39*4 ± 2*2
15-7 ± 1-9 
18*7 ± 0-9 
31*2 ± 4*1 
24*0 ± 3*5
Cytosol
Control
Suramin
PBT
Suramin + PBT
21*2 ± O' 1 
24*8 ± 1*9 
39*2 ± 1-8 
26-4 ± 1-2
21*6 ± 2-0 
14-8 ± 1*4 
19*6 ± 0*9 
19-7 ± 0*6
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TABLE XX
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AKTD WISTAR STRAINS 
OF RAT TO A 24-HOUR TREATMENT WITH EITHER SURAMIN AND/OR 
PHENOBARBITONE - SUBCELLULAR DISTRIBUTION OF LIVER LIPID 
PHOSPHORUS AS jlMOL PO„/g TISSUE
(Results as means of duplicate determinations ± s.e.m. on 6 animals)
Sprague-Dawley Wistar
Particulate Fraction
Control
Suramin
PBT
Suramin + PBT
42*7 ± 0-8 
42*5 ± 1'6 
47-6 ± I'l 
40*9 ± 0*7
105*5 ± 3*5 
120*1 ± 2*1 
135*6 ± 2*4 
130*4 ± 2*0
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
40-1 ± 1-9
36-3 ± 1-8
37-8 ± 1*5 
40*4 ± 0*4
139-6 ± 5*7 
180*0 ± 4*8 
141*3 ± 4*3 
143*0 ± 5*2
Microsomes
Control
Suramin
PBT
Suramin + PBT
33*2 ± 3*1 
32*7 ± 2*9 
14*5 ± 0*9 
15*4 ± 1*1
132*8 ± 11*1 
89*6 ± 5*2 
77*6 ± 9*0 
132*2 ± 9*0
Cytosol
Control
Suramin
PBT
Suramin + PBT
16*8 ± 0*6 
12*3 ± 0*8 
31*5 ± 3*8 
34*6 ± 3*6
39*9 ± 2*1 
30*6 ± 2*0 
26*6 ± 1*1 
28*5 ± 1*7
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TABLE XXI
COMPARISON OF RESPONSES OF SPPAGUE-DAV7LEY AND WISTAR STRAINS 
OF RAT TO A 24-HOUR TREATMENT WITH EITHER SURAMIN AND/OR 
PHENOBARBITONE - SUBCELLULAR DISTRIBUTION OF ^-GLUCURONIDASE 
ACTIVITY AS mMOL SUBSTRATE HYDROLYSED/HR/q LIVER
(Results as means of duplicate determinations ± s.e.m. on 6 animals)
Sprague-Dawley Wistar
Particulate Fraction
Control
Suramin
PBT
Suramin + PBT
1*66 ± 0*05 
1*74 ± 0*09 
1-76 ± 0-03 
1*67 ± 0-03
1*42 ± 0-18 
1-74 ± 0*04 
1-77 ± 0*06 
1*72 ± 0-03
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
4-29 ± 0-15 
4-13 ± 0-14 
3*63 ± 0-35 
4-23 ± 0-09
4-48 ± 0*13 
4*20 ± 0*09 
4*06 ± 0*16 ' 
4-04 ± 0-23
Microsomes
Control
Suramin
PBT
Suramin + PBT
4-32 ± 0*25 
4*53 ± 0-31 
4-01 ± 0*52 
5*07 ± 0-30
1-72 ± 0*03 
1-59 ± 0*07 
1-59 ± 0*02 
1-54 ± 0-06
Cytosol
Control
Suramin
PBT
Suramin + PBT
1'17 ± O'13 
1'12 ± 0*07 
0*79 ± O'06 
1*29 ± 0'17
2'23 ± 0'21 
1'82 ± O'11 
1*86 ± O'24 
1'68 ± O'13
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TABLE XXII
COMPARISON OF RESPONSES OF SPRAGUE-DAWLEY AND WISTAR STRAINS 
OF RAT TO A 24-HOUR TREATMENT WITH EITHER SURAMIN AND/OR 
PHENOBARBITONE - SUBCELLULAR DISTRIBUTION OF ACID PHOSPHATASE 
ACTIVITY AS irJ-lOL SUBSTRATE HYDROLYSED/HR/g LIVER
(Results as means ± s.e.m. for 6 duplicate determinations)
' Spr ague-Dawley Wistar
Particulate Fraction
Control
Suramin
PBT
Suramin + PBT
416 ± 18 
525 ± 39 
454 ± 30 
513 ± 32
383 ± 36 
448 ± 27 
400 ± 38 
418 ± 18
10,000 g Supernatant
Control
Suramin
PBT
Suramin + PBT
199 ± 24 
193 ± 11 
153 ± 14 
177 ± 13
186 ± 13
187 ± 10 
168 ± 12 
169 ± 13
Microsomes
Control
Suramin
PBT
Suramin + PBT
98 ± 20 
100 ± 14 
103 ± 15 
103 ± 19
119 ± 19 
160 ± 26 
147 ± 14 
144 ± 12
Cytosol
Control
Suramin
PBT
Suramin + PBT
133 ± 21 
123 ± 14 
125 ± 17 
185 ± 32
50 ± 12 
34 ± 4 
25 ± 8 
25 ± 6
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TABLE XXIII
DETOXICATING ENZYME ACTIVITIES OF THE MICROSOMAL MEMBRANE 
PREPARATION FROM 6 SPRAGUE-DAWLEY RATS, 24 HOURS AFTER 
ADMINISTRATION OF DRUGS
Demethylase (expressed as fimol HCHO formed/hr/mg 
microsomal protein ± s.e.m.)
Control 0*24 ± 0-04
Suramin 0*25 ± 0-03
PBT 0*44 ± 0*06
-
Suramin + 
PBT
0*31 ± 0*04
Cytochrome P450 (nmol/mg microsomal protein ± s.e.m.)
Control 0-75 ± 0*08
Suramin 0*79 ± 0-06
PBT 1*76 ± O'10
Suramin + 
PBT
1*10 ± 0*09
Cytochrome (nmol/mg microsomal protein ± s.e.m.)
Control 0*35 ± 0*04
Suramin 0-35 ± 0*05
PBT 0-72 ± 0*08
Suramin + 
PBT
0*51 ± 0-06
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TABLE XXIV
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - 4-WEEK RECORD
OF BODYWEIGHTS IN GRAMS
(Means of 6 animals ± s.e.m.)
Day Control Suramin PBT GSL
1 72*7 ± 2-2 70'1 ± 1*5 69*9 ± 3*2 67*3 ± 2*2
3 82*7 ± 3*0 70*9 ± 1-2 83*8 ± 3*4 81*0 ± 3*6
5 95-5 ± 0-98 90'6 ± 2'3 90'2 ± 2'8 93'6 ± I'O
7 106*7 ± 3*3 104'9 ± 3'7 104'3 ± 6'5 107'5 ± 3'6
14 118-0 ± 4*8 114'5 ± 5'4 120'0 ± 4'5 126'2 ± 4'8
21 165*6 ± 6*6 154'6 ± 4'4 160'9 ± 5'3 158'3 ± 1'7
28 176-1 ± 5*8 173'8 ± 1'6 160'7 ± 4'0 170'7 ± 2'3
TABLE XXV
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - MEAN BODYWEIGHT
INCREASES IN GRAMS
Day Control Suramin PBT GSL
1-3 10*0 0*8 13*9 13*7
3-5 12*8 19*7 6*4 12*6
5-7 11*2 14*3 14*1 13*9
7-14 12*3 9*6 15*7 18*7
14-21 47-6 40*1 40*9 32*1
21-28 10*5 19*2 -0*2 12*4
TOTAL 104*4 103*7 90*8 103*4
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TABLE XXVI
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-V7EEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - MEAN LIVER WEIGHTS
(Means
IN GRAMS 
of 6 animals ± s.e.m.)
Day Control Suramin PBT GSL
1 3"10 ± 0*45 3-33 ± O'10 3'70 ± O'17 3'40 ± 0'03
3 3*82 ± O'12 3'46 ± O'18 4'20 ± 0'41 3*93 ± 0*26
5 4'46 ± 0'23 3'90 ± 0'21 4*03 ± 0"31 3'96 ± 0'58
7 4'90 ± O'11 4'86 ± 0'40 5'03 ± 0'03 4'96 ± 0"63
14 5'90 ± 0'20 5'73 ± O'38 5'63 ± 0'63 6'40 ± 0'08
21 7'42 ± 0'41 7'53 ± 0'39 8'13 ± 0'28 7'36 ± 0'65
28 8'02 ± 0'51 8'35 ± 0'15 7'93 ± 0'31 7'40 ± 0'47
TABLE XXVII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A'4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - LIVER WEIGHTS AS
PERCENTAGES OF BODYWEIGHTS
(Results as means ± s.e.m. for 6 animals/group)
Day Control Suramin PBT GSL
1 4'22 ± 0'35 4'70 ± O '10 5'21 ± O ' 16 5'13 ± 0'27
3 4'63 ± 0*03 4'88 ± 0'27 4'98 ± 0'18 4'87 ± O ' 11
5 4'67 ± 0'24 4'31 ± O '13 4'46 ± 0'22 4'23 ± O ' 12
7 4'59 ± 0'05 4'63 ± 0'34 4'86 ± 0'30 4'62 ± 0'08
14 4*99 ± O '10 5'02 ± 0'08 5'49 ± 0'39 5'03 ± 0'08
21 4'48 ± 0'07 4'87 ± O ' 12 5'06 ± O ' 17 4*66 ± 0'06
28 4'57 ± 0'41 4'80 ± 0'04 4'92 ± O'14 4'34 ± 0'20 ■
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TABLE XXVIII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-\<IEEK PERIOD OF TREATMENT
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - VJHOLE LIVER
PROTEIN CONTENT AS mg/g TISSUE
(Results as means ± s.e.m. for duplicate assays on 6 animals)
Day Control Suramin PBT GSL
1 97*4 ± 2*1 92*4 ± 1*8 113*6 ± 1*1 107*1 ± 1*5
3 93*8 ± 1*7 101*3 ± 1*4 108*7 ± 1*8 101*1 ± 2*1
5 104*2 ± 1*5 116*2 ± 2*3 97*2 ± 1*4 96*4 ± 1*4
7 95*5 ± 1*7 97*0 ± 2*0 89*4 ± 1*9 117*3 ± 1*7
14 114*3 ± 1*8 93*8 ± 2*1 106*3 ± 0*7 121*3 ± 1*9
21 108*9 ± 0*9 102*2 ± 1*5 113*5 ± 1*4 118*5 ± 1*1
28 125*3 ± 2*2 119*4 ± 1*7 98*6 ± 1*6 107*2 ± 2*3
TABLE XXIX
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - WHOLE LIVER
TOTAL HEXOSES AS mg GLUCOSE/g TISSUE
(Results as means ± s.e.m. for duplicate assays on 6 animals)
Day Control Suramin PBT GSL
1 71*8 ± 6*2 113*9 ± 9*7 107*3 ± 3*3 55*5 ± 4*4
3 72*2 ± 3*4 78*6 ±10*8 65*5 ± 7*7 31*6 ± 2*8
5 58*1 ± 7*3 61*6 ± 8*6 70*2 ± 3*1 30*4 ± 3*7
7 79*2 ±10*5 58*5 ± 5*9 63*6 ±11*8 26*7 ± 4*2
14 76*4 ± 7*8 64*5 ± 8*1 68*8 ± 5*7 28*1 ± 2*9
21 94*8 ±11*1 74*0 ± 7*2 73*5 ± 4*2 33*6 ± 3*1
28 88*4 ± 8*7 84*8 ± 3*9 82*4 ± 2*4 33*4 ± 3*4
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TABLE XXX
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - WHOLE LIVER 
CHLOROFORM-METHANOL EXTRACTABLE LIPID WEIGHTS AS mg/g TISSUE
(Results as means ± s.e.m. for duplicate determinations on 6 animals)
Day Control Suramin PBT GSL
1 87*5 ± 6*3 83*1 ± 4*2 88*4 ± 3*1 93*2 ± 4*2
3 89*4 ± 4*2 80*2 ± 3*7 87*3 ± 2*2 84*5 ± 5*1
5 85"3 ± 4-1 86*3 ± 2*9 90*5 ± 3*3 89*5 ± 6*3
7 79*2 ± 3*9 80*1 ± 5*2 85*4 ± 2*9 82*3 ± 1*8
14 75*4 ± 4*2 70*0 ± 4*7 77*7 ± 4*4 72*1 ± 2*9
21 66*6 ± 4"3 64*3 ± 3*9 68*3 ± 5*1 66*4 ± 3*3
28 64*4 ± 3*5 59*4 ± 4*1 56*8 ± 3*9 62*3 ± 4*0
TABLE XXXI
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - WHOLE LIVER 
CHLOROFORM-METHANOL EXTRACTABLE LIPID PHOSPORUS CONTENT AS pmol/g TISSUE
(Results as means ± s.e.m. for duplicate determinations on 6 animals)
Day Control Suramin PBT GSL
1 91*1 ± 3*4 01*0 ± 6*5 90*5 ± 2*2 88*6 ± 6*2
3 81*1 ± 2*8 86*7 ± 2*9 91*2 ± 1*3 83*3 ± 1*7
5 89*1 ± 1*1 87*1 ± 2*5 88*2 ± 5*6 85*2 ± 3*0
7 89*8 ± 3*7 80*9 ± 1*9 81*1 ± 2*6 87*2 ± 2*0
14 83*6 ± 6*9 88*4 ± 6*1 86*0 ± 1*7 90*7 ± 6*4
21 88*8 ± 2*9 85*8 ± 5*1 87*6 ± 4*4 87*1 ± 5*5
28 89*0 ± 3*7 93*1 ± 4*2 92*1 ± 2*5 89*5 ± 2*4
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TABLE XXXII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-VJEEK PERIOD OF TREATMENT
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - WHOLE LIVER
^-GLUCURONIDASE ACTIVITY AS mmol SUBSTRATE HYDROLYSED/HR/g TISSUE
(Results as means ± s.e.m. for duplicate determinations on 6 animals)
Day Control Suramin PBT GSL
1 102-3 ± 5'6 94*9 ± 9*8 89*1 ± 6*7 92*6 ± 4*4
3 93*8 ± 2*6 87*9 ± 2*9 90*8 ± 5*5 84*2 ± 7*6
5 107*2 ± 4*4 105*7 ± 3*1 96*7 ± 2*5 113*0 ± 7*5
7 96*7 ± 3*4 94*5 ± 5*2 102*5 ± 1*4 95*5 ± 1*9
14 85*4 ± 1*7 89*3 ± 1*1 75*4 ± 2*9 100*3 ± 3*9
21 91*4 ± 3*5 90*2 ± 4*6 84*7 ± 3*1 82*2 ± 4*2
28 98*5 ± 4*7 92*3 ± 2*9 88*2 ± 3*0 89*5 ± 2*8
TABLE XXXIII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - ['THOLE LIVER 
ACID PHOSPHATASE ACTIVITY AS mmol SUBSTRATE HYDROLYSED/HR/q TISSUE
(Results as mean ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 430 ± 32 379 ± 17 308 ± 22 366 ± 21
3 388 ± 4 334 ± 9 413 ± 16 369 ± 17
5 488 ± 18 431 ± 16 440 ± 19 450 ± 14
7 472 ± 16 430 ± 21 468 ± 23 500 ± 29
14 456 ± 17 389 ± 18 377 ± 19 468 ± 28
21 405 ± 19 428 ± 14 404 ± 16 400 ± 23
28 399 ± 17 397 ± 19 423 ± 21 396 ± 15
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TABLE XXXIV
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - PROTEIN
CONTENT OF LIVER MICROSOMES AS mg/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 16*8 ± 0*6 21*3 ± 0*8 21*5 ± 0*7 17'3 ± 0'6
3 13*2 ± 0*8 24*8 ± 0*9 28*9 ± 0*8 14*4 ± 0'6
5 15*4 ± 0*4 19*5 ± 0-7 22*2 ± 0-7 15'0 ± 0'6
7 13*2 ± 0*6 13*5 ± 0*6 14'1 ± 0*6 14'6 ± 0*5
14 12*9 ± 0*8 11*6 ± 0*4 11*7 ± 0*6 12'1 ± 0*6
21 16*5 ± 0*7 14'1 ± 0*8 13'8 ± 0*6 13"1 ± 0*7
28 14*9 ± 0*7 15*2 ± 0*8 15*4 ± 0*8 14*9 ± 0*7
TABLE XXXV
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - TOTAL HEXOSES OF 
LIVER MICROSOMES AS mg GLUCOSE/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 12*4 ± 2*0 25*1 ± 2*9 20*2 ± 1*2 4*54 ± G'47
3 16*1 ± 0*6 19'6 ± 2'2 18*2 ± 1-3 3'8G ± G'2G
5 13"1 ± 0*5 14*0 ± 1*6 16'7 ± 1'5 2"88 ± G'21
7 10*8 ± 0*6 12*3 ± 1*6 16'0 ± 1*2 2'92 ± G'43
14 17*9 ± 0'8 ll'l ± I'l 12*8 ± 0*7 1*72 ± G'27
21 9*9 ± 1*6 ll'l ± I'O 13*7 ± 1*2 2'74 ± G'18
28 11*7 ± I'l IG'6 ± 1*9 11'5 ± I'l 2'13 ± G'2G
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TABLE XXXVI
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - LIPID CONTENT
OF LIVER MICROSOMES AS mg/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 16'8 ± 2'2 13*3 ± 1*9 16'5 ± 2'9 14'7 ^ 0'"5
3 22'4 ± 1*2 26*4 ± 0*4 28'9 ± 0*5 24'5 ± 0*9
5 20'6 ± 2*0 28*0 ± 1*8 27'8 ± 1*4 28'6 ± I'l
7 32'8 ± 2*4 32*2 ± 2'5 28'8 ± 2'8 34'4 ± 0*9
14 26*1 ± 0*8 19*0 ± 0*4 25*2 ± 0*4 27'5 ± 2*0
21 18*5 ± 1*3 20*3 ± 1*1 23*0 ± 0*8 23'2 ± I'O
28 19*4 ± 1*2 21*5 ± I'O 22'9 ± 0*8 20'1 ± 0*8
TABLE XXXVII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - PHOSPHORUS 
CONTENT OF MICROSOMAL LIPIDS AS pmol/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 15'0 ± 0*5 14'7 ± 0*9 15*0 ± 0*6 15'2 ± 0"6
3 16'4 ± 0*6 18'5 ± 0*6 15'3 ± I'O 17*0 ± 1*3
5 13'6 ± O'l 13'4 ± 0*7 14'9 ± 0*5 14'1 ± 0*8
7 20'6 ± 0*7 17'2 ± O'l 16'7 ± 1*5 16'5 ± 0*4
14 17'9 ± 0*7 15'8 ± I'O 14*4 ± 0*2 16*3 ± I'O
21 16'4 ± 0*7 14'1 ± 0*7 15'0 ± 0*7 17'7 ± 0*8
28 17'9 ± 0*6 13'9 ± 0*6 17'6 ± 0*8 14'7 ± 0*6
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TABLE XXXVIII
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-V7EEK PERIOD OF TREATMENT
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - B"GLUCURONIDASE
ACTIVITY OF LIVER MICROSOMES AS mmol SUBSTRATE HYDROLYSED/HR/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Day Control Suramin PBT GSL
1 4*21 ± 0*23 4*68 ± 0*10 4*40 ± 0*19 4*30 ± 0*06
3 4*58 ± 0*19 4*76 ± 0*10 4*77 ± 0*17 4*85 ± 0*06
5 5*22 ± 0*10 5*51 ± 0*15 5*38 ± 0*10 5*10 ± 0*13
7 7*14 ± 0*35 6*83 ± 0*26 7*96 ± 0*19 6*99 ± 0*18
14 11*90 ± 0*48 10*40 ± 0*28 11*80 ± 0*39 11*60 ± 0*40
21 14*60 ± 0*60 15*30 ± 0*89 14*70 ± 0*71 15*20 ± 0*65
28 18*70 ± 1*60
■ 1 I—
17*50 ± 1*60 18*90 ± 1*00 19*30 ± 0*94
TABLE XXXIX
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - ACID PHOSPHATASE 
ACTIVITY OF LIVER MICROSOMES AS mmol SUBSTRATE HYDROLYSED/HR/g TISSUE
(Results as means ± s.e.m. for 6 duplicate assays/group)
Day Control Suramin PBT GSL
1 100 ± 11 62 ± 9 95 ± 12 100 ± 11
3 90 ± 8-5 94 ± 12 125 ± 10 103 ± 12
5 95 ± 12 . 116 ± 8 146 ± 12 98 ± 8
7 101 ± 14 119 ± 8 128 ± 9 124 ± 12
14 79 ± 9 110 ± 12 119 ± 12 115 ± 9
21 113 ± 13 92 ± 12 112 ± 10 96 ± 18
28 8 9 + 1 1 76 ± 11 124 ± 12 102 ± 13
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TABLE XL
RESPONSES OF SPRAGUE-DAWLEY RATS OVER A 4-WEEK•PERIOD'OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - MICROSOMAL 
CYTOCHROME P,^ ^^  AS nmol/mg MICROSOMAL PROTEIN
(Results as means ± s.e.m. for 6 determinations)
Day Control Suramin PBT GSL
1 0*76 ± 0*02 0*74 ± 0*02 1*75 ± 0*03 0*75 ± 0*02
3 1*70 ± 0*03 1*15 ± 0*02 3*00 ± 0*03 1*64 ± 0*04
5 1*58 ± 0*04 1*86 ± 0*02 4*12 ± 0*03 1*69 ± 0*03
7 1*80 ± 0*03 2*06 ± 0*04 4*07 ± 0*04 1*89 ± 0*04
14 1*79 ± 0*04 2*97 ± 0*05 7*69 ± 0*05 2*33 ± 0*05
21 1*87 ± 0*04 2*86 ± 0*05 9*16 ± 0*06 2*46 ± 0*05
28 2*00 ± 0*04 2*70 ± 0*05 9*89 ± 0*07 2*99 ± 0*05
TABLE XLI
RESPONSES OF SPRAGUE-DAWLEY PATS OVER A 4-WEEK PERIOD OF TREATMENT 
WITH SURAMIN, PHENOBARBITONE OR GLUCOSACCHAROLACTONE - MICROSOMAL "
(Results as means ± s.e.m. for 6 determinations)
Day Control Suramin PBT GSL
1 0*35 ± 0*02 0*34 ± 0*02 0*73 ± 0*03 0*35 ± 0*02
3 0*39 ± 0*02 0*36 ± 0*02 0*82 ± 0*03 0*59 ± 0*02
5 0*86 ± 0*03 0*83 ± 0*03 1*65 ± 0*04 0*83 ± 0*03
7 0*75 ± 0*03 1*09 ± 0*03 1*68 ± 0*05 0*77 ± 0*02
14 0*86 ± 0*04 1*44 ± 0*04 2*68 ± 0*04 1*03 ± 0*04
21 0*74 ± 0*03 1*04 ± 0*04 2*20 ± 0*04 0*85 ± 0*03
28 0*60 ± 0*02 0*93 ± 0*04 2*15 ± 0*05 0*85 ± 0*04
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TABLE XLII
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAJ4IN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - ANIMALS 
WEEKLY WEIGHT RECORDS IN GRAMS
(Results are means ± s.e.m. for 6 animals)
Treatment Week 0 Week 1 Week 2 Week 3 Week 4
Control 54*5 88*5 133*3 169*6 196*2
PBT 59*1 87*1 131*5 163*6 196*2
Suramin 55*0 90*3 128*0 168*6 199*0
Suramin/PBT 53*2 89*3 123*0 148*0 179*0
GSL 60*0 97*1 134*0 167*4 198*2
Suramin/GSL 60*1 102*0 142*0 168*3 202*3
PBT/GSL 60*4 92*0 120*8 138*8 169*5
Suramin/PBT/GSL 63*0 106*1 137*3 168*1 208*0
TABLE XLIII
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHARALACTONE - MEAN
BODY WEIGHT INCREASES IN GRAMS
(Results are means ± s.e.m. for 6 animals)
Treatment Week 0-1 Week 1-2 Week 2-3 Week 3-4 Total
Control 34*0 44*8 36*3 26*6 141*7
PBT 28*0 44*4 32*1 32*6 137*1
Suramin 45*3 37*7 40*6 30*4 154*0
Suramin/PBT 36*1 33*7 25*0 32*0 125*8
GSL 37*1 36*9 33*4 30*8 140*2
Suramin/GSL 41*9 40*1 26*2 34*0 142*2
PBT/GSL 31*6 28*8 18*0 30*7 109*1
Suramin/PBT/GSL 43*1 31*2 20*8 39*9 135*0
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TABLE XLIV
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - LIVER 
WEIGHTS IN ABSOLUTE AND PERCENTAGE TERMS, AND LIVER WATER CONTENT
(Results as means ± s.e.m. for 6 animals)
Treatment Liver Weight 
(g ± s.e.m.)
Liver Weight 
as %
Body Weiaht
Liver Water 
Content as 
% ± s.e.m.
Control 10*13 ± 0*87 5* 14 72*0 ± 0*2
PBT 9*75 ± 0*62 4*98 71*8 ± 0*6
Suramin 10*82 ± 0*72 5*45 72*5 ± 0*7
Suramin/PBT 10*60 ± 1*14 5*93 70*0 ± 2*1
GSL 9*84 ± 0*53 4*97 71*8 ± 0*4
Suramin/GSL 9*00 ± 0*42 4*46 71*3 ± 1*0
PBT/GSL 8*32 ± 0*84 4*92 75*0 ± 2*0
Suramin/PBT/GSL 10*93 ± 0*50 5*26 71*0 ± 0*3
TABLE XLV
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - SUBCELLULAR 
DISTRIBUTION OF LIVER PROTEIN AS rng/g TISSUE
(Results as means ± s.e.m. of 6 duplicate determinations)
Treatment Whole Liver
Particulate
Fraction
10,000 g 
Supernatant
Microsomes Cytosol
Control 75*78 ± 2*22 42*13 ± 1*31 33*75 ± 0*84 19*92 ± 1*14 9*55 ± 0*45
PBT 69*36 ± 1*46 48*54 ± 1*04 33*04 ± 0*75 16*02 ± 1*02 13*86 ± 0*51
Suramin 67*74 ± 2*00 42*25 ± 1*89 32*81 ± 1*02 15*99 ± 0*98 9*64 ± 0*49
Suramin/PBT 66*14 ± 1*03 43*04 ± 1*45 36*91 ± 0*77 17*12 ± 0*62 13*10 ± 0*50
GSL 54*78 ± 1*76 31*28 ± 2*01 28*45 ± 0*83 16*40 ± 0*42 7*45 ± 0*51
Suramin/GSL 67*94 ± 1*08 34*59 ± 1*45 31*31 ± 1*00 17*32 ± 1*08 8*23 ± 0*38
PBT/GSL 69*66 ± 1*73 41*67 ± 1*11 34*25 ± 0*76 17*72 ± 0*35 13*34 ± 0*47
Suramin/PBT/GSL 64*74 ± 2*80 40*74 ± 1*63 33*89 ± 0*82 17*62 ± 1*28 12*85 ± 0*53
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TABLE XLVI
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - SUBCELLULAR 
DISTRIBUTION OF TOTAL HEXOSES (AS mq GLUCOSE/g TISSUE) IN THE LIVER
(Results as means ± s.e.m. for 6 duplicate determinations)
Treatment Whole Liver Particulate
Fraction
10,000 g 
Supernatant
Microsomes Cytosol
Control 50*00 + 2 13 42*71 + 1*91 3*84 + 0*12 1*50 ± 0*19 0*966 ± 0*057
PBT 42*66 + 2 58 36*49 + 2*02 3*61 + 0*12 1*51 ± 0*37 0*557 ± 0*052
Suramin 41*94 + 1 49 31*33 + 2*22 3*55 ± 0*11 1*29 ± 0*15 0*855 ± 0*046
Suramin/PBT 31*40 + 1 40 26*04 + 1*07 1*81 ± 0*10 0*74 + 0*16 1*162 ± 0*070
GSL 37*80 ± 1 38 29*45 + 1*13 1*22 + 0*09 0*86 + 0*16 0*319 0*031
Suramin/GSL 27*24 + 1 97 20*22 + 1*24 1*04 + 0*09 0*59 + 0*24 0*202 ± 0*038
PBT/GSL 16*80 ± 0 66 17*25 + 0*90 1*16 + 0*10 0*78 + 0*12 0*281 i 0*041
Suramin/PBT/GEL 35*54 + 1 89 38*96 + 0*99 2*09 ± 0*13 1*06 ± 0*15 0*743 ± 0*044
TABLE XI.VII*
RESPONSES OF SPPAGTJE-DAV7LEY PATS TO 4 ^W.EYS OF TP.EATîŒITT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAPCLACTONE - SUBCELLULAR 
DISTRIBUTION OF LIVER LIPIDS AS rno/q TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Treatment Whole Liver
Particulate
Fraction
10,000 g 
Supernatant
Kicrosc:mes Cytosol
Control 56*9 + 4*0 36*41 + 1*80 17*55 + 0*34 16*67 ± 0*21 2*57 1*09
PBT 52*4 ± 2*7 30*15 + 1*43 22*31 + 0*31 17*75 ± 0*22 9*87 1*10
Suramin 59*6 + 4*7 36*47 + 0*85 20*14 + 0*47 16*64 ± 0*23 6*26 4- 0*89
Suramin/PBT 67*8 + 4*0 39*23 + 1*21 19*45 + 0*22 17*02 0*27 6*07 0*94
GSL 64*4 + 1*4 38*77 + 1*33 16*71 + 0*24 17*18 + 0*21 3*12 ± 0*63
Suramin/GSL 62*5 3*1 41*05 + 1*42 17*55 + 0*19 16*47 0*21 7*42 ± 0*70
PBT/GSL 71*2 + 3*2 43*81 + 1*17 13*67 + 0*21 17*75 '4- 0*22 6*99 0*78
Suramin/PBT/GSL 71*0 ± 2*7 42*25 + 1*03 21*45 0*29 18*56 0*24 8* 34 ± 0-82
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TABLE XLVIII
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 V7EEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - SUBCELLULAR 
d i s t r i b u t i o n of l i v e r LIPID PHOSPHORUS AS pmol/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Treatment Whole Liver Particulate
Fraction
10,000 g 
Supernatant
Microsomes Cytosol
Control 80*9 ± 3*4 38*5 ± 1*4 36*1 ± 0*9 15*99 ± 0*81 16*8 ± 0*5
PBT 84*5 ± 3*6 46*9 ± 1*2 39*2 ± 1*0 17*73 ± 0*78 21*5 ± 0*6
Suramin 106*3 ± 8*4 40*1 ± 1*5 33*4 ± 0*9 15*71 ± 0*16 12*3 ± 0*3
Suramin/PBT 97*2 ± 8*8 41*2 ± 1*0 42*5 ± 0*8 18*81 ± 0*99 24*6 ± 0*4
GSL 83*6 ± 1*9 37*5 ± 0*9 34*2 ± 1*2 15*62 ± 0*31 15*6 ± 0*4
Suramin/GSL 91*6 ± 2*3 39*4 ± 0*9 34*1 ± 1*1 16*36 ± 0*16 18*1 ± 0*6
PBT/GSL 86*0 ± 3*1 43*1 ± 1*1 38*9 ± 0*9 16*97 ± 0*76 22*1 ± 0*4
Suramin/PBT/GSL 91*1 ± 2*6 42*7 ± 1*0 38*4 ± 1*0 17*68 ± 0*63 21*5 ± 0*3
TABLE XLIX
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATIÆNT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - SUBCELLULAR 
DISTRIBUTION OF LIVER 6-GLUCURONIDASE ACTIVITY 
AS mmol SUBSTRATE HYDROLYSED/HR/q TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Treatment Whole Liver
Particulate
Fraction
10,000 g 
Supernatant
Microsomes Cytosol
Control 129*7 ± 0*6 5*64 ± 0*10 18*6 ± 0*6 19 * 5 ± 0*8 1*17 ± 0*13
PBT 137*4 ± 1*1 4*98 ± 0*11 18*4 ± 0*8 19*8 ± 1*85 0.79 ± 0*66
Suramin 129*7 ± 0*7 5*94 ± 0*09 17*5 ± 0*4 18*9 ± 1*4 1.12 ± 0*07
Suramin/PBT 120*2 ± 0*8 5*05 ± 0*07 19*1 ± 0*5 16*7 ± 0*8 1.29 ± 0*17
GSL 134*9 ± 0*9 4*87 ± 0*04 18*3 ± 0*5 18*9 ± 1*4 0*94 ± 0*08
Suramin/GSL 134*0 ± 1*2 4*73 ± 0*07 18*0 ± 0*7 19*1 ± 2*8 0.98 ± 0*07
PBT/GSL 158*9 ± 1*6 5*22 ± 0*10 17*8 ± 0*4 16*5 ± 1*4 0.84 ± 0*06
Suramin/PBT/GSL 127*4 ± 0*7 5*54 ± 0*12 19*4 ± 0*4 21*4 ± 1*6 0*99 ± 0*66
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TABLE L
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - SUBCELLULAR 
DISTRIBUTION OF LIVER ACID PHOSPHATASE ACTIVITY AS mmol SUBSTRATE
HYDROLYSED/HR/g TISSUE
(Results as means ± s.e.m. for 6 duplicate determinations)
Treatment Whole Liver Particulate
Fraction
10,000 g 
Supernatant
Microsomes Cytosol
Control 253 ± 15 404 ± 24 199 ± 11 142 ± 12 18 ± 0*4
PBT 258 ± 15 451 ± 27 154 ± 11 112 ± 8 .14 ± 0*3
Suramin 291 ± 21 385 ± 21 176 ± 16 116 ± 10 14 ± 0*4
Suramin/PBT 259 ± 21 406 ± 21 165 ± 9 102 ± 16 13 ± 0*3
GSL 277 ± 27 425 ± 27 189 ± 10 136 ± 8 15 ± 0*5
Suramin/GSL 258 ± 16 399 ± 21 174 ± 13 141 ± 11 17 ± 0*4
PBT/GSL 279 ± 18 467 ± 21 188 ± 18 114 ± 8 16 ± 0*3
Suramin/PBT/GSL 258 ± 14 426 ± 12 179 ± 11 133 ± 9 15 ± 0*4
TABLE LI
RESPONSES OF SPRAGUE-DAWLEY RATS TO 4 WEEKS OF TREATMENT WITH 
SURAMIN AND/OR PHENOBARBITONE AND/OR GLUCOSACCHAROLACTONE - MICROSOMAL 
CYTOCHROMES P450 AND bg AS nmol/mg MICROSOMAL PROTEIN
(Results as means ± s.e.m. for 6 assays)
Treatment P450 bs
Control 1*95 ± 0*21 0*36 ± 0*04
PBT 10*33 ± 0*82 0*72 ± 0*06
Suramin 2*76 ± 0*17 0*37 ± 0*02
Suramin/PBT 8*85 ± 0*81 0*65 ± 0*07
GSL 2*88 ± 0*17 0*51 ± 0*07
Suramin/GSL 2*72 ± 0*19 0*42 ± 0*04
PBT/GSL 8*33 ± 0*54 0*69 ± 0*05
Suramin/PBT/GSL 8*89 ± 0*69 0*63 ± 0*06
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4. Studies on Rat Uteri
As results from the liver were somewhat equivocal, attention 
was diverted to the rat uterus. It v/as hoped that, although in the 
case of liver no definitive inhibition of lysosomal enzymes could be 
measured directly, it might be possible to see in vivo the result 
of enzymic inhibition, apparent as a reduced rate of weight loss in 
the involuting uterus. Subsequent to the weight loss observations, 
a variety of characteristics in the composition of the uterus was 
checked. Results of all these observations are tabulated below 
(Tables LII - LXI).
TABLE LII
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - UTERINE WEIGHTS AND 
THE EFFECTS OF SURAMIN
(Results as mean weight in mg ± s.e.m. for 6 animals)
Days Post Partum Untreated Control Suramin Treated
0 3366*1 ± 180*4
1 1772*5 ± 32*8 1935*8 ± 53*4
2 979*0 ± 32*7 1372*4 ± 66*1
3 825*9 ± 25*0 905*0 ± 31*5
5 529*4 ± 21*0 629*7 ± 13*4
8 318*8 ± 15*8 364*7 ± 10*8
12 295*8 ± 7*8 351*6 ± 6*3
15 255*8 ± 4*8 326*4 ± 5*6
Virgin Uterus 487*8 ± 30*1
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TABLE L I U
RESULTS OF EXPERir4ENT TO SHOW THE EFFECTS OF SURAMIN
ON RAT UTERINE INVOLUTION - EFFECT OF SURAMIN ON THE
DRY WEIGHT OF UTERI
(Results as mean percentage of wet weight ± s.e.m. for 6 animals)
Days Post Partum Untreated Control Suramin Treated
0 ± 0-3
1 17*1 ± 0*3 15-6 ± 0"4
2 16*7 ± 0*6 17*3 ± 0'5
3 17*2 ± 0*3 18-4 ± 0'5
5 17*9 ± 0*2 18*3 ± O'l
8 19*7 ± 0*3 20*7 ± 0*4
12 21*3 ± 0*4 20"3 ± 0-2
15 19*7 ± 0*4 20"1 ± 0*3
Virgin Uterus 19'1 ± 0'3
TABLE LIV
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - UTERINE PROTEIN CONTENT 
AS mg/FALLOPIAN TUBE AND THE EFFECT OF SURAMIN
(Results as means ± s.e.m. for 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 /g^'7 ± 12'7
1 83*7 ± 6'8 83*9 ± 4'1
2 50"1 ± 3'8 47*0 ± 3*8
3 38'7 ± 3*1 40'0 ± 1-2
5 28'5 ± 1*5 31-5 ± 1*4
8 12'7 ± 0*3 15'2 ± 1*3
12 14*8 ± 1"7 12*7 ± 0*8
15 10*7 ± 0*7 13'8 ± I'l
Virgin Controls 19*5 i I'O
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TABLE LV
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN
ON RAT UTERINE INVOLUTION - TOTAL HEXOSES AS
mq GLUCOSE/FALLOPIAN TUBE AND THE EFFECT OF SURAMIN
(Results as means ± s.e.m. for 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 19-8 ± 2*6
1 9*1 ± 1'4 12*4 ± 1*2
2 5*4 ± 0*4 6*0 ± 0*9
3 4*6 ± 0*2 4*9 ± 0*6
5 3*6 ± 0*3 4*1 ± 0*5
8 2*3 ± 0*3 2*8 ± 0*4
12 2*6 ± 0*4 2*0 ± 0*1
15 1*9 ± 0*1 1*9 ± 0*2
Virgin Controls 7*4 ± 0*6
TABLE LVI
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - EFFECT OF SURAMIN ON 
UTERINE HEXOSAMINS CONTENT AS fAq GLUCOSAMINE/FALLOPIAN TUBE
(Results as means ± s.e.m. for 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 3000 ± 73
1 - 2050 ± 134 2210 ± 193
2 1250 ± 109 1340 ± 93
3 1160 ± 114 1169 ± 126
5 602 ± 66 771 ± 45
8 476 ± 67 637 ± 57
12 488 ± 48 519 ± 19
15 598 ± 34 612 ± 59
Virgin Controls 334
-------------- -------
t 24
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TABLE LVII
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN
ON RAT UTERINE INVOLUTION - TOTAL HYDROXYPROLINE CONTENT
AS pg/FALLOPIAN TUBE AND THE EFFECT OF SURAMIN
(Results as means ± s.e.m. for 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 4010 ± 361 3040 236
1 2850 ± 123 3040 ±236
2 1572 ± 173 1870 ± 185
3 1017 ± 98 1147 ± 118
5 608 ± 59 688 ± 84
8 402 ± 37 498 ± 58
12 675 ± 83 685 ± 28
15 563 ± 84 629 ± 67
Virgin Controls 1630 ± 340
TABLE LVIII
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - EFFECT OF SURAMIN ON THE 
COLLAGEN CGI TIENT OF INVOLUTING UTERI AS mg/FALLOPIAN TUBE
(Results as means ± s.e.m. for 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 23*40 ± 2*10
1 20*30 ± 1*20 15*48 ± 0*91
2 8*52 ± 0*41 10*79 ± 0*35
3 5*97 ± 0*28 6*61 ± 0*31
5 4*20 ± 0*31 3*77 ± 0*24
8 2*54 ± 0*25 2*48 ± 0*20
12 2*35 ± 0*21 2*98 ± 0*23
15 2*63 ± 0*23 2*84 ± 0*22
Virgin Controls 2.10 ± 0*15
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TABLE LIX
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - ELASTIN IN INVOLUTING UTERI
AS mg/FALLOPIAN TUBE AND THE EFFECT OF SURAMIN 
(Results as means ± s.e.m. of 6 duplicate assays)
Days Post Partum Untreated Control Suramin Treated
0 48-60 ± 2-20
1 39*80 ± 1*20 54*70 ± 2*30 .
2 18*40 ± 0*78 20*00 ± 0*90
3 11*50 ± 0*43 17*90 ± 0*64
5 8*16 ± 0*53 9*61 ± 0*41
8 6*47 ± 0*51 8*31 ± 0*34
12 5*82 ± 0*37 7*79 ± 0*30
15 6*20 ± 0*48 7*70 ± 0*28
Virgin Controls 9*84 ± 0*25
TABLE LX
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - LEVELS OF 6-GLUCURONIDASE 
ACTIVITY BOTH AS mmol SUBSTRATE HYDROLYSED/HR/FALLOPIAN TUBE 
AND AS mmol SUBSTRATE HYDROLYSED/HR/g FRESH TISSUE 
AND THE Ei'FECT OF SURAMIN
(Results as means ± s.e.m. of 6 duplicate assays)
Activity/Fallopian Tube Activity/g Tissue
Days Post 
Partum
.Untreated
Control
Suramin
Treated
Untreated
Control
Suramin
Treated
0 24*10 + 1*60 7*16
1 22*80 ± 0*90 20*30 + 1*40 12*90 10*50
2 17*50 ± 1*20 14*00 ± 1*10 17*90 10*20
3 15*70 ± 0*90 14*80 ± 0*20 18*90 16*30
5 9*60 ± 0*40 7*95 ± 1*30 18* 10 12*60
8 8*85 i 1*58 3*67 ± 0*45 27*80 10*00
12 3*91 ± 0*31 1*89 + 0*42 13*30 5*40
15 1*83 i 0*44 1*52 + 0*20 7*20 4*70
Virgin
Controls
3*36 ± 0*22 6*90
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TABLE LXI
RESULTS OF EXPERIMENT TO SHOW THE EFFECTS OF SURAMIN 
ON RAT UTERINE INVOLUTION - LEVELS OF ACID PHOSPHATASE 
ACTIVITY BOTH AS mmol SUBSTRATE HYDROLYSED/HR/FALLOPIAN TUBE 
AND AS mmol SUBSTRATE HYDROLYSED/HR/g FRESH TISSUE
(Results as means ± s.e.m. for 6 duplicate assays)
Activity/Fallopian Tube Activity/g Tissue
Days Post 
Partum
Untreated
Control
Suramin
Treated
Untreated
Control
Suramin
Treated
0 65*80 ± 0*50 19*6
1 64* 10 ± 0* 80 60*8 ± 0 * 3 36*2 31*4
2 57*10 ± 2*00 46*5 ± 2 * 8 58*4 33*9
3 51*50 ± 1*70 29*3 ± 4 * 3 62*5 32*4
5 39*90 ± 2*50 29*0 ± 1*4 75*6 46*2
8 28*80 ± 1*70 12*2 ± 1*3 90*5 33*7
12 11*30 ± 1*30 5*7 ± 0*5 38*4 16*2
15 3*79 ± 0*12 4*0 ± 0* 5 14*9 12*4
Virgin 6*69 ± 0*12 141*4
Controls
5, Ancillary Observations
Some other,subsidiary,observations were made during this study. 
For example, it was felt that although there was no tangible change in 
BCD activity observed in rat livers, some change might be detectable 
in the enzyme’s kinetic character. To test this theory whole liver 
homogenates from rats treated for either 24 hours or 28 days with 
Suramin, PBT,or the two compounds together, were fractionated to give 
a 10,000g pellet and the 10,000g supernatant. and V^ax values were
determined by Lineweaver—Burk regression calculations for each fraction 
(Tables LXII, LXIII, LXIV and LXV).
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TABLE LXII
KINETIC CHARACTERISTICS OF RAT LIVER g-GLUCURONIDASE IN 
THE 10,000g PELLET 24 HRS AFTER SURAI4IN AND/OR PHENOBARBITONE
(Results as means of triplicate determinations)
Treatment %m Vmax
Control
Suramin
PBT
Suramin + PBT
19-4 X lo"*M 
_4
12'6 X 10 M 
11*6 X lo'^M
-«tl*87x 10 M
13*2
8*84
5*82
5*82
^max as mmol substrate hydrolysed/hr,
TABLE LXIII
KINETIC CHARACTERISTICS OF RAT LIVER B-GLUCURONIDASE IN 
THE 10,000g SUPERNATANT 24 HRS AFTER SURAMIN AND/OR PHENOBARBITONE
(Results as means of triplicate determinations)
Treatment %m Vmax
Control 2*37 X lOr^M 6'12
Suramin 1*98 X 10-^M 6 • 66
PBT 1*52 X 10-^M 6'47
Suramin + PBT 2*80 X 10-^M 10*20
V given as mmol substrate hydrolysed/hr. 
max
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TABLE LXIV
KINETIC CHARACTERISTICS OF RAT LIVER g-GLUCURONIDASE IN THE 
10,000g PELLET AFTER 28 DAYS' TREATMENT WITH SURAMIN 
AND/OR PHENOBARBITONE
(Results as means of triplicate determinations)
Treatment K
m
V
max
Control 9*57 X lO-^M 4*68
Suramin 7*93 X lO-^M 4*96
PBT 8*77 X 10-^M 6*04
Suramin + PBT 11*93 X 10"‘*M 8*02
^max as mmol substrate hydrolysed/hr
TABLE LXV
KINETIC CHARACTERISTICS OF RAT LIVER B-GLUCURONIDASE IN THE 
10,000g SUPERNATANT AFTER 28 DAYS' TREATMENT WITH SURAMIN 
AND/OR PHENOBARBITONE
(Results as means of triplicate determinations)
Treatment Km
V
max
Control 19*8 X 10“‘*M 13*40
Suramin 11*6 X lO-^M 5*86
PBT 12*7 X 10-^M 8*89
Suramin + PBT 8*9 X 10"*’M 5*85
V given as mmol substrate hydrolysed/hr 
max
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An attempt was also made to show the degree of reversibility 
of Suramin inhibition. This was done on a whole rat liver extract 
which had been purified by affinity chromatography, according to 
the method of Harris et al. (1973) , and also on a commercial bovine 
BCD preparation.
The technique was to take two aliquots of the enzyme solution,
adding to one, an equal volume of acetate/NaCl buffer, pH 5*0, and to
the other an equal volume of Suramin (1 mg/ml) in the same acetate/
NaCl buffer. These two aliquots were then halved, one half of each
being stored at 4°C, while the other half was dialysed against 1 litre
of the acetate/NaCI buffer. The two dialysed samples were each
reduced to the same volume as the undialysed samples by means of the
Amicon ultrafiltration pressure vessel, before any estimates of their
activities were made. The kinetic characteristics of the four
enzyme samples so obtained from each preparation were then checked,
K and V values being established as shown below (Tables LXVI and m max
LXVII).
TABLE LXVI
KINETIC CHARACTERISTICS OF g-GLUCURONIDASE FROM WHOLE RAT 
LIVER IN THE PRESENCE AND ABSENCE OF SURAMIN
AND THE EFFECT OF DIALYSIS 
(Results are means of triplicate determinations)
Vmax
Normal Enzyme 380 X 1Q“®M 20*0
Dialysed Enzyme 295 X 1Q-®M 15-0
Enzyme + Suramin 1570 X lO-^M 17*0
Dialysed (Enzyme + Suramin) 323 X 10"^M 11*1
^max as mmol substrate hydrolysed/hr
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TABLE LXVII
KINETIC CHARACTERISTICS OF BOVINE g-GLUCURONIDASE IN THE 
PRESENCE AND ABSENCE OF SURAMIN AND THE EFFECT OF DIALYSIS
(Results are means of triplicate determinations)
K
m
V
max
Normal Enzyme 564 X 10"^M 50*5
Dialysed Enzyme 1090 X 10"^M 81*4
Enzyme + Suramin 1330 X lO-^M 28*7
Dialysed (Enzyme + Suramin) 246 X lO'^M 71*4
V given as mmol substrate hydrolused/hr 
max
Another contribution to the rat liver study was to take samples 
of normal and Suramin-treated rat liver for electron microscopy. No 
histochemistry was done, simply a direct observation of ultrastructural 
morphology, to see whether Suramin caused any significant changes at 
this level. No changes were observed, although it should be added 
that such a study should really have been made by a trained E.M. 
operator observing a large number of livers. In this case, two 
controls and two Suramin-treated livers were observed, after fixing 
in glutaraldehyde (25%) and staining in Gomori's lead citrate.
Some electrophoretic studies were made on both bovine and rat 
BGD. Two media were used, cellulose acetate papers and acrylamide gel, 
The object of this was to discover whether the presence of the strongly 
negatively charged Suramin would alter the mobility of the enzyme 
molecule. In neither case was it possible to obtain a high enough 
degree of separation between the enzyme and other bands of protein 
present in the preparation to be able to measure migration distances
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satisfactorily. Measurement was also complicated by the fact that 
Suramin inhibited the enzymic activity and one could then stain only 
non-specifically for protein with a dye such as amido black. A com­
parison of enzyme/Suramin complexes formed at several pH values between 
4*0 and 7*5 was carried out, but no distinction could be made by either 
acrylamide gel or acetate strip electrophoresis.
6. Appendix: Results of an Experiment using L1210 Leukaemia
At one stage during this study a group of 40 DBA2/C57BI mice 
became available (20 male, 20 female), and an experiment was made to 
test the effect of Suramin on L1210 leukaemia. The red and white 
cells were counted (Table LXVIII) and the mean survival times were 
recorded (Table LXIX). As these animals were not regularly available 
no further experiments were made on L1210 leukaemia.
TABLE LXVIII
EFFECT OF SURAMIN ON BLOOD CELL COUNTS OF L1210 LEUKAEMIA-BEARING MICE
Cell Counts Control (L1210) L1210 + Suramin
Males
Red cells/ml 
White cells/ml
357*2 ± 15*2 X 10** 
47*1 ± 12*9 X 10^
370*8 ± 6*9 X lo'* 
55*7 ± 2*9 X 10^
Females
Red cells/ml 
White cells/ml
349*2 ± 14*3 X 10** 
55*6 ± 5*2 X 10^
303*7 ± 12*1 X lO** 
53*6 ± 4*7 X 10^
TABLE LXIX
INFLUENCE OF SURAMIN TREATMENT ON SURVIVAL TIMES OF Ll210-BEARING MICE
Control Test
Males
Females
8*30 days 
8*70 days
8*80 days 
11"25 days *
* In this group there were also two animals which v/ere still 
alive 28 days after the experiment: these could be considered
either as "cures" or as "non-takes".
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CHAPTER VII
DISCUSSION
1. Studies on Isolated Enzymes
The preparation of bovine BGD showed a marked sensitivity to 
Suramin below pH 5*5, in the pH range where, in the absence of the 
inhibitor, normal enziyme activity is greatest (Fig. 5). This 
observation is consistent with the report of Wills and Wormall (1950) 
that, at pH values below the isoelectric point of the enzyme. Suramin 
shows a large effect, while the inhibition is much reduced above 
this pH.
The reduced level of enzyme activity noticed even at pH 5*5 
in the presence of Suramin may reflect a partial dénaturation or 
steric distortion of the enzyme complex by Suramin. This suggestion 
is supported by the observation that there seems to be an enzyme 
complex containing most of the BGD activity, associated invariably 
with some APT activity. Moreover, elimination of the APT activity 
by a combination of affinity chromatography, isoelectric focussing 
and, finally, acrylamide gel electrophoresis, resulted in an enzyme 
of very high specific activity with no APT activity present. The 
resultant BGD activity was only 10-12% of the original and discarded 
fractions accounted for only some 40-50%.
Both crude and purified preparations of the enzyme showed linear 
progress curves in the presence of excess substrate (Fig. 6). This 
characteristic was invaluable for the study of low enzyme activities 
such as were found in the Ehrlich ascites tumour fluid. APT also 
showed this useful feature.
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Interestingly, though perhaps predictably, the normal rat BGD 
from liver and lactating breast showed very similar pH-dependence 
(Figs. 7 and 8), though both differed quite markedly from the bovine 
enzyme (Fig. 5). In the presence of Suramin, however, differences 
between the two rat preparations became apparent. The liver enzyme 
responded in a manner almost identical with that of the bovine 
enzyme, whilst the rat breast BGD showed a 40-45% inhibition in 
maximum activity and a very distinct change in optimum pH from 4*5 to 
5*5 -6*0. This result was obtained with several different enzyme 
preparations. The effect of Suramin could conceivably lie in its 
specific action on a single molecular species in a quarternary 
isoenzyme complex of BGD (Smith and Mills established in 1953 that 
at least two forms of the enzyme can be found, both in ox spleen and 
ox liver). This explanation could aTso apply to the divergence from 
normality seen in the Huggins tumour enzyme (Fig. 9), which not only 
shows a pH-dependence different from the enzymes of the normal rat, 
but is also strongly inhibited by Suramin.
Similar differences between the pH-dependence of normal rat tissue 
APT and that of the Huggins tumour were also observed (Figs. 10, 11 and 
12). In this case, the Huggins tumour showed near maximum activity 
from pH 4*0 to pH 6*5, while both the normal enzymes showed clear 
optima at pH 5*0. Analagous effects of Suramin were observed on the 
tumour APT activity, which fell virtually to zero over the pH range 
4*0 to 7*5, while the normal enzymes were both less sensitive and 
displayed their sensitivity over a much reduced range from pH 3*5 to 
5*0.
There was much less difference between normal and tumour enzymes 
in the case of aryl sulphatase (Figs. 13 and 14). The normal enzyme
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showed a plateau of activity with little change over the pH range 
5*0 to 8*5, while the tumour enzyme showed a steady decrease in 
activity from pH 4*0 to 8*5. The effect of Suramin on the two 
preparations was small: with the normal enzyme it caused enhanced
activity at pH 4 to 4*5 and had very little effect at higher pH 
values. With the Huggins tumour enzyme, some 50% inhibition by 
Suramin was observed in the pH range 4*0 to 5*5, though above pH 6*0 
the effect was almost eliminated.
Perhaps the most interesting observation in relation to aryl 
sulphatase was that no enzyme activity could be detected in the 
lysosomal enzyme extract from lactating rat breast. The extraction 
procedure was identical with that used for the other tissues and gave 
the expected yields of BGD and APT activities. It would seem, 
therefore, that the preparation was satisfactory, and one may suggest 
either that aryl sulphatase is absent from lactating rat breast or 
that the tissue contains not only the enzyme but also a very effective, 
naturally-occurring inhibitor. This observation was not followed up, 
but such a study might have an interesting outcome, particularly as 
the regression stage of the lactating tissues is presumably mediated 
by the activity of lysosomal enzymes, which normally, include aryl 
sulphatase. At that stage one would expect the aryl sulphatase to 
be present. Two questions which may therefore arise are: If the
enzyme is present later, at what stage does it appear? Alternatively, 
if it does not appear, does its absence modify the rate or characteristics 
of the tissue regression?
The kinetic characteristics of BGD from rat liver, lactating 
breast and Huggins tumour were compared at pH 4*5 and pH 5*0 (Table I).
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The tumour enzyme showed little sensitivity to the change in pH, as 
might have been inferred from the broad maximum in its pH-activity 
curve. The other two enzymes from breast and liver both showed 
changes with pH: the of the liver enzyme virtually trebled,
while that of the breast enzyme dropped by a third when the pH was 
changed from 4*5 to 5*0, The values obtained for these three 
enzyme preparations appear to agree quite closely with other published 
data: Contractor and Shane (1972) report values for human placental
BGD of 3*6 X 10 at pH 4*5, and 8*3 x 1Q“‘*m  at pH 5*0. Ohishi and 
Shioya (1971) record a rabbit liver BGD of 1*4 x 1Q“‘*m , while Walker 
and L e w y  (1953) report the of mouse liver BGD as 15 x 10“**m . The 
latter workers are fairly close in their results to the work reported 
by Baccino and Zuretti (1975) , though their figure of 6*9 x 1 0 " does 
seem rather high in comparison with other data available. Spencer and 
Williams (1951) did not record values, but did mention two pH optima,
at 4'1 and 5*2, for ox liver BGD. These values are in the same range
as the rat liver enzyme used in this study.
The for GSL was found to be 2*61 x 10”.^ M in liver, 1*07 x 10”®
in breast and 4*09 x 10”^M in Huggins tumour BGD at pH 4*5 (Table II). 
These figures are comparable with those of L e w y  et al. (1958), who 
reported a of 1*05 x 10”^M in liver. The rat mammary enzyme gives a
lower figure than the other enzymes: why the discrepancy should be
so marked is not easily explained. The difference is larger than can
be attributed to experimental error, however, and similar results were
obtained with separate preparations of the enzyme. Thus, it seems 
that the lysosomal enzymes of abnormally active tissue may have 
characteristics different from those of a more stable tissue. (In 
retrospect, it would have been of interest if some kinetic studies had
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been made on the enzymes of the rat uterus, and perhaps also on the 
rapidly developing ascitic tumour colonies. Unfortunately, these 
ideas did not evolve until the facilities for such experiments were 
no longer available.)
The determinations for Suramin (Table II) gave values with 
BGD which were rather higher than those for GSL, being 234 x 10~^M 
for liver, 22*3 x 10”^M for breast tissue at pH 4*5, and 109*5 x 1Q“®M 
and 21*1 x 10 for liver and breast respectively at pH 5*0. The 
Huggins tumour gave values of 194*8 x 10~^M and 17*9 x 10”^M at pH 4*5 
and 5*0 respectively.
Assays in vitro had shown that the presence of non-enzyme 
protein would "protect" the enzyme from the full inhibitory effects 
of Suramin. This observation, which confirmed the suggestion made 
by Wills (1953), was felt not to detract too much from the drug's 
potential in the light of reports from Smeester and Jacques (1968) and 
Davies et al. (1971), who had shovm that,at least in the liver. Suramin 
appeared to be sequestered in the lysosomes. A reason for this can 
be deduced from the observations of Wormall's group, who showed hov; 
Suramin bound to many proteins with avidity. Such binding in the 
living animal would lead to an effective "dénaturation" of the protein 
and probably to some degree of consequent immune response by the host, 
aimed at removal of the modified protein. Such removal involves 
micropinocytosis of the protein and fusion with a primary lysosoine 
to form a secondary lysosome. Suramin would thus be transported to 
the lysosome, the intended target of this study. Pinocytotic activity 
has been shown to be very high in invasive tumour tissue (Butterworth, 
1970) and, from the uterine involution study, would seem to occur in the 
uterus too. Consequently, it seems likely that the drug might well
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passively "seek out" the tumour or any other site of high pinocytotic 
activity and, in this way, reduce the local lysosomal enzyme activity. 
Such concentrated inhibition would be in addition to the more 
generalised non-specific lowering of humoral enzyme activities caused 
simply by the presence of the drug in the body fluids.
It was found in the event to be very difficult to demonstrate the 
hoped-for inhibition of lysosomal enzymes in normal liver homogenates 
(Tables XXI, XXII, XXXII, XXXIII, XXXVIII, XXXIX, XLIX and L). The 
explanation for this failure would seem to be that Suramin has a high 
non-specific affinity for protein. This will mean that, once a tissue 
containing the drug has been disrupted and the lysosomes damaged, then 
the limited and strictly defined internal environment of the lysosomes 
will be destroyed. Consequently, the Suramin will have available a 
vast selection of protein targets apart from those with which it had 
once been sequestered. If one assumes that, in common with most 
surface adsorption phenomena, the Suramin-protein association is 
dynamic, then addition of protein to the Suramin-enzyme complex will 
reduce the amount of inhibition in a degree proportional to the quantity 
of extra protein present. It is hence not difficult to accept the 
observations made in this study which show virtually no inhibition of 
lysosomal enzymes in the liver. Mention should be made here, however, 
of the elegant work of Davies et al, (1971) on Suramin inhibition of 
lysosomal proteinase. They proved conclusively that Suramin can and 
does modify the activity of lysosomal enzymes while the integrity of 
the lysosomal membranes is maintained. For work on BGD and APT, 
however, such labelled substrates were not available.
— 186 —
A large proportion of the results obtained from rat liver 
studies can be regarded only as negative data. They do, however, 
serve to show that little or no significant change can be detected 
between normal, healthy, untreated liver and Suramin-treated liver 
over a 4-week period. In view of the small amount of toxicological 
data available about this drug, the present study makes a significant 
increase in our knowledge of the effects this drug has in vivo. 
Subsequent studies on dynamic systems free from unphysiological 
trauma gave results more relevant to metastasis, and these will be 
discussed later.
Among the results for APT, the first surprising observation 
was that the lysosomal enzyme extract (which was by no means a pure 
enzyme preparation but simply an enriched fraction with some protein 
removed) always showed, regardless of its source, two activity peaks 
in response to varying substrate concentrations. This was assumed 
to be due to two isoenzymes, each showing sigmoid characteristics in 
Michaelis-Menten curves, and thus suggesting a homotropic allosteric 
nature, as well as substrate inhibition at high substrate concentrations, 
Such a concept is not new and many workers have reported phosphatase 
isoenzymes in various tissues. It may be of significance that two 
fairly distinct phosphatase activities appear in the lysosome-rich 
fraction. The lysosomes may thus more easily dispose of a variety 
of ingested substrates. The values obtained for the two enzyme 
activities are widely different: whether the values are determined
at pH 4*5 or 5*0, those obtained for any given tissue differ by some 
three orders of magnitude. The APT in the Huggins breast tumour 
seems to have more similarity with the normal lactating breast than
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with the liver tissue. One might expect this to be the case, but 
it must be remembered that the Huggins tumour used for this work 
had been maintained since 1967 in close proximity to the liver of 
a healthy rat. As the passage of the tumour required a 6-8 week 
period, the tissue used for these studies had undergone at least 
30 passages - quite long enough to have modified dramatically from 
the original breast tissue type. Similarities between breast and 
Huggins tissue may be taken to show that the tissue retained some 
characteristics of the original breast tissue.
The APT with low from all three sources showed a marked 
substrate inhibition. In all cases it seemed from the Michaelis- 
Menten plots (Figs. 15 and 16) that inhibition by substrate prevented 
the maximum rate of hydrolysis from being achieved. Obviously, in 
such circumstances, calculation of Kj^  values cannot be accurate, but 
the figures obtained are probably in the right order of magnitude.
Whether the two activities detected were due to the two 
components of a single enzyme complex, or whether two completely 
separate and separable enzymes were present, was not determined: 
no attempt was made to resolve the two activities.
In terms of Suramin sensitivity and pH response, the Huggins 
enzyme (Fig. 12) showed a marked difference from the two enzymes 
derived from normal tissue (Figs. 10 and 11), suggesting that, although 
kinetically similar to the original mammary enzyme, some modification 
of the protein structure may have occurred which resulted in a stronger 
inhibition by Suramin. Such a difference could conceivably be due 
to inclusion in the enzyme structure of more positively-charged amino 
acid residues. Alternatively, such residues already present could 
have become more readily available to the strongly anionic inhibitor
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molecule. A third possibility exists - that the active site itself 
is modified in the tumour enzyme. However, the latter explanation 
seems less likely, if only because of the strong similarity between 
the kinetic characteristics of mammary and tumour tissue enzymes.
One would expect some marked difference to show if changes have 
occurred in the chemistry of the active site.
The effects of Suramin on the third lysosomal enzyme, aryl 
sulphatase, were somewhat equivocal. If one compares the tumour 
enzyme (Fig. 14) with the liver enzyme (Fig. 13) (not, perhaps, a 
strictly valid comparison since the two tissues involved are different), 
it seems that the tumour enzyme is more Suramin-sensitive than the 
liver enzyme at pH values below 6*0. Liver aryl sulphatase activity 
is elevated by the presence of Suramin between pH 4*0 and 4*5. Such 
a disparity between the two enzymes suggests the possibility of a 
diagnostic test which might distinguish between normal and tumour 
tissue, though more work is evidently required on this point.
As a result of these comparisons of the three lysosomal enzymes, 
it can be seen that the original premise made out for this study, 
that Suramin may act on more than one of the lysosomal enzymes, is 
supported unequivocally and gives considerable justification for 
continuing studies in vivo,
2. Experiments on Living Animals
Part of this work dealt with normal rats and the effects of 
Suramin and GSL on the characteristics of the liver. The use of PBT 
in this research was not aimed at following the detoxication 
metabolism of the drug. It must be emphasised that the object was 
not to observe the toxic effects per se, but was primarily intended
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to show whether or not the lysosomal enzyme activities could be 
inhibited and, if so, whether the inhibition would cause a decrease 
in the rate of tissue degradation. The latter might, by implication, 
be taken to equate with a decrease in metastatic activity. Therefore, 
although any observation made on the cytochromes could have indicated 
their possible involvement in Suramin metabolism, the main reason 
for using PBT was that the drug had been well established as a 
stimulant of specific and easily-assayed protein synthesis.
It seemed possible, therefore, to initiate a well-documented 
chain of events which could be monitored by assaying cytochromes P^gg 
and bg, the levels of which might indicate whether or not Suramin 
(or GSL) would interfere with the enzymes involved in the synthesis of 
these cytochromes. If no interference were detected, it could not be 
stated that Suramin did not inhibit any stage of protein synthesis: 
Suramin is indeed reported to bind strongly to DNA (Tovm et al., 1950), 
so it is very probable that the drug would inhibit protein synthesis 
at least in a cell-free system. Further experiments might then clarify 
just how much the drug penetrated throughout the cell structure and 
thereby suggest possible harmful side effects in the protein synthetic 
processes.
When these studies were completed and the results tabulated 
(Tables XIV to LI), it became clear that there were very few 
outstanding results from this part of the work. Over a 4-week period 
the cytochrome P^^^ in both Suramin- and GSL-treated rats rose by about 
50% over the level found in control animals (Tables XL, XLI and LI).
The increase is not easily explained when compared with the PBT-induced 
increase over the same period, which was in the order of a five-fold
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enhancement over the level of the control livers. The small 
elevation in the cytochrome levels, due apparently to Suramin or 
GSL, might have derived from other causes, such as minor infections 
arising from injection, or an unknown component of the GSL tablets 
used. It seems most unlikely that GSL itself should stimulate 
cytochrome synthesis. Conversely, there was no apparent depression 
in cytochrome synthesis caused by Suramin in the PBT-stimulated 
synthesis of cytochromes P^gg and bg, as has been reported by 
Basu et al, (1973).
The rats treated with GSL were given the compound in their 
drinking water at a concentration of 1 mg/ml. Careful monitoring 
of the amount of drinking water consumed daily throughout the experiment 
showed that the average dose of GSL rose from 17 ml/day for a rat of 
65-70 g to 26 ml/day for a rat of 160-170 g (Fig. 23) - i.e. the GSL 
dose fell from about 260 mg/kg at the beginning of the experiment to 
nearer 150 mg/kg at the end of the 4-week period. Suramin and PBT were 
both given at fixed dose levels, of 20 mg/kg and 100 mg/kg respectively, 
throughout these experiments.
The changes observed in cytochrome P^gg were also found in 
cytochrome bg levels. These, too, increased by around 50% in the 
Suramin- and GSL-treated groups, while the increase was in the order 
of 400% in the PBT-treated animals.
In the more complex experiment where all three compounds (Suramin, 
GSL and PBT) were administered individually, in pairs, and all together, 
very few points stood out (Tables XLII to LI). However, it became 
apparent that the synthesis of cytochromes was not greatly influenced 
by Suramin or GSL either alone or together, and regardless of whether
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the cytochromes had been induced by PBT or more simply developing 
at their normal, un-induced rates.
The most surprising feature of this experiment was perhaps the 
consistently low level of total hexoses found in GSL-treated animals.
The anthrone assay used took account of all the hexoses present, 
including glycogen, which one would consider to be the main contributor 
to the total hexoses detected in the liver. Therefore, if the total 
hexose content was drastically reduced, one must assume that this 
was due to a reduction in liver glycogen. The fall in total hexoses 
per liver varied between about 15% -60% of those found in control 
livers, but whether the GSL was administered alone or together with 
either or both of the other two drugs, levels were consistently 
depressed. The total weight of carbohydrate consumed per rat per day 
was in the order of 5 g (as determined by monitoring average daily 
food consumption), while the intake of GSL was, at most, some 30 mg 
per day. The GSL thus appears to reduce the normal deposition of 
glycogen without contributing significantly to the animals' carbohydrate 
intake. This is yet another observation which offered the possibility 
of fruitful study, which, in the context of the present work, was 
felt to be too far from the objective. One could speculate at 
considerable length over this observation, particularly as the animals 
treated with GSL seemed in no way physically inferior to other groups 
of animals in the experiments: weight gain, behaviour and appearance
all compared favourably with those of the others. Whether the animals 
on GSL would have endured so well if they had been given treadmill 
exercise daily, or had been treated with glucagon, or had been given 
low carbohydrate diets, must remain questions for future study.
Carr (1947) reports that feeding potassium saccharate for three
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generations of rat caused no change in the animals' condition or 
fertility: this seems to be the only observation reported on the
effects of a relevant compound.
Very little difference was detected between Wistar and Sprague- 
Dawley rats: one of the few differences was that the Wistars appeared
to be a little more sensitive to hexobarbitone than the Sprague- 
Dawleys, Their sleeping time tended to be slightly longer, although 
after treatment with PBT no difference was observed. Another slight 
difference between the strains was that the Wistar animals seemed to 
have a higher level of lipid phosphorus (and therefore, presumably, 
a higher content of phospholipid) in their tissues. Levels of
cytochromes P and b were not compared.
450 5
There seems little more information that can be drawn from the 
analytical data for the rat livers. The lack of meaningful differences 
in the studies on liver composition is rather disappointing, but some 
consolation can be drawn from the fact that none of the experimental 
animals either died or showed other signs of deterioration during these 
experiments - surely an indication that neither Suramin nor GSL was a 
particularly harmful drug.
On the basis of the results obtained, it is apparent that GSL 
is not very promising as an antimetastatic agent. The compound is 
well known as an unstable lactone, retaining its integrity only in acid
conditions. It is prone to spontaneous rearrangement to the 3,5 lactone
under normal physiological conditions, an isomer which is ineffectual 
as an inhibitor of BGD (Levvy, 1952). Since the compound is a hexose 
sugar derivative it is presumably subject to very rapid metabolic 
degradation and utilisation in vivo. Probably the only reason why
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Boylcuid et al, (1958) were able to show reduced urinary BGD activity 
after giving this compound was because, by giving four 1 g doses per 
day, traces of the lactone must have passed unaltered from the blood 
through the kidneys to the urine. With such an extraordinarily low 
Kj^  with BGD, only traces would be required to cause dramatic 
reductions in activity. Also, one assumes that, once the lactone- 
enzyme complex is formed, the lactone is stabilised. Moreover, little 
or no metabolic degradation of sugars is likely to occur in the bladder. 
In this way inhibition of urinary BGD could be shown, though one should 
remember perhaps that the bladder milieu is not strictly an in vivo 
situation and therefore what happens there cannot necessarily be 
expected to occur elsewhere in the animal.
If BGD can be shown to be a significant contributor to the 
metastatic process, then one should consider other methods of 
presentation of GSL. A very promising method could be the "parcelling" 
of the lactone in a controlled environment, to protect it until it 
reaches the enzyme target. (This technique is apparently being used 
successfully to treat glycogen storage diseases, using the "liposome" 
discussed by Bangham (1968) to protect injected enzymes during 
sequestration in the liver.) The principle used would be to add a 
solution of the relevant material (in this case, GSL in acid solution) 
to a suitable lipid/phospholipid complex, resulting in the formation 
of micelles and lipid vacuoles filled with the solution. These would 
be washed free of excess acid and injected into the bloodstream from 
whence they would travel to the liver (and other sites of pinocytosis) 
and ultimately would be united with lysosomes after pinocytosis. Thus 
the GSL could, at least theoretically, be introduced into the lysosomes
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before the BGD is liberated to start extra lysosomal hydrolysis, and 
in this way it might be possible to inhibit metastasis.
By analogy with the effect of Suramin on the involuting uterus, 
it seems likely that the pinocytotic process could well lead to the 
liposomes being taken up by tissues other than the liver, and thus 
inhibit BGD in those tissues. However, such studies were thought to 
be too complex to be included as part of the present work, and* indeed 
one would first have to prove that BGD was a significant contributor 
to the metastatic process before embarking on such a project.
From experiments made in this study it became obvious that GSL, 
unprotected from metabolic degradation, is of little use as an in vivo 
inhibitor of BGD in spite of the fact that in vitro it has an extra­
ordinarily powerful affinity for BGD. Without any form of protection 
from either metabolic degradation or spontaneous molecular rearrangement, 
it seems therefore to have little to offer as an antimetastatic agent.
Results of experiments performed more completely in vivo were 
perhaps significant in a more positive way. Tlie results for Ehrlich 
ascites tumour (EAT) show a remarkable reduction in the tumour size after 
Suramin treatment (Figs, 17 and 18, and Tables III, IV .and VI - XIII). 
Over the 15-day period of the tumour's development, the tumour-bearing 
animals gained a total of 14-15 g, while normal animals increased by 
2-2*5 g over the same period. Suramin-treated, EAT-bearing animals 
had an intermediate growth rate, indicating a significant retardation 
in tumour development (Fig. 17).
The growth pattern of the untreated tumour as used in this study 
differed from both the tumour used by Lucke and Berwick (1954) and that 
of Svlven et el, (1959). The latter used a tumour apparently similar
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in its growth pattern to that of the present tumour after treatment 
with Suramin, However, there was some similarity between the present 
tumour and that used by Patt and Blackford (1957), at least insofar 
as their growth patterns were concerned.
The chromosome number of the tumour was determined and found 
to be 44*5. Since the normal number for the mouse is 40, this tumour 
was apparently a hyperdiploid strain and therefore could not be too 
closely compared with the tumours studied in detail by Klein and 
Revesz (1953), Lucke and Berwick (1954), Sylven et al, (1959) or Patt 
and Blackford (1954) . This is not very surprising for, as Yoshida 
(1971) pointed out, there are very many variations and sub-strains of 
ascitic tumours available, and the original solid Ehrlich sarcoma from 
which the EAT was developed bears no resemblance at all to the ascitic 
tumour. Thus, one must simply define one's own particular strain as 
fully as possible. In this case, the EAT used was hyperdiploid and had 
a passage time of 14-20 days in outbred Swiss T.O. albino mice.
However, the work of Klein and Revesz was very useful in providing 
suggestions for the way in which the ascitic tumour work was carried out. 
By calibration of the Coulter Counter it was possible to study the 
effects of Suramin on the size and frequency of occurrence of tumour 
cells. A typical cell-size frequency pattern in shown in Fig. 18.
The largest changes resulting from Suramin treatment were seen in two 
cell size groups, 500-1000 and 1000-1500 . In each category the
increase over the control animals was around 13,000% for the untreated 
animals, and about 2,500% for the Suramin-treated ones, indicating 
that the untreated 5-day old tumour was developing at about five times 
the rate of the Suramin-treated tumour. The increase in apparently
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larger cells is probably due to cell clumping, a phenomenon reported 
by others working on cancer (Malmgren, 1968).
Photomicrographs were made to compare normal, untreated EAT 
cells with Suramin-treated cells (Figs. 20 and 21). A colleague.
Dr. N.P. Bishun, a cytogeneticist with many years' experience of EAT 
cells, identified the ill-defined, fluffy, larger cells as malignant 
tumour cells, and the smaller, darker-staining, well-defined cells 
as normal lymphocytes, indicated by "T" and "L" respectively in the 
pictures. If this is so, one must conclude that the effect of Suramin 
on the host animal is, at least in part, to stimulate the host's 
natural immune response to the tumour.
Whether such interpretation is accurate remains to be seen: 
from this study, it is quite obvious that the number of cells in 
the tumour is dramatically reduced af^er Suramin treatment, and also 
that the morphology of the cell population is much nearer to that of the 
normal mouse. It must be added that intraperitoneal injection of 
Suramin to normal, healthy mice showed no significant change in their 
peritoneal cell population, either numerically (Table V), morphologically 
or electrophoretically (Fig. 22).
These observations can be extended further by considering the 
electrophoretic data (Fig. 22). It must be admitted that these are 
woefully meagre, being derived from only four mice in each of four 
groups (injected with either saline. Suramin, EAT or EAT and Suramin) 
observed over the 8th and 9th days of the tumour's development. This 
observation was not repeated because of the lack of apparatus.
However, the results that were obtained are consistent within any 
one group and show quite clearly that, in the healthy mouse, Suramin 
has little effect, while in the EAT-bearing mouse there is a dramatic
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change. The EAT itself appears from these data to be an aberrant 
form of a normally occurring cell, since in the control animals a 
small peak (about 17*5% of the cell population) is seen, which 
coincides with the majority of the tumour cells for mobility.
Addition of Suramin reduced dramatically the proportion of "tumour" 
cells from about 33% of the total to about 10% of the total. At the 
same time an electrophoretically different cell type appeared, having 
a very low mobility and comprising some 34% of the cells observed.
How this change occurs is not immediately apparent. The 
mobility of all these cells is a function of their electro-negativity 
and for the tumour cells was virtually identical with the EAT cell 
mobility reported by Bangham et al. (1962). This suggests that the 
strain is not greatly different from at least one other EAT strain.
The negative charge found on cell surfaces is due largely to 
two surface components, sialic acids and phospholipids. The major 
component of sialic acid residues is N-acetylneuraminic acid, and 
many observations have been reported that treatment of electro­
phoretically mobile cells with neuraminidase reduces their mobility 
(Vassar et al ., 1966> Yarnell and Ambrose, 1969). Cook et al. (1960) 
report that trypsin treatment of human erythrocytes has a similar 
effect. Some of the mobility - generally a minor component - is also 
due to the phospholipid phosphate, which may be present on the cell 
surface. However, from enzymic treatment of malignant cells, the 
major charged component seems to be the negative sialic acids (Ambrose, 
1966b). Suramin, too, is negatively charged, to the extent of six 
charges per molecule. It follows that, if Suramin binds to the cell 
surface, it probably does so via positively charged centres, and will
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thus reduce the cell's positive charge complement, enhancing the 
effective negative charge density.
One would thus predict a more strongly negative charge than 
ever on the cell surface. What in fact occurs, however, is exactly 
the opposite, with a large reduction in cell mobility and therefore, 
one assumes, a reduction in the net negative charge on the cell surface 
being observed. Without the facilities to follow the time course of 
this neutralisation of charge, it is difficult to explain. It is 
possible that the drug enters the cells and, perhaps by virtue of its 
somewhat hydrophobic chain structure, interferes with the membrane 
activities of the Golgi apparatus. This may prevent the transport 
of newly-synthesised sialic acid residues to the cell surface. 
Alternatively, the Suramin may prevent the sialic acid on the surface 
from exerting its full charge simply by altering the cell surface/water 
interphase area: the negative region of the drug molecule could
conceivably bind to the cell surface, leaving the aromatic backbone 
of the molecule exposed to the surrounding medium and influencing the 
degree of solvation of the cell surface.
Another possibility to be considered is that perhaps the surface 
sialic acids are originally formed with the charge-bearing groups 
masked in some way, and that these are only revealed by the activity 
of some extra-cellular hydrolytic enzyme. Inhibition of this enzyme 
by the Suramin would prevent the revelation of the negative charges, 
and hence reduce the overall negativity of the cell surface, which 
would be detected as a reduction in cell mobility.
In order to determine the degree to which extracellular hydrolases 
might modify these surface charges, the activity of several extracellular
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hydrolytic enzymes of the ascitic fluid was measured. The 
enzymes observed were BGD, APT, non-specific proteinase and 
N-acetylneuraminidase (Tables VII, VIII, IX, X and XIII). In 
every case, the effect of Suramin was to reduce greatly the level 
of activity found in the untreated ascitic fluid. Thus it seems 
feasible that the drug was having a modifying effect on the structure 
of the tumour cell's surface, by preventing a normally-occurring 
enzymic modification of the cell surface.
A further effect of Suramin on EAT development was that the 
weight of Suramin-treated, tumour-bearing animals increased at a 
slower rate compared with that of mice carrying the untreated tumour 
(Fig. 17). This suggested that the tumour was developing more 
slowly, a proposition supported by the reduced cell counts found 
in such tumours. Further support for this suggestion is found in 
the observation that the enzyme activity of the peritoneal fluid in 
Suramin-treated animals was reduced, implying that either the enzymes 
were being inhibited and/or less of the enzymes was being synthesised, 
In fact, it seemed likely that both these events were occurring: 
in vitro assays have shown that these enzymes were Suramin- 
sensitive and would therefore show reduced activity. Also, the 
amount of extracellular enzyme activity in EAT fluid corresponds 
in some degree to the number of tumour cells present, so one might 
expect that,if the number if cells is reduced, then the amount of 
extracellular enzyme may also be reduced.
Moreover, the total enzyme activity from the entire volume of 
peritoneal fluid present in a given animal was far less in Suramin- 
treated than in untreated EAT. This is true for comparisons of
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APT activity either in the ascitic fluid or in the ascitic cells 
themselves (Table VIII). Suramin causes an even more marked change 
in the BCD content of the tumour cells: there is a constant and
major reduction in the intracellular enzyme activity after day 2, 
and a similar change in the extracellular activity. These changes 
lasted throughout the 14-day period of observation (Tables VII to X 
and Table XIII) , and could perhaps be caused by interference with the 
normal function of the Golgi apparatus, resulting in less enzyme 
being secreted to the ascitic fluid.
Here then was a very promising response to Suramin, one which 
fitted at least in part with the suggestions of Schersten et al. (1972) 
that the metastatic tumour requires extracellular hydrolytic enzyme 
activity for normal growth. In this context, it must be remembered 
that EAT was chosen as an experimental model of a metastatic tumour, 
not simply as a tumour in its own right.
The regime of Suramin therapy was varied, in order to determine 
just how much of the drug was required and whether two applications 
were more effective than one. This experiment was made over an 
8-day period, comparing untreated EAT cell counts with those made on 
animals treated at Day 1, or Day 5, or Days 1 and 5, the cell counts 
being made on Day 8 (Table XI), Oddly enough, the most effective 
of these treatments was the single dose at Day 1. Delaying treatment 
until Day 5 caused a predictably lessened response to the therapy.
The curious observation, however, was that a second Suramin injection 
at Day 5 seemed to promote the tumour's activity. These studies 
were made on the basis of both cell counts and photomicrographic 
observation of smears made from cell suspensions. On both bases, a 
single injection seemed to be the most effective treatment.
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Subsequently, a comparison was made of the’ usual 20 mg/kg 
dose level with one of 200 mg/kg. Very little difference between 
the effects of these two dose levels could be detected on the basis 
of either cell count or morphology. However, the total BGD activity 
was reduced by the increase in Suramin administered (Table XIII) and 
there seemed to be a longer-lasting inhibition of cell numbers 
(Table XII). In fact, without going into a detailed study of* 
dose/response it seemed that the purely arbitrary choice of 20 mg/kg 
for Suramin therapy administered 24 hours after the tumour's 
inoculation was quite close to the optimum treatment.
Of course, if one is trying to clarify the suggestion that 
the extracellular enzymes are an essential part of metastasis, one 
must not only show that the metastatic model can be influenced by 
the drug, but also that, in the in vivo situation, the enzymes concerned 
are sensitive to the drug. It was for this reason that effects of 
Suramin were sought in the involuting rat uterus.
Tlie work of Harkness and Harkness (1^5 , 1956a, b,c), of 
Harkness and Moralee (1956) and of Woessner (1962, 1963, 1965) provided 
useful background data for this aspect of the study: the results
reported here (Tables LII - LXI) fit well with these authors' data.
The effects of Suramin on the various tissue constituents observed 
were not of themselves dramatic, but seemed to be quite consistent 
overall. Thus the retardation in the rate of uterine involution 
(Table LII) seemed to be reflected in reduced hydrolytic enzyme 
activities (Tables LX, LXI) and slower rates of loss of structural 
components.
These responses were the result of single intraperitoneal 
injections of the drug at Day 0, given at a level of 20 mg/kg body
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weight. Probably, a higher dose given intravenously would have had 
a more dramatic effect. However, the observations made with this 
simple protocol seem to support the general idea that the lysosomal 
enzymes are subject to inhibition by Suramin in vivo.
The work of Davies et al. (1971) shows that liver lysosomes 
were sensitive in this way, and indeed Smeesters and Jacques (1968) 
had previously claimed that the drug was taken up into the liver 
lysosomes - an observation reiterated by Smeesters in 1973. However, 
an interesting addendum to their observations is now possible, i.e. 
that lysosomes in another tissue, the uterus, may also take up the 
drug.
The changes in weight observed after Suramin treatment do not 
seem to be due to water retention. Only on Day 1 is there any great 
difference in water content between test and control animals (Table LIII) 
Even here, because of sample variation, the difference is not 
statistically significant.
Similarly, the protein content (Table LIV), as measured by the 
Lowry method, does not alter, suggesting that the different rates of 
weight loss are not due to changes in the rate of protein degradation. 
Slightly more interesting data came from observation of hexose levels 
(Table LV) in the uteri (assumed to indicate glycogen content), which 
were on average about 10% higher in test than control animals. Very 
similar differences of around 10% were observed for the glucosamine 
(Table LVI) and hydroxyproline levels (Table LVII).
The hydroxyproline was not, apparently, due to collagen (Table 
LVIII), which seemed to be degraded at roughly similar rates in both 
treated and untreated uteri. There was a large difference in elastin 
levels (Table LIX) throughout the 15-day post-partum period of obser­
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vation, averaging 28-30% higher content in the treated uteri. 
Conversely, the BGD (Table LX) and APT (Table LXI) levels were 
both reduced by Suramin, in each case to about 75% of the control 
uterine activity.
These observations were felt to be far more encouraging than 
those for the liver, not only because the reductions were predicted 
but also because they were associated with other symptoms, such as 
the slowed rate of involution and the change in uterine composition.
Consequently, it was felt that the potential of Suramin as an 
inhibitor of lysosomal enzyme activity in a controlled, physiologically 
normal degradation of tissue had been demonstrated with some success.
Although the apparent effect of Suramin on liver was not
significant, at least in terms of observed enzyme activities, the
fact that no dramatic changes were recorded suggested that the drug
was not likely to be particularly harmful. The uterine results
suggest that, in the right circumstances and with the appropriate
tumour type. Suramin could exert some degree of antimetastasis. This
is supported by the Suramin-stimulated increase in and decrease in
V observed in liver BGD preparations (Tables LXII, LXIII), which max XT IT
together suggest that, in vivo, there would probably be a reduction 
in the enzymic activity, because both its affinity for substrate and 
its maximal rate are reduced. Obviously, changes in these quantities 
were not detectable under the assay conditions used in this study, and 
only became apparent when specific kinetic observations were made.
The kinetics of rat liver BGD were found to change slightly as 
the animals aged. Those used for the 24-hour study were about four 
weeks younger than those killed at the end of the 28-day experiment.
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This age difference was particularly important as the study was
made soon after the animals were weaned, and they were not only at
a stage when they were growing very rapidly, therefore, but in addition
a 4-week period represented a large proportion of their total lifespan.
In untreated control animals, the of the enzyme in the
particulate pellet (Tables LXII and LXIV) dropped from 19*42 x lO'^M
to 9*57 X 10 **M, while the V fell from 13*17 to 4*68 ul4/hr. The
max T"
of Suramin-treated liver enzyme changed from 12*63 x 1Q“‘*m  to 7*93 x 1Q“‘*m
while that of the PBT-treated enzyme fell slightly from 11*59 x 1Q"^M to
8*77 X 10 **M over the 4-week period. Conversely, the of BGD treated
with Suramin and PBT together rose from 1*87 x 10~*^M to 11*93 x lO'^M.
This suggests two things: firstly, that as the liver growth
rate slows (as the animal approaches full size), the enzyme activity
falls off. It is well established tlTat the enzymic activity increases
markedly during tissue growth, e.g. during liver regeneration. This
reduction may well be, therefore, the result of a change in the
and V of the enzyme. Secondly, while either Suramin or PBT will 
max
have a small effect over a short period, more disturbance is caused by
prolonged therapy over a 28-day period. When applied together, these
drugs result in a near-20% increase in the of BGD over that of the
untreated control. This may be compensated for to some extent by a
virtual doubling in the V , but even so could conceivably lead to
max
some change in metabolic processes. It could be interpreted as a 
biochemical response to interference with the lysosomes, or could 
equally well be due to some other artifact caused by these drugs.
The microsome/cytosol BGD would seem to be different from the 
particle pellet enzyme (Tables LXIII and LXV). Firstly, the for
- 205 -
the control liver enzyme was only a sixth of that of the nuclear
enzyme, while the V was about half. Secondly, the effect of
max
Suramin or PBT after 24 hours was much less than on the particulate
pellet enzyme: there was virtually no change in either or
values, although the two drugs together almost doubled the
(a change similar to that seen in the particulate pellet enzyme after
28 days). After 28 days, the of the microsomal enzyme showed a
six-fold increase in control. Suramin- or PBT-treated animals, though
while the V of the control animal enzyme almost doubled, there 
max
was no change in the values for Suramin- or PBT-treated enzyme.
Treatment with Suramin and PBT together caused an 80% increase in
V , but no real difference in K , though after 28 days' treatment, 
max m
the was about half that of the control liver enzyme.
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EPILOGUE
In retrospect, it is possible to propose several other 
experiments which could shed more light on the effect of Suramin 
and its mechanism of action. For example, an extended, daily 
Suramin therapy of EAT-bearing mice, coupled with cell counts as 
well as enzymological and electrophoretic observations, might 
indicate the most effective means of treating the tumour, and the 
way in which the extracellular enzymes were produced. No-one 
has shown conclusively that they are the product of either the host 
or the tumour exclusively, or whether both contribute to the total 
enzyme activity. Further, such a study might show whether the 
enzymes modify the tumour cell surfaces, or whether the electrical 
charge distribution on the tumour cells is the result or the (partial) 
cause of their malignancy, and whether such intensively treated cells, 
after they are controlled in their host, in fact retain their malig­
nancy when transferred to a new, healthy host. No attempt was made 
during the course of this study to determine the continuing malignancy 
of Suramin-treated cells during subsequent passage. This idea in 
itself could form the basis of an interesting project.
Having collected and surveyed all these data, it now seems 
that perhaps observation of partially hepatectomised animals and 
their responses to Suramin might have shed light on the drug's activity. 
Although such an experiment could not really be justified in the context 
of metastatic development, it could well provide a valuable indication 
of the need of a growing tissue for hyperactive lysosomal enzymes.
Indeed, the studies made in the course of this work do not seem 
to have cast much light on the role of the lysosomal enzymes themselves
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in the metastatic process, although a very significant retardation 
was achieved in the development of the EAT, with a concomitant 
reduction in the activity of extracellular enzymes normally associated 
with the lysosomes. However, one must remember that the object of 
using the EAT was simply to produce an experimental system which 
could be likened to a metastasising tumour, not to use it as a tumour 
which had to be cured.
The overall picture of Suramin as an antimetastatic agent really 
seemed quite promising and well worth following up in other experi­
mental models. To this end, a quantity of the drug was sent to 
Dr. T.A. Connors of the Chester Beatty Institute, who determined the 
LD5Q in mice, and then tested the drug against one of the Chester 
Beatty standard tumour lines, the TLX5 lymphoma. Dr. Connors reports 
that the maximum tolerated dose in mice is 320 mg/kg for five days, 
and that even with dose levels as high as this there was no change 
in the survival time of his tumour-bearing mice when treated with 
Suramin. Of itself, such a report does not warrant the rejection 
of Suramin, but simply suggests that, in the light of the promising 
effects the drug has shown in these studies, it should be screened 
against a variety of other metastatic tumours. After all, if it is 
shown that Suramin is capable of retarding metastasis in only one 
type of cancer invasion, and rendering an otherwise incurable disease 
curable by surgery, then many lives could be saved and a great deal 
of human suffering and grief eliminated.
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